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ABSTRACT

MELATONIN-MICRONUTRIENTS OSTEOPENIA TREATMENT STUDY (MOTS): A
TRANSLATIONAL STUDY ASSESSING THE EFFECTS OF MELATONIN, STRONTIUM
CITRATE, VITAMIN D3 AND VITAMIN K2 ON BONE DENSITY, BONE MARKERS
TURNOVER AND HEALTH-RELATED QUALITY OF LIFE IN POSTMENOPAUSAL
OSTEOPENIA FOLLOWING A ONE-YEAR DOUBLE-BLIND RANDOMIZED PLACEBOCONTROLLED TRIAL AND ON OSTEOBLAST-OSTEOCLAST CO-CULTURES.
By
Sifat Maria
May 2018

Dissertation supervised by Dr. Paula A. Witt-Enderby
Objective: The purpose of this study was to assess if a novel combination of melatonin and three
other natural bone-aiding micronutrients: strontium citrate, vitamins D3 and K2 (MSDK) could
improve bone health by modulating the activity of osteoblasts and osteoclasts in favor of balanced
bone remodeling and by improving the overall health-related quality of life in postmenopausal
osteopenic women.
Methods: The Melatonin-micronutrients Osteopenia Treatment Study (MOTS) is a translational
research study that used both clinical and in vitro approaches to assess the efficacy of MSDK on
bone health in women and to identify potential mechanisms for its effects. The clinical component
of this study was designed as a one-year double-blind, placebo-controlled randomized trial, which
assessed the effects of nightly MSDK supplementation containing 5 mg melatonin, 450 mg
strontium citrate, 2000 IU vitamin D3 and 60 mcg vitamin K2 (MK7) on bone mineral density
(BMD), bone marker turnover and quality of life (QOL) in postmenopausal osteopenic women. A
total of 22 women (ages 49–75) were randomized to receive either MSDK (n = 11) or placebo (n
iv

= 11) p.o. nightly for 12 months. Bone mineral density (BMD) was measured by dual-energy Xray absorptiometry (DXA) and Achilles ultrasound. Bone turnover markers total procollagen type
1 amino-terminal propeptide (P1NP), osteocalcin (OC; both intact and N-terminal mid-fragments)
and collagen type I c-telopeptide (CTx) were assessed at months 0, 6 and 12 in serum. Participants’
serum vitamin D3 and C-reactive protein (CRP) levels were measured at months 0, 6 and 12.
Nocturnal urinary melatonin levels were measured at month 12. Quality of life questionnaires
measuring menopausal symptoms (MENQOL), anxiety (STAI), stress (PSS) and depression (CESD) were administered at months 0, 6 and 12. Participants were given a daily diary to keep track of
their pill intake, sleep duration, exercise, supplement usage and other information relevant to their
general health and mood throughout the study.
The in vitro component of this translational study focused on identifying potential
mechanisms underlying MSDK’s effect on bone cell differentiation and activity using two coculture systems containing human adult mesenchymal stem cells (hMSCs) and human peripheral
blood monocytes (hPBMCs). Using a novel in vitro treatment paradigm that closely mimics the in
vivo condition, hMSCs/hPBMCs were co-cultured for 21 days either separately using transwell
culture dishes (transwell co-culture) or by seeding hPBMCs directly on top of differentiating
hMSCs (layered co-culture). The effect of MSDK on the differentiation and activity of bone cells
was measured via alizarin red staining assay for osteoblast activity and TRAP and resorption pit
assays for osteoclast activity, respectively. This study further assessed various signaling cascades
underlying MSDK’s effects on osteoblastogenesis and osteoclastogenesis that included:
OPG/RANKL, ERK1/2 and 5, RUNX2, INTEGRIN β1, NFκB, PPARγ, GLUT4 and INSULIN
Rβ.

v

Results: One-year of MSDK treatment significantly increased lumbar spine BMD (4.3%), left
femoral neck BMD (2.2%), with an upward trend for total left hip BMD (5.03% vs. 2.2% in
placebo; p=.069) in postmenopausal osteopenic women taking MSDK compared to placebo.
MSDK also decreased the ten-year probability of vertebral fracture risk by 6.48% compared to the
10.8% increase observed in placebo. MSDK reduced bone turnover (CTx:P1NP ratio) primarily
by increasing the serum bone formation marker P1NP (vs. placebo; p = 0.023 and p = 0.004 at
months 6 and 12, respectively); the bone resorption marker, CTx remained constant throughout
the study. Serum OC levels also did not change with MSDK throughout the study. Serum CRP
levels showed a downward trend, suggesting potentially positive effects of MSDK on one’s
inflammatory status. MSDK produced no effect on height, weight and lean body mass; however,
MSDK resulted in less variability in weight gain or loss compared to women taking placebo which
could positively contribute to bone health. MSDK exhibited beneficial effects on the quality of
life, perhaps by lessening the sexual symptoms of menopause (not significant vs. placebo) and
showing some improvements with respect to sleep quality. MSDK did not produce adverse effects
psychologically or physically in our cohort and there was a high compliance rate (92.4%).
MSDK-exposed human mesenchymal stem cells (hMSCs) and human peripheral blood
monocytes (hPBMCs) plated in transwells or layered co-cultures demonstrated increases in
osteoblastogenesis, decreases in osteoclastogenesis, increases in the ratio of OPG:RANKL by both
increasing OPG and decreasing RANKL expression in osteoblasts. In transwell osteoblasts,
MSDK increased pERK1/2 and RUNX2 levels; decreased ERK5; and did not affect the expression
of NFκB and INTEGRIN β1. In layered osteoblasts, MSDK also decreased expression of the
metabolic proteins PPARγ and GLUT4. These findings demonstrate that MSDK may be a novel,
safe and efficacious therapy for treating those afflicted with osteopenia.
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Chapter 1: Introduction
1.1. Bone physiology
1.1.1. Modeling and remodeling
Vertebrates embrace a unique skeletal morphology made up of bone and cartilage. Nearly
80% of the adult human bones are comprised of compact, smooth outer layer called “cortex”; the
remaining 20% are the spongy, honeycomb-like inner layer known as “trabecular” or “cancellous”
bone. Cortical and trabecular bones are organized in a lamellar pattern to maintain structural
rigidity (Clarke 2008). The tissue structure of bone consists of mineralized and non-mineralized
matrix (osteoid) and three major bone cells—bone-forming osteoblasts, bone-lining osteocytes and
bone-resorbing osteoclasts. The evolution and activity of these cells as well as communication
between them are the chief controllers of skeletal development, bone adaptation (modeling) and
bone preservation (remodeling) (Gasser and Kneissel 2017).
Bone modeling is the process where osteoblastic bone formation and osteoclastic bone
resorption occur as two independent events. Bone modeling is predominant during the first twenty
years of life at the endocortical and trabecular surface to attain peak bone mass and then continues
at a low level throughout the life. Bone modeling alters bone shape or optimizes bone mass to
encounter and adapt mechanical forces without bending or cracking while at the same time helps
bone to resist deformation from impact loading. Thus, it primarily regulates skeletal growth and
provides mechanical support during hematopoiesis and endocrine function (Burr and Allen 2013,
Currey 2013, Iolascon, Frizzi et al. 2014, Gasser and Kneissel 2017).
Once skeletal growth is accomplished, each of the adult 206 bones undergoes bone
remodeling for the rest of one’s life via a tightly coupled bone formation and bone resorption
process. This essential reparation process substitutes primary juvenile bones as well as age- and
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stress-related microfractured bones with the new healthy, strong and more mechanicallycompetent bones. Bone microdamage accumulates when the magnitude of an applied load exceeds
the structural strength of bone eventually leading to bone deterioration and fracture. The unique
ability of bone to immaculately carry mechanical load and resist fracture is determined by bone
mass and their spatial distribution (microarchitecture), which relies on the steady bone remodeling
(Clarke 2008, Seeman 2008, Iolascon, Frizzi et al. 2014, Gasser and Kneissel 2017).
1.1.2. Role of osteoblast-osteoclast communication in bone remodeling
Balanced bone remodeling is a hallmark of skeletal integrity, which is defined by the
balanced function of two major bone cells— osteoblasts and osteoclasts. Osteoblastic lineage cells,
including mesenchymal stem cell progenitors, pre-osteoblasts, osteoblasts and osteocytes control
osteoclast function which includes the fusion of monocytic pronuclei and their attachment, activity
and apoptosis during bone remodeling. Osteoclasts, on the other hand, resorb bone and regulate
osteoblast function by both membrane-bound and secreted factors and through the release of
factors within the matrix (Sims and Gooi 2008). In cellular fos (c-fos) and macrophage colony
stimulating factor (M-CSF) knockout mice, the absence of osteoclasts leads to defective bone
formation, suggesting essential roles of these factors in maintaining bone integrity (Henriksen,
Neutzsky-Wulff et al. 2009, Eriksen 2010). Therefore, a constant flow of communication between
osteoclasts and osteoblasts is essential to maintain synchronization between bone formation and
resorption during bone remodeling (Matsuo and Irie 2008, Sims and Gooi 2008, Raggatt and
Partridge 2010).
Remodeling starts with the activation of latent bone-lining osteoblast precursors in
response to mechanical load shifts. Mesenchymal stem cells and pre-osteoblasts increase their own
surface expression of receptor activator of nuclear factor κB ligand (RANKL) and M-CSF.
2

RANKL and M-CSF promote the release of immature progenitors of osteoclasts, such as
mononuclear monocytes into the circulation and their recruitment to the resorption surface. They
also bind to their respective cell surface receptors on pre- osteoclasts [(i.e. RANKL to RANK and
M-CSF to colony stimulating factor 1 receptor (CSF1R)] to stimulate the fusion of monocytes into
pre-osteoclasts and eventually into multinucleated fully functional osteoclasts. The osteoclastic
activation phase lasts for approximately 10 days and precedes bone resorption, reversal and
formation (Figure 1).
In the resorption phase, osteoclasts attach to the underlying bone matrix and produce actin
ring-shaped sealing zones enclosed by a ruffled border, which isolates the bone resorbing
compartment from the surrounding extracellular fluid. Osteoclasts then secrete tartrate resistant
acid phosphatase (TRAP), cathepsin K and matrix metalloproteinases (MMP) 9 and 13, resulting
in the dissolution of inorganic minerals from the bone leading to the degradation of organic matrix.
The resorption phase continues for two to three weeks (~21 days) and ends with osteoclast
apoptosis.
The five-day reversal phase starts afterwards, which involves cessation of the resorption
phase and then a transition towards the osteoblast-mediated formation phase. Osteoclasts stimulate
bone formation following resorption by releasing stimulatory paracrine factors embedded in the
bone matrix, including insulin like growth factor (IGF) I and II, fibroblast growth factor (FGF),
transforming growth factor (TGF) 1 and 2, bone morphogenetic proteins (BMPs) 2, 3, 4, 6 and 7
and platelet-derived growth factor (PDGF). In addition, the osteoblast-osteoclast contactdependent ephrin signaling pathway, which mediates the interaction between osteoclast-derived
ephrinB2 and osteoblast-derived EphB4, suppresses osteoclastogenesis when the two bone cells
come into contact with each other to initiate osteoblastogenesis (Sims and Gooi 2008, Henriksen,
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Neutzsky-Wulff et al. 2009, Eriksen 2010).

Figure 1. Different phases of bone remodeling cycle. Activation, resorption, reversal and
formation. RANKL= receptor activator of nuclear factor κB ligand, M-CSF= macrophage colony
stimulating factor, CSF1R= colony stimulating factor 1 receptor, OPG= osteoprotegerin, BMP=
bone morphogenetic protein, FGF= fibroblast growth factor, TGFβ= transforming growth factor
β, ALP= alkaline phosphatase, OC= osteocalcin, TRAP= tartrate resistant acid phosphatase,
MMP= matrix metalloproteinase. Figure adapted from Maria et al, 2014 (Maria and Witt‐Enderby
2014).
Mature osteoblasts start producing osteoprotegerin (OPG), which acts as a decoy receptor
4

for RANKL to negatively regulate RANK-RANKL binding and osteoclastogenesis. An inverse
correlation exists between OPG and RANKL expression levels, which depends on the state of
osteoblast differentiation (i.e., OPG levels are highest when osteoblasts are mature and RANKL
levels are highest in immature pre-osteoblasts). Bone formation takes place for four to six months.
Here, osteoblasts proliferate and synthesize new bone matrix (osteoid) that serves as a template
for mineralization resulting from the accumulation of calcium phosphate hydroxyapatite crystals.
Several other factors contribute to osteoblastic bone formation which include alkaline phosphatase
(ALP) and osteocalcin (OC). ALP is used as a marker of bone formation because its activity
increases with an increase in osteoblast differentiation; however, ALP activity does not always
correlate with bone mineralization. OC is another bone formation marker, which increases bone
mineralization by regulating the growth of apatite crystals and also plays an important role in
fracture resistance (Gasser and Kneissel 2017). Osteoblasts then undergo one of the following
three fates—they either undergo apoptosis, they become entrapped in the mineralized bone matrix
as terminally differentiated ‘osteocytes’ or they remain as inactive cells lining the bone surface.
These apparently quiescent cells reactivate when new bone formation is required. Primary
mineralization accounts for approximately 70% of the mineral deposition that occurs in bone and
this process takes two to three weeks. Secondary mineralization, which entails the maturation of
mineralization crystals, may require more than a year to accomplish. During high bone turnover,
tissue mineralization decreases and the degree of heterogeneity in mineralized matrix increases
leading to bone loss. Balanced mineralization is required for optimal bone quality as high degree
of mineralization makes new bone more rigid but breakable, whereas low mineralization makes
bone less rigid but tough (Boyce and Xing 2008, Matsuo and Irie 2008, Seeman 2008, Sims and
Gooi 2008, Henriksen, Neutzsky-Wulff et al. 2009, Eriksen 2010, Raggatt and Partridge 2010,
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Iolascon, Frizzi et al. 2014, Gasser and Kneissel 2017). The mechanisms governing bone
remodeling are still not clear. An accurate understanding of the mechanism(s) that couples bone
formation and resorption is essential to successfully design interventions for preventing bone loss
while upholding bone quality.

1.2 Bone loss- osteopenia and osteoporosis
1.2.1. Introduction to osteopenia and osteoporosis
Osteopenia and osteoporosis primarily emerge from a disruption in the well-orchestrated
and equalized functions of osteoblast and osteoclast and shifting towards greater osteoclastic bone
resorption in bone remodeling (Feng and McDonald 2011). Osteopenia (from Greek ‘ostoun’
meaning bone and ‘penia’ meaning deficiency), also known as “low bone mass”, is the first stage
of bone loss where bone mass begins to decline because of irregular bone remodeling. Osteopenia
is characterized as below normal bone density and the precursor to osteoporosis, with a T-score
that is between or equal to -1 and -2.5 (Maria and Witt‐Enderby 2014) (Figure 2). Bone loss
typically progresses insidiously and unnoticed during osteopenia until a fracture occurs and/or
osteoporosis develops. If a bone density scan by DXA is performed during the osteopenic stage, it
can serve as a baseline bone mineral density (BMD) assessment for diagnosis and future
monitoring.
The systemic bone disease osteoporosis (from Greek ‘ostoun’ meaning bone and ‘poros’
meaning passage or pore) is defined based on World Health Organization (WHO) diagnostic
criterion of a T-score less than -2.5. This implies that the bone density is moving towards a
worsening of bone density by 2.5 standard deviations from the mean bone density of a 30 years
old. Characteristic features of osteopenia-osteoporosis include reduction of bone density,
degradation of bone tissue and disturbance of bone microarchitecture. This leads to compromised
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bone strength and increased fracture risk following minor or no trauma such as a fall from standing
height. A normal bone remodeling cycle causes nearly zero net change in bone mass and strength.
High osteoclast activity in imbalanced remodeling leads to low bone mass and high intra-cortical
and trabecular porosity, resulting in cortical fragility and loss of trabecular continuity. Defective
bone microarchitecture accompanied by poor matrix mineralization weakens the bone’s ability to
withstand mechanical load below the threshold level. As a result, even typical load produces more
stress on bone, predisposing one to osteopenia-osteoporosis and fragility fractures (Seeman 2002,
Seeman 2008, Baron and Hesse 2012, Cosman, De Beur et al. 2014, Siris, Adler et al. 2014). Hip
and other osteoporotic fractures, which typically occur at the lumbar spine, femoral neck and wrist,
are associated with high morbidity and mortality (Baron and Hesse 2012).

Figure 2: Different stages of bone loss
1.2.2. Risk factors for osteopenia and osteoporosis
Osteopenia-osteoporosis can be classified as primary or secondary based on underlying
risk factors. Primary bone loss progresses with age and typically results in approximately 10% loss
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of bone mineral mass and trabecular bone volume per decade starting after age 40 (Hui, Slemenda
et al. 1990). Although the structural bone damage is similar in men and women during youth,
elderly women are often more vulnerable to bone loss than elderly men. This is due, in part, to the
fact that men have larger skeletons than women and have thicker trabecular density and so their
bones can tolerate more absolute loads. Menopause-related estrogen deficiency is another great
contributor to bone loss in elderly women and a rapid decline in bone is observed in the first three
years of menopause (Seeman 2002, Seeman 2008, Macdonald, Nishiyama et al. 2011, Baucom,
Pizzorno et al. 2014). Other common risk factors for primary osteopenia-osteoporosis include
malnutrition, smoking, sedentary and/or irregular lifestyle, family history, inadequate intake of
calcium, and heavy alcohol consumption (Loh and Shong 2007, Cosman, De Beur et al. 2014).
Vitamin D3 insufficiency has been established in several studies in the last 20 years as yet another
significant risk factor of primary osteopenia-osteoporosis (Baucom, Pizzorno et al. 2014).
Secondary osteopenia-osteoporosis mostly emerges from prolonged use of glucocorticoid therapy
(Angeli, Guglielmi et al. 2006), or from diseases such as thyroid disorders, rheumatoid arthritis,
diabetes mellitus (Inaba 2004), and numerous hematological, gastrointestinal, neurological and
mobility disorders (Loh and Shong 2007, Mohammad, Khan et al. 2009, Cheng, Lin et al. 2014,
Cosman, De Beur et al. 2014). Psychological conditions such as depression as well as poor sleep
also contribute to bone loss, osteopenia and osteoporosis and related fractures (Brassington, King
et al. 2000, Cizza, Primma et al. 2009). Finally, recent studies have shown that chronic circadian,
sleep and melatonin disruption (e.g. in shift workers) can adversely affect bone resulting in low
bone density and increased risk of hip and wrist fractures (Quevedo and Zuniga 2010, Kim, Choi
et al. 2013, St Hilaire, Rahman et al. 2018) .

8

1.2.3. Prevalence of osteopenia and osteoporosis
Osteopenia and osteoporosis are among the most common skeletal disorders worldwide,
taking a toll on our world’s overall health status. The International Osteoporotic Foundation (IOF)
has reported ~ 200 million sufferers (age > 50) of osteoporosis worldwide (Reginster and Burlet
2006). Based on a recent survey by the National Osteoporosis Foundation (NOF), it is estimated
that 10.2 million US adults suffer from osteoporosis at present and another 43.4 million osteopenic
population are under great threat of developing osteoporosis in the near future. This accounts for
54.2% of the total US adult population with bone loss irrespective of ethnicity (Wright, Looker et
al. 2014). These numbers are predicted to increase up to 11.9 million for osteoporosis and 64.3
million for osteopenia by 2030 (Maria and Witt‐Enderby 2014). The European Union also shows
a similar prevalence with an estimated 22 million women and 5.5 million men (50-84 years) with
bone loss and, if left untreated, these numbers will rise to 23% by 2030 (Hernlund, Svedbom et al.
2013). For the rest of the world, bone loss scenarios are similar. For example, in Asia a high
prevalence for osteopenia and osteoporosis exists and these are conservative estimates considering
that bone loss is highly undiagnosed in most Asian countries until a fracture occurs and, even if
this happens, many fractures are treated conservatively at home rather than in hospitals (Siris,
Adler et al. 2014).
The increased prevalence of bone loss is also rapidly increasing the risk of its lifethreatening consequence— fractures. Nearly 8.9 million annual fractures are reported worldwide,
accounting for one fracture every three seconds. Fracture rate is higher in women than men with
one in three women and one in five men over age 50 experiencing a fracture. Overall 61% of
osteoporotic fractures occur in women and most occur in the humerus, hip and spine (Johnell and
Kanis 2006, Sale, Beaton et al. 2014). In the US, the annual fracture rate is 1.5 to 2 million per
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year (Burge, Dawson‐Hughes et al. 2007) and the rate is expected to increase to 3 million by 2025.
Among all fractures, hip fractures are responsible for 8.4 to 36% mortality within a year of
incidence in the US. Only 40% of the population with hip fractures fully recover to their prefracture health following long-term care. Even though vertebral fractures are clinically silent at the
initial phase, they are the chief predictor of future fracture risk. For example, if one experiences a
vertebral fracture, then their risk for a subsequent vertebral fracture increases 5-fold. For a nonvertebral fracture, the risk increases 2- to 3-fold (Cosman, De Beur et al. 2014). Twice the number
of fractures arise in women with osteopenia. This is significant considering that women with
osteopenia represent almost 50% of the total population at risk (Pasco, Seeman et al. 2006) and
the prevalence of osteopenia is 3.4 times more than osteoporosis (Pfister, Welch et al. 2016).
Bone-related disorders also contribute to the global health burden in an indirect way
through back pain, height loss, spine deformity and disability (Cosman, De Beur et al. 2014).
Fracture is often accompanied by long-term chronic pain, greater disability, poor quality of life
(QOL) and early death. On a day-to-day basis, osteoporosis affects one’s physical state of health
such as chronic daily backache, a limited social life and loss of free movement (Brenneman,
Barrett‐Connor et al. 2006, Masaryková, Fulmeková et al. 2015). Besides these, morbidity and
mortality rates associated with osteoporotic fractures are increasing and posing huge economic and
social burdens. For example, the annual fracture-related treatment and post-treatment care expense
is $19 billion in the US, and €37 billion in the European Union (Johnell and Kanis 2006, Burge,
Dawson‐Hughes et al. 2007, Kanis, Odén et al. 2012, Hernlund, Svedbom et al. 2013, Maria and
Witt‐Enderby 2014). The projected annual total fracture cost across all fracture types for US
women is more than 18 billion by 2025, which is more than that of myocardial infarction, stroke
and breast cancer (Singer, Exuzides et al. 2015).
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1.3. Menopause and bone loss
The menopausal transition is characterized by irregular lengths of the menstrual cycle and
natural amenorrhea (absence of menstrual period) for at least one year accompanied by elevated
serum levels of follicle-stimulating hormone (FSH). Postmenopause refers to the period where
menstruation ceases permanently due to a complete loss of follicular activity in the ovary. Despite
being a natural physiological phenomenon, the menopausal transition is often accompanied by
debilitating consequences of osteopenia, osteoporosis and related fractures (Greendale, Sowers et
al. 2012, Finkelstein, Brockwell et al. 2013). In addition to age and gender, hormonal status affects
the steady diurnal rhythm of bone remodeling (Maria and Witt‐Enderby 2014). Low estrogen
levels as observed in postmenopause increases the life span of osteoclasts and stimulates loss of
connectivity between trabecular bone units. Increases in trabecular porosity leads to attenuated
bone strength, specifically in the vertebrae; this results in more vertebral fractures in women than
men (Seeman 2002, Seeman 2008).
Women begin to experience bone loss during late perimenopause, which continues even
after menopause. The annual rate of bone loss is typically slow and steady with a rate of ~ 0.4%,
which increases to 2 to 5% per year for the first 5 to 10 years following menopause (Riis, Hansen
et al. 1996). Total trabecular and cortical bone loss in women during the course of their lifetime is
about 50% and 30%, respectively, half of which occurs in the first 10 years of menopause
(Finkelstein, Brockwell et al. 2013). After the first 15 years of menopause, cortical bone loss
surpasses trabecular bone loss, resulting in fragility fractures (Zebaze, Ghasem-Zadeh et al. 2010).
Bone biopsies of normal postmenopausal women show an increase in the number of resorption
pits on the bone surface indicating an increase in bone resorption (Garnero, Sornay‐Rendu et al.
1996).
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Currently, about 30% of postmenopausal women in the western world are suffering from
osteoporosis and 40% of them have high risk of having one or more fractures in their lifetime
(Reginster and Burlet 2006). The US Preventive Services Task Forces recommends that all women
aged 65 years or older should undergo regular BMD screening. The International Society for
Clinical Densitometry recommends an earlier screening for women (age <65 years), who are at
high risk of developing fracture due to low body weight, prior fracture history or high-risk
medication intake; the screening age for men is usually 70 years or above (Lim, Hoeksema et al.
2009). Interestingly, a study involving 149,524 white postmenopausal women (mean age 64.5
years) estimates that 82% of new fractures occurs in women with low bone mass (osteopenia) after
one year (Siris, Chen et al. 2004). Similar outcomes were observed in a 5.6-year study with
postmenopausal women (Pasco, Seeman et al. 2006), suggesting that although osteoporosis is a
high risk stage for recurrent fractures in postmenopausal women, initial fractures mostly arise in
this cohort when they are osteopenic. All these factors necessitate the need of proper attention and
care for the osteopenic population as well as the osteoporotic population to minimize fracturerelated morbidity and mortality.
In addition to bone loss, more than 80% postmenopausal women suffer from numerous
physical and psychological symptoms with varying degrees of severity that disrupt their life. Major
menopause-related physical symptoms include hot flashes, night sweats, fatigue, sleep
disturbances, breast pain, palpitations, weight gain, urinary incontinence and vaginal dryness.
Psychological health disturbances result in the emergence of anxiety, stress and depression. In fact,
studies show that women experience at least one or more of these symptoms while transitioning
through menopause. The large multiethnic Study of Women’s Health Across the Nation (SWAN)
explained that all these changes collectively have a debilitating effect on the overall health-related
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quality of life in this cohort. Health-related quality of life (QOL) is a part of the broad,
multidimensional concept “Quality of life” that specifically measures how an individual’s life is
affected by changes in his/her health status based on following aspects: physical health and
performance, emotional activity, role limitations, and social functioning. The impact of menopause
on health-related QOL is an important outcome measure in health sectors to provide effective
treatment and care to the symptomatic postmenopausal women (Avis, Colvin et al. 2009,
Greenblum, Rowe et al. 2013).

1.4. Bone loss therapy—current and future perspectives
Most of the conventional pharmaceutical bone loss therapies are treatment-focused rather
than preventative, focusing primarily on attenuating further bone loss by inhibiting osteoclast
function. Although these antiresorptive therapies lower fracture rate by 30 to 50%, they do not
result in new bone formation or cortical microarchitecture improvement, which is essential during
late-stage osteoporosis to maintain bone health and prevent fragility fractures. Even though clinical
trials show increases in BMD with antiresorptives, this occurs by the secondary mineralization of
existing (but declined) bone tissue rather than through the formation of new healthy bone. For
instance, bisphosphonates (e.g. alendronate), which are the most effective first line bone loss
therapies prevent degeneration of cancellous bone and thinning of cortex by inhibiting bone
resorption; however, alendronate does not improve bone mass and microarchitecture. Bone
anabolism needs to be an integral part of new bone loss therapies to aid in restoring bone mass and
microarchitecture to protect mechanical integrity. A lack of bone-tropic properties in current
antiresorptives makes them less than ideal for improving bone quality, density and bone strength
(Boivin and Meunier 2002, Lyritis, Georgoulas et al. 2010, Iolascon, Frizzi et al. 2014).
Despite the ample availability of conventional osteoporosis drugs, an alarming rise in the
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prevalence of osteopenia-osteoporosis as well as the rate of fracture-related morbidity and
mortality are still being observed in the geriatric population (Reginster and Burlet 2006). The
reasons for this are not clear but probably associated with their adverse effects in the body and due
to a lack of compliance (Caro, Ishak et al. 2004). Bisphosphates remain in the bone remodeling
area for years even after discontinuation of the therapy due to their high affinity for calcium. This
long residence time in bone contributes to the occurrence of osteonecrosis of the jaw, atypical
femoral shaft fractures and hypocalcemia. The concept of a “three to five years bisphosphonate
drug holiday” has emerged to avoid these circumstances. Discontinuation of bisphosphonate
therapy, however, will halt these adverse effects, but will not prevent further bone loss and may,
in fact, accelerate bone loss (Watts and Diab 2010). Denosumab, a monoclonal RANKL inhibitor,
has been found to produce eczema and cellulitis in the FREEDOM (Fracture Reduction Evaluation
of Denosumab in Osteoporosis Every 6 Months) and HALT (Hormone Ablation Bone Loss Trial)
clinical trials, as well as osteonecrosis of the jaw and atypical femur fractures, result from its blood
calcium lowering effects (Scotland, Waugh et al. 2011, Diz, López-Cedrún et al. 2012). Hormone
therapy (HT) such as selective estrogen receptor modulators (SERMs) are popular among women
going through the menopausal transition due to their positive effects on menopausal symptoms
(e.g., vasomotor symptoms). However, awareness has risen towards the serious side-effects such
as mammary cancer, deep venous thrombosis and other cardiovascular events associated with
long-term use of HT (Grady, Ettinger et al. 2004, Baucom, Pizzorno et al. 2014). The only anabolic
therapy available in the market is teriparatide— a parathyroid hormone (PTH) analog. Because
long-term teriparatide treatment increases the incidence of rat osteosarcoma, its use is FDArestricted to two years (Vahle, Sato et al. 2002). These factors contribute to limited adherence and
poor compliance amongst those with diagnosed osteoporosis to the current antiresorptive

14

therapies. Particularly in postmenopausal women, where the relationship between compliance and
adherence to the therapy was measured by their medication possession ratio, low compliance
caused a 17% increase in fracture rate, a 37% increase in the risk of hospitalization and associated
cost of medical services. Bisphosphonate studies show that among the osteoporotic women aged
45 years or older, only 50% new users were compliant after first three months, which dropped to
30% after one year and 16% after three years (Warriner and Curtis 2009, Silverman and Gold
2010, Genuis and Bouchard 2012).
For those individuals with osteopenia, the pharmacological treatment regimen is typically
delayed or given “watchful waiting” until the transition to osteoporosis is diagnosed (T-score less
than -2.5 at the femoral neck/spine). Interventions may also occur if the individual with osteopenia
has a history of having a previous hip or vertebral fracture; or when the T score is between -1.0
and -2.5 at the femoral neck/spine and the 10-year risk of hip fracture ≥ 3%; or the 10-year risk of
major osteoporosis-related fracture ≥ 20% by Fracture Risk Assessment Tool (FRAX®) calculation
(Watts, Lewiecki et al. 2008). The osteopenic phase of bone loss consists mostly of unawareness,
no treatment or a non-pharmacological self-care approach through diet, exercise and micronutrient
supplementation. The non-pharmacologic treatment guidelines for osteopenia and osteoporosis
routinely recommend calcium and vitamin D supplementation as a prevention; however, neither
alone has proven to have any significant effect for reducing the incidence of fractures or preventing
osteoporosis; and taking the combination of calcium plus D only slightly reduces the risk of hip
and other fractures (Avenell, Mak et al. 2014, Bolland, Leung et al. 2015). A diagnosis of
osteopenia is important considering the fact that a majority of osteopenic individuals will develop
osteoporosis within 10 years (Kanis and Organization 2008). Osteopenia often carries a significant
treatment uncertainty during the time of the greatest fracture risk burden (Pfister, Welch et al.
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2016). Therefore, the current treatment approach to osteopenia as compared to osteoporosis could
be analogous to the progression and treatment options of prediabetes as compared to diabetes,
considering the similar risk factors between two phases of each disease. Interventions at this stage
focusing on bone anabolism would be a critical first step for maintaining normal bone integrity
and to prevent future fractures (Lyritis, Georgoulas et al. 2010). Thus, novel and safe bone loss
therapies targeting the function of both osteoclasts and osteoblasts to minimize bone loss and
advance bone growth without producing adverse effects is warranted.

1.5. Research objective
The “silent” disease osteopenia and subsequent osteoporosis are creating a loud impact in
terms of morbidity, mortality and greater economic burden in the life of postmenopausal women.
In addition to bone loss, their transitioning through several menopausal and psychological changes
as well as the side effects and treatment costs associated with current therapies tallying to their
suffering and thus worsening their health-related QOL and reducing compliance rate. Therefore,
an ideal bone therapy that is efficacious with high compliance for postmenopausal cohort should
satisfy both the objective health outcome (e.g., improves bone growth) and subjective health
outcome (e.g., improves compliance). These observations lend support for the development of a
safe alternative to current therapies to ensure maximum bone health improvement with minimum
side effects.
The objective of this study entitled Melatonin-micronutrients Osteopenia Treatment Study
(MOTS) was to develop a safe and effective bone loss therapy for the osteopenic population.
Interventions given at this stage of bone loss are expected to not only stop bone loss but also enrich
new bone growth and improve overall QOL to prevent its progression to osteoporosis and
fractures. In pursuit of study goal, a unique combination of natural bone tropic agents— melatonin,
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strontium citrate, vitamin K2 and vitamin D3 was developed and referred to as “MSDK”. The
MOTS investigated if MSDK could improve bone density and bone turnover and health-related
QOL in postmenopausal women and if this was due to MSDK-mediated modulation of the bone
remodeling process.

1.6. Effects of melatonin, strontium citrate, vitamin D3 and vitamin K2 on bone
1.6.1. Melatonin
Melatonin, the first compound of interest in this therapy, is the endogenous chronobiotic
molecule that is synthesized and secreted during the hours of darkness from the pineal gland.
Melatonin is well known for its effects on sleep; however, supplementation with melatonin also
produces favorable effects on bone including increasing bone density and reversing bone loss in
models of osteoporosis as reviewed (Maria and Witt‐Enderby 2014). Melatonin synchronizes
circadian rhythms in bone metabolism, in part, and favors bone growth when present at a higher
level (Witt‐Enderby, Radio et al. 2006, Maria and Witt‐Enderby 2014). This is yet another
important mechanism of melatonin’s considering that decreased nocturnal melatonin levels due to
aging, light exposure at night or poor sleep quality increases the risk of bone loss and related
fractures (Sandyk and Awerbuch 1992, Cardinali, Ladizesky et al. 2003, Ostrowska, Kos-Kudla
et al. 2003, Feskanich, Hankinson et al. 2009, Witt‐Enderby, Slater et al. 2012, Maria and WittEnderby 2017). Melatonin has been shown clinically in the Melatonin Osteoporosis Prevention
Study (MOPS; NCT01152580) to renormalize osteoclast:osteoblast ratios (NTx: Osteocalcin)
back to equilibrium and improve the physical symptoms of menopause in healthy perimenopausal
women; this occurred following a nightly intake of 3 mg melatonin for six months (Kotlarczyk,
Lassila et al. 2012). The MOPS was a double-blind randomized placebo-controlled trial (RCT)
involving 18 perimenopausal women (ages 45-54) with a T-score > -2.0. In a follow-up study of
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the MOPS using a therapeutically equivalent concentration of melatonin, it was shown that
melatonin (50nM) given for 21 days to human mesenchymal stem cells (hMSCs) and peripheral
blood monocytes (hPBMCs) grown as co-cultures induces osteoblast differentiation. The effect of
melatonin on osteoclast differentiation is dependent upon the type of co-culture—layered or
transwell where melatonin inhibits osteoclast differentiation in the layered co-culture (when
hMSCs and hPBMCs were in contact with one another) and is without effect in the transwell coculture (when hMSCs communicated with hPBMCs via paracrine effects) (Maria, Samsonraj et
al. 2017). The Treatment of Osteopenia with Melatonin study (MelaOst), which was another
double-blind placebo-controlled RCT involving 81 postmenopausal women with osteopenia (ages
56-73), demonstrates that one-year nightly dosing with melatonin (1mg, 3mg) increases femoral
neck BMD compared to placebo. This study also demonstrates that urinary calcium excretion
decreases in women taking melatonin as compared to those taking placebo suggesting that the bone
density increases were due, in part, to melatonin-mediated increases in bone mineralization.
Melatonin is shown to benefit metabolic conditions in this cohort as a decrease in total fat mass
and a trend towards an increase in lean body mass occurs in women taking melatonin but not
placebo (Amstrup, Sikjaer et al. 2015, Amstrup, Sikjaer et al. 2015). This important clinical finding
served as the rationale as to why the metabolic proteins, peroxisome proliferator-activated receptor
gamma (PPAR), glucose transporter type 4 (GLUT4) and beta subunit of insulin receptor (IRβ),
were assessed in the co-culture model because melatonin may induce osteoblastogenesis by
regulating the fate of the mesenchymal stem cell from adipogenesis to osteogenesis as recently
reported (Maria, Samsonraj et al. 2017).
The outcomes from the two clinical studies, MOPS and MelaOst, are supported by myriad
preclinical and in vitro models, which revealed melatonin’s inducing effects on osteoblastogenesis;
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inhibitory effects on osteoclastogenesis; and inducing effects on bone formation (Maria and Witt‐
Enderby 2014). Melatonin promotes osteoblastogenesis by enhancing the differentiation of
mesenchymal stem cells (hMSCs) and pre-osteoblasts into osteoblasts (Radio, Doctor et al. 2006,
Zaminy, Ragerdi Kashani et al. 2008, Sethi, Radio et al. 2010, Zhang, Su et al. 2010, Park, Kang
et al. 2011). Melatonin stimulates osteoblast proliferation (Nakade, Koyama et al. 1999, Satomura,
Tobiume et al. 2007); and suppresses osteoclastogenesis and bone resorption (Koyama, Nakade et
al. 2002, Suzuki and Hattori 2002) in vitro. These data correlate with in vivo findings from our lab
where exogenous melatonin intake for one year increases bone density in an intact female mouse
model similar to that induced by HT (Witt‐Enderby, Slater et al. 2012). Melatonin linked to
calcium aluminate scaffolds also induces bone regeneration in ovariectomized (estrogen-depleted)
female rats (Clafshenkel, Rutkowski et al. 2012) and augments the bone-forming effects of
estradiol in ovariectomized female rats (Ladizesky, Boggio et al. 2003). Because these models
mimic the postmenopausal condition where levels of both estrogen and melatonin decline suggests
that restoration of nocturnal melatonin peaks with exogenous melatonin may help to offset the
bone loss that also occurs during this time in a woman’s life as reviewed (Witt‐Enderby, Radio et
al. 2006).
Besides producing direct effects on bone density, melatonin shows favorable effects on the
physical symptoms of menopause (such as vasomotor symptoms and bloating) in the MOPS cohort
(Kotlarczyk, Lassila et al. 2012). Further assessments of the MOPS daily diary logs also reveal
that melatonin improves subject-reported mood and sleep quality in this cohort (Maria, Samsonraj
et al. 2017) and also improves depression, anxiety and stress (Bellipanni, Bianchi et al. 2001,
Haridas, Kumar et al. 2013, Hansen, Andersen et al. 2014, Sun, Wang et al. 2017, Zhang, Guo et
al. 2017). Psychological health plays a prominent role in maintaining bone health. For example,
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depression is found to significantly correlate with lower BMD in the lumbar spine and femur and
high cortisol levels in postmenopausal women (Furlan, Ten Have et al. 2005). Sleep deficiency
due to shift work (Feskanich, Hankinson et al. 2009, Quevedo and Zuniga 2010, Kim, Choi et al.
2013, Wang, Wu et al. 2015) or stress produces adverse effects on bone and these may be attributed
to their effects on melatonin levels; because shift work and stress have been shown to decrease
melatonin levels as reviewed (Maria and Witt-Enderby 2017). All these findings coupled with its
relative safety in aging population (Witt‐Enderby, Radio et al. 2006, Maria and Witt‐Enderby
2014) makes melatonin an important component of MSDK to improve not only bone health, but
also QOL and compliance associated with it.
1.6.2. Strontium
Strontium is the 15th most abundant alkaline earth metal named after the Scottish village
Strontian where it was first discovered (Murray 1993). The adult body burden of strontium is about
0.3–0.4 g, with 99% found in the skeleton as bone or teeth (Cabrera, Schrooten et al. 1999).
Strontium is available as ranelate, citrate, chloride, carbonate or lactate. Among them, strontium
ranelate is an approved therapy for osteoporosis treatment in Europe and Australia. In the US,
strontium citrate is the FDA-approved bone support supplement. It is available over-the-counter
with a typical 680mg recommended dosage as compared to the 2g therapeutic dose for strontium
ranelate (Hernlund, Svedbom et al. 2013).
Numerous clinical studies have shown beneficial effects of elemental strontium on bone
health in the postmenopausal osteopenic and osteoporotic population, specifically on vertebral and
femoral bone density and vertebral and non-vertebral fracture risk (Meunier, Roux et al. 2004,
Reginster, Seeman et al. 2005, Malaise, Bruyere et al. 2007). The therapeutic efficacy of strontium
ranelate in postmenopausal osteoporosis was established following two major clinical trials:
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Treatment of Peripheral Osteoporosis (TROPOS) and Spinal Osteoporosis Therapeutic
Intervention (SOTI), respectively. SOTI was a phase III double-blind placebo-controlled RCT,
which included 1649 postmenopausal women (mean age 70) with osteoporosis and at least one
vertebral fracture. This cohort received 2gm of strontium ranelate or placebo orally daily for one
to three years. In this study, strontium ranelate increases lumbar spine and femoral neck BMD by
12.7% and 7.2%, respectively, after one year; which increases up to 14.4% and 8.3%, respectively,
after three years compared to placebo (Meunier, Roux et al. 2004). TROPOS was another doubleblind placebo-controlled RCT involving 5091 postmenopausal women with osteoporosis (age
>70). In this study, strontium ranelate (2gm/day) increases femoral neck and total hip BMD by
8.2% and 9.8%, respectively after three years vs. placebo (Reginster, Seeman et al. 2005). A posthoc analysis performed on 1428 postmenopausal osteopenic women chosen from the SOTI and
TROPOS cohort (based on having osteopenia at a non-osteoporotic site at baseline) reveals that
strontium ranelate renormalizes spine and hip BMD at a progressive level after one, two and three
years of treatment and is well-tolerated in this population (Malaise, Bruyere et al. 2007). Strontium
incorporates mostly in newly formed mineralized bone structures without replacing calcium from
the existing bones; this is to maintain secondary mineralization at a normal level. This is supported
by the analysis of bone biopsies in postmenopausal women treated chronically with strontium
ranelate, which demonstrates that strontium preserves bone microarchitecture and quality by
preserving bone mineralization (density and heterogeneity at tissue level). These findings further
support a role for strontium at reducing fracture risk (Ammann, Badoud et al. 2007, Li, Paris et al.
2010, Doublier, Farlay et al. 2011).
Despite being available as an over-the-counter supplement for bone health, the underlying
mechanism of strontium citrate on bone health has yet to be determined. To our knowledge, the
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MOTS is one of the first trials to evaluate the efficacy and safety of strontium citrate in treating
postmenopausal osteopenia when used in a combination with melatonin, vitamin D3 and vitamin
K2. Out of the very few studies available on strontium citrate, one significant study worth
mentioning is the Combination of Micronutrients for Bone (COMB) study. The COMB assessed
the efficacy of a one-year treatment with strontium citrate (680mg), vitamin D3 (2000IU) and
vitamin K2 (100mcg) on bone density in 77 participants; 72 of the 77 were females of which 56
were postmenopausal and 5 of the 77 were males (Genuis and Bouchard 2012). Although the
citrate form slightly differs from the ranelate in terms of their chemical structure, the efficacy of
strontium citrate in improving BMD is equal to that of strontium ranelate (Genuis and Bouchard
2012), probably because strontium is equally delivered to bone regardless of the analogues (Wohl,
Chettle et al. 2013). However, strontium citrate is associated with less side effects (Genuis and
Bouchard 2012).
In vitro and preclinical studies have also supported the clinical data by demonstrating that
strontium maintains skeletal morphology and bone remodeling via multiple mechanisms (Figure
3). Strontium stimulates osteoblast growth, maturation, function and survival (Atkins, Welldon et
al. 2009, Fromigué, Haÿ et al. 2009, Peng, Zhou et al. 2009, Saidak, Haÿ et al. 2012, Querido and
Farina 2013, Almeida, Nani et al. 2016) and inhibits osteoclastogenesis (Bonnelye, Chabadel et
al. 2008, Yamaguchi and Weitzmann 2012). Strontium induces vertebral bone mass in intact
female mice with no deleterious effect on bone mineralization (Delannoy, Bazot et al. 2002). It
attenuates loss of trabecular bone, conserves bone strength and microarchitecture while facilitating
the fracture healing process in ovariectomized rats (Bain, Jerome et al. 2009, Thormann, Ray et
al. 2013).
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1.6.3. Vitamin D3
Vitamin D, also known as the “sunshine vitamin”, has been recognized as an essential
nutrient for bone health since 1930 (Wacker and Holick 2013). Adequate levels of vitamin D3
(cholecalciferol) are critical for increasing the intestinal absorption of calcium from 10% to 3040% (Kidd 2010). Also, an attenuation of bone loss in the hip is observed with a minimum daily
dose of 1000 IU vitamin D3 in postmenopausal women (Macdonald, Wood et al. 2013). Apart
from vitamin D3’s action on the calcium absorption, it performs a dual mode of action on bone
favoring both osteogenesis (Anderson, Lam et al. 2013, Chen, Dosier et al. 2013, Yang, Atkins et
al. 2013) and bone resorption (Bar-Shavit, Teitelbaum et al. 1983, Kitazawa, Kajimoto et al. 2003,
Kogawa, Findlay et al. 2010, Anderson, Lam et al. 2013) (Figure 3)
1.6.4. Vitamin K2
Vitamin K2 (menaquinone 7; MK7) is the approved dietary supplement for osteoporosis in
Japan for its efficacy in carboxylating osteocalcin, a crucial biomarker of bone matrix formation.
Carboxylation of osteocalcin decreases osteoclast activity and so, during the bone remodeling
process, carboxylated osteocalcin will remain in the bone under bone resorption is required where
it will then be decarboxylated to activate osteoclasts (Lacombe and Ferron 2015). A majority of
the observational studies found correlations between low vitamin K2 intake, low bone mass and
increases in the risk of fracture (Frandsen and Gordeladze 2017). In healthy postmenopausal
women, vitamin K2 (MK7) intake at a dose of 180 mcg/day for three years significantly induces
serum levels of vitamin K and attenuates age-related decreases in lumbar spine and femoral neck
BMD. Vitamin K2 supplementation also improves bone strength and prevents loss of vertebral
height at the lower thoracic region of vertebrae (Knapen, Drummen et al. 2013). Other studies in
postmenopausal women demonstrate that vitamin K2 (MK7, 375mcg per day for one year) reverses
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osteopenia and improves bone microarchitecture (Rønn, Harsløf et al. 2016). The mechanisms
underlying vitamin K2’s effects on bone appear to target bone microarchitecture and bone tissue
quality by improving cortical thickness, trabecular number and connectivity (Ammann, Badoud et
al. 2007, Iolascon, Frizzi et al. 2014) and by increasing collagen production (Sato 2014). In vitro
studies demonstrate stimulatory effects of MK7 on osteoblastogenesis and suppressive effects on
osteoclastogenesis (Yamaguchi, Sugimoto et al. 2001, Katsuyama, Otsuki et al. 2005, Atkins,
Welldon et al. 2009, Yamaguchi and Weitzmann 2011) (Figure 3).
Although, the MK7 analogue of vitamin K2 is relatively less studied than the MK4
(menaquinone 4) analogue, the MOTS used MK7 due to its longer half-life in the circulation, its
better bioavailability than MK4 and its relative safety when used as a dietary supplement (Sato
2014, Marles, Roe et al. 2017). This supports our contention that a lower dose of MK7 (60 mcg)
will lead to greater K2 accumulation in extrahepatic tissues compared to MK4 where higher doses
would be required to achieve the same effect (Sato, Schurgers et al. 2012).

1.7. Rationale for choosing melatonin, strontium citrate, vitamin D3 and K2 (MSDK)
Combination therapies have demonstrated a greater benefit to preserving bone versus
monotherapies since each drug targets a different mechanism (Figure 3). Clinically, this is also
supported. For example, combination of vitamin D3 and K2 increases vertebral bone density in
postmenopausal women with osteopenia and osteoporosis compared to each alone (Ushiroyama,
Ikeda et al. 2002). Also, a recent study demonstrates that severe deficiency in vitamins D3 and K2
are associated with femoral fracture; these findings imply that adequate supplementation with both
of these vitamins is essential when treating patients with osteopenia and osteoporosis (Franke
2017). Improved vitamin D3 status in postmenopausal women also significantly enhances BMD in
response to strontium ranelate, particularly in the femoral neck (Catalano, Morabito et al. 2015).
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The effects of elemental strontium as well as other micronutrients (vitamin D3 and K2) on bone
health in postmenopausal cohort are more pronounced when used in combination. This is
demonstrated in the COMB study where a majority (81%) of the postmenopausal cohort with
osteopenia or osteoporosis show an increase in BMD in the femoral neck (4%), total hip (3%) and
spine (6%). In fact, this supplementation is found as effective as bisphosphonates and strontium
ranelate at increasing BMD in a postmenopausal population (Genuis and Bouchard 2012).
Although the micronutrients used in the COMB study successfully improves bone density,
37 out of 114 participants (32.45%) either were non-compliant or did not complete the intervention
(Genuis and Bouchard 2012). Compliance is a critical factor in developing long-term therapies as
low compliance limits adherence and severely hampers the effectiveness of the therapy. Unique to
the MOTS was the inclusion of melatonin, which is known for its soporific effects and positive
effects on menopause-related physical symptoms, mood and sleep quality (Kotlarczyk, Lassila et
al. 2012, Maria, Samsonraj et al. 2017). In the MelaOst trial, melatonin increases BMD, decreases
total fat mass and shows trend towards an improvement in sleep especially in those with poor sleep
as measured by a Pittsburgh Sleep Quality Index (PSQI) score greater than 5 (Amstrup, Sikjaer et
al. 2015, Amstrup, Sikjaer et al. 2015, Amstrup, Sikjaer et al. 2015). Because melatonin improves
both objective and subjective measures—all of which could improve bone health—melatonin was
added in combination with a lower dose of strontium citrate (450mg), vitamin K2 (60 mcg) and
vitamin D3 (2000 IU) to enhance bone density and improve compliance. Melatonin was also given
at night to supplement the nocturnal surge in melatonin which was based on past studies
demonstrating that factors that inhibit melatonin production at night, for example, light exposure
at night, pinealectomy (Ostrowska, Kos-Kudla et al. 2003) and shift work (Feskanich, Hankinson
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et al. 2009) reduce BMD and increase the risk of fractures (Feskanich, Hankinson et al. 2009,
Quevedo and Zuniga 2010, Kim, Choi et al. 2013).
The MOTS used four drugs (MSDK) combined in a unique formulation using specific
dosages of each melatonin (5mg), strontium citrate (450mg), vitamin D3 (2000IU) and vitamin K2
(60mcg) and timed for intake at night to achieve maximal therapeutic efficacy and to minimize
adverse effects. The 60mcg dose of vitamin K2 was expected to minimize any possible risk of
blood coagulation although no such adverse effects are reported in clinical studies using MK7 at a
higher dose and for a longer time (Kanellakis, Moschonis et al. 2012, Knapen, Drummen et al.
2013). Unlike the COMB study, the MOTS also targeted the more fracture-prone stage of bone
loss—osteopenia. Moreover, these compounds of MSDK share common signaling pathways
involved in osteoblastogenesis, osteoclastogenesis and bone mineralization (Figure 3).
As shown in Figure 3, melatonin induces the expression of RUNX2, the master regulator
of osteoblastogenesis and TGF-ß, BMP and/or Wnt/ß-catenin (Maria and Witt‐Enderby 2014).
Melatonin, like strontium, can also govern the lineage allocation of mesenchymal stem cells from
adipocytes to osteoblasts through the MAPKs— MEK1/2 and MEK5 and through the metabolic
proteins— PPARγ and GLUT4 (Maria, Samsonraj et al. 2017). Strontium works through the
calcium sensing receptor in osteoblasts via activation of MAPK-ERK1/2 and Wnt signaling,
leading to increased bone formation, decreased adipogenesis and increased bone mass in vivo
(Saidak and Marie 2012). Vitamin K2 produces osteoblast-inducing effects via TGF-ß and the
Wnt/ß-catenin pathway (Yamaguchi 2014). Both melatonin and strontium decrease RANKL in
osteoblast precursors resulting in an inhibition of osteoclast formation (Koyama, Nakade et al.
2002, Saidak and Marie 2012). For melatonin, these inhibitory effects on osteoclast differentiation
are dependent upon contact with osteoclasts (Maria, Samsonraj et al. 2017). Vitamin K2 also
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antagonizes RANKL-induced activation of the NFκB pathway, which is crucial for
osteoclastogenesis (Yamaguchi 2014). An exception to these compounds is vitamin D3, which
induces both osteoblast and osteoclast to balance bone remodeling and promote mineralization
(Anderson, Lam et al. 2013, Nahas-Neto, Cangussu et al. 2017).

Figure 3. Regulation of signaling pathways in osteoblast and osteoclast and bone remodeling
by melatonin (Mel), strontium (Sr), vitamins D3 and K2. Stimulation of MAPKs (ERK1/2, p38 or
JNK) pathways by melatonin and strontium, TGF-ß by melatonin and vitamin K2 and Wnt/ßcatenin pathways by melatonin, strontium and vitamin K2— all lead to increased expression of
osteogenic genes (RUNX2, BMP2, OSTERIX and OSTEOCALCIN) and subsequent osteoblast
differentiation and bone formation. RANKL, released from osteoblast progenitors, binds to RANK
on osteoclast precursors and recruits the adaptor protein, TRAF6. TRAF6 then activates multiple
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signaling cascades including: NFκB, Akt/PKB, mTOR and MAPKs (JNK, ERK, and p38)
resulting in osteoclast differentiation and bone resorption. Inhibition of RANKL by melatonin or
strontium inhibits osteoclastogenesis and bone resorption. Vitamin K2 specifically blocks the
NFκB pathway in osteoclasts and inhibits resorption. Vitamin D3 primarily enhances
mineralization by increasing calcium uptake. It also supports both bone formation and resorption
in an optimal way, aiding in balanced bone remodeling. Furthermore, strontium and vitamin K2
improve bone microarchitecture, aiding in bone quality. TGF= transforming growth factor,
MEK1/2= MAP kinase/ERK kinase, ERK1/2= extracellular signal-regulated kinase, JNK= c-Jun
N-terminal kinases, ALP= alkaline phosphatase, RUNX2= runt-related transcription factor 2,
BMP-2= bone morphogenetic protein 2, Wnt= wingless type, M-CSF= macrophage colonystimulating factor, c-Fms= colony-stimulating factor 1 receptor, RANKL= receptor activator of
NFκB ligand, RANK= receptor activator of NFκB, OPG= osteoprotegerin, TRAF6= TNF
receptor-associated factor, mTOR= mammalian target of rapamycin, Akt/ PKB= protein kinase B,
NFATc1= nuclear factor of activated t cells calcineurin-dependent 1, TRAP= tartrate-resistant acid
phosphatase, CTR= calcitonin receptor, GSK= glycogen synthase kinase, R-Smad= receptorregulated Smad, Co-Smad= common mediator Smad, OCN= osteocalcin. Figure adapted from
Maria et al 2014 (Maria and Witt‐Enderby 2014).

In addition to improving bone health outcomes in people, a recent budget impact analysis
determines that the introduction of melatonin into an osteoporosis treatment formulary may result
in a saving of $1.3 million in annual treatment costs (Bondi, Khairnar et al. 2015), thereby lowering
the economic burden associated with bone loss therapies. All these findings provide the rationale
for the testing of MSDK as a potential therapeutic candidate for postmenopausal osteopenia.
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1.8. Hypothesis
Combination therapy using melatonin, strontium citrate, vitamin D3 and vitamin K2 will
improve bone formation and prevent bone loss by increasing osteoblast activity, by reducing
osteoclast activity and by improving the overall health-related QOL in postmenopausal women
with osteopenia.

1.9. Specific aims
A translational research approach was taken using both clinical and in vitro
hMSCs/hPBMCs co-culture models to test the study hypothesis. The clinical component of this
translational research study involved the assessment of MSDK’s effect on bone health and QOL
in postmenopausal osteopenic women whereas the in vitro component of this study assessed the
molecular mechanisms underlying the clinical effects of MSDK therapy, particularly focusing on
its role in regulating the activity of osteoblasts and osteoclasts. The specific aims include:
1. Assess the effects of melatonin/strontium citrate/vitamin D3/vitamin K2 (MSDK) on bone
density, bone marker turnover and fracture risk in postmenopausal osteopenia.
2. Assess the effects of melatonin/strontium citrate/ vitamin D3/vitamin K2 (MSDK) on
menopause-specific quality of life, perceived stress, anxiety, depression and general
well-being in postmenopausal osteopenia.
3. Assess the effects of melatonin/strontium citrate/vitamin D3/vitamin K2 (MSDK) on
human bone cells (osteoblast and osteoclast) viability and activity in vitro in
hMSCs/hPBMCs co-cultures grown as transwell or layered.
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Chapter 2: MOTS clinical trial— Assessing the effects of melatonin, strontium
citrate, vitamin D3 and vitamin K2 (MSDK) on bone health (bone density, bone
markers turnover, fracture risk and health-related quality of life in postmenopausal
osteopenia
2.1. Materials and Methods
2.1.1. Recruitment and enrollment
The clinical component of this translational study was designed as a randomized doubleblind placebo-controlled one-year trial and referred to as “Melatonin-micronutrient Osteopenia
Treatment Study (MOTS)”. All study-related investigations were conducted in accordance with
the ethical standards and following the Declaration of Helsinki and national and international
guidelines. The clinical trial received IRB approval by the Duquesne University Institutional
Review Board on May 23, 2013 (IRB Grant protocol number 13-59) and was documented at the
clinicaltrials.gov on June 5, 2013 (Identification no.: NCT01870115) (see Appendix I).
Study subject recruitment was initiated soon after the study received IRB approval and the
MOTS was approved by clinicaltrials.gov. Strategies for recruiting participants included
publishing of study-related articles in neighborhood and city newspapers (e.g. South Hills
Almanac and Pittsburgh Post-Gazette) and in the Duquesne University’s DU Daily website,
advertising on Craigslist and posting of flyers around the Pittsburgh community. Samples of
materials used for recruitment are shown in Appendix II. During the phone interview, potential
participants were first informed in detail about the study expectations and procedures and then
were screened for their eligibility criteria.
Inclusion criteria included being postmenopausal with osteopenia (T-score between -1 to 2.5), willingness to participate in a 12-month study, willingness to take the therapy right before
30

bed, must not consume alcohol with the medication, willingness to undergo testing of bone
markers and other biochemical parameters before and after the drug therapies, and willingness to
provide a self-assessment on the quality of life throughout the program. Once all the inclusion
criteria were satisfied, subjects were screened further and eliminated based on our exclusion
criteria. Exclusion criteria primarily focused on eliminating the factors that might have any
positive or negative impact on bone health and quality of life or could interfere with the treatment
effects. Women who already developed osteoporosis (T-score less than -2.5), while being on
medication or not, were excluded because our study intent to examine the treatment effect on
osteopenia. Also, if bone deterioration proceeds towards an advanced stage of bone loss leading
to osteoporosis, established pharmacotherapy is required to avoid serious consequences such as
fracture. Other exclusion criteria included: women who developed osteopenia because of other
medical conditions such as hyperparathyroidism, metastatic bone disease, multiple myeloma or
chronic steroid use; and women who were recently taking any medications or treatment that could
potentially improve or deteriorate bone health and affect their quality of life. These included:
hormone therapy (HT), birth control pills, prescription medications for bone loss such as
bisphosphonates, sleep, depression or anxiety, ulcerative colitis or regulation of blood pressure;
and steroids used either recently or chronically for the past 6 months. Moreover, women with other
medical conditions such as uncontrolled hypertension, moderate or severe hepatic impairment,
severe sleep apnea, chronic obstructive pulmonary disease, and current use of tobacco were
excluded from the study. The rationale for choosing these criteria has been discussed further in the
Discussion.
Individuals who satisfied both the inclusion and exclusion criteria were invited to schedule
an initial visit with the study team at the Center for Pharmacy Care at Duquesne University. Prior
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to the visit, an information package was sent to their addresses. This package contained the consent
form in which all necessary study-related information were described (e.g., purpose of the study,
risks and benefits of joining the study, possible side effects of the medications, study
confidentiality and participant’s rights) along with the study team contact information. The
package also contained a welcome letter, directions and map to the Center for Pharmacy Care at
Duquesne University and a sheet containing frequently asked questions. The information packet
was sent beforehand to provide sufficient time for the potential participants to review the study
documents and to familiarize themselves with the overall study plan.
At the first visit, participants’ osteopenia was confirmed by their recent DXA report. Free
DXA scans were given to the potential participants who fulfilled all other eligibility criteria but
did not present a recent DXA report. Osteopenia was also verified by heel ultrasonography using
the Achilles Insight Ultrasonometer (GE Healthcare, USA) even though the heel ultrasonography
was only used to assess its validity against DXA. Blood pressure readings were taken from both
arms to ensure that participants had an average blood pressure between 140/90 and 100/60. Women
who fulfilled the bone density and blood pressure requirements were invited to enroll in the study.
Women who were excluded because of the DXA scores revealing osteoporosis (T-score <-2.5),
high blood pressure or any other serious medical issues were encouraged to contact their primary
care physician. Enrolled participants then completed a baseline intake form (Figure 4) detailing
basic demographic information and consumption of any prescription and nonprescription drugs
and/or supplements. An experienced registered nurse blinded to the group assignments performed
the study-related health assessments and blood draws. Participants were randomly assigned to the
MSDK or placebo groups based on a block randomization design (see section 2.1.2.) and were
then given an adequate supply of study capsules and diary pages for two months. Participants also
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were given necessary instructions about pill intake, diary pages and study-related appointments.
An initial visit form was prepared to crosscheck if all the procedures were performed correctly
(see Appendix III). After the interview, the form was completed by the study coordinator and
signed by the principal investigator.
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Figure 4. Baseline intake form
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Figure 4 (continued). Baseline intake form
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Figure 4 (continued). Baseline intake form
2.1.2. Randomization and treatment allocation
As determined by mixed model analysis and based on the means and standard deviations
obtained for the serum bone marker data from the MOPS (Kotlarczyk, Lassila et al. 2012), a
difference of 10% in T-scores (12 month-baseline; average of % increases in lumbar spine density)
would be necessary to achieve a statistically significant result. Thus, a sample size of 10 per group
would provide enough participants to detect a significant (i.e., 10%) change in lumbar bone density
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with 80% power, and an alpha of .05. Recruiting 12 per group factors in a 20% attrition rate. A
computer-generated block randomization scheme was designed to assign the recruited participants
(n=22) in either placebo (n=11) or MSDK (n=11) group. MSDK referred to the group receiving
the medication. The block randomization method was chosen to preserve the balance in sample
size between groups throughout the study period (Suresh 2011). In this process, participants were
recruited in small blocks in a way that randomly allocated half of the participants to placebo and
the other half to MSDK within each block. Random allocation was performed using a list of
numbers generated with the statistical software Microsoft Excel (version 2012). Since there were
only two treatment groups in our study (i.e. placebo and MSDK), a block size of 4 was utilized.
Both the study subjects and investigators were blinded to the group assignments ensuring a doubleblind structure and, upon enrollment, each participant received an identification number to
maintain anonymity. Study participants were unblinded only after the treatment interventions had
been completed and study data were analyzed. Since the MOTS followed a highly selective
inclusion and exclusion criteria to avoid any bias, it took nearly 21 months to achieve the optimum
number of participants. Allocation concealment was maintained among the participants and the
MOTS team throughout the entire study ensuring the validity of study outcome.
2.1.3. Treatment regimen
Treatment capsules, referred to as “MSDK” were formulated using 5 mg melatonin, 450
mg strontium citrate, 2000 IU vitamin D3 and 60μg vitamin K2 divided into two capsules.
Therefore, each capsule contained melatonin 2.5 mg / strontium citrate 225 mg / K2 (MK7) 30 mcg
/ D3 1000 IU). This dosage regimen was previously used by the naturopathy specialist Dr. Mark
Swanson, where it demonstrated therapeutic efficacy. Besides, this study intended to use the
compounds at a low therapeutic dose in the combination therapy MSDK to ensure safety while
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maintaining efficacy. Identical placebo capsules matching in size, shape and color contained plant
fiber. Study capsules were formulated and manufactured according to the principal investigators’
specifications and supplied by Pure Encapsulations, Inc. (Sudbury, MA, USA). Both MSDK and
placebo were supplied in identical pill bottles as shown in Figure 5. The groups were coded as A
and B and only the graduate student on the study team was unblinded to this coding procedure and
was responsible for delivering the pill bottles. Subjects were instructed to take two capsules by
mouth daily at night at their usual bedtime. Pill bottles contained a medication label (see Appendix
IV), where the dosing regimen, date of delivery and other necessary information about the study
were clearly described. In addition to the study pills, participants were allowed to take <1000 IU
of vitamin D3 and 600 mg of calcium daily for ethical reasons; however, the amount and duration
of their use were recorded by each participant through the daily diaries.

Figure 5. Study medications (MSDK and Placebo) in identical bottles
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2.1.4. Treatment follow-up
After the first visit, bimonthly visits (at months 2, 4, 6, 8, 10 and 12) were arranged at the
Center for Pharmacy Care at Duquesne University over a 12-month period. Study-related physical
examinations were performed by the same nurse co-investigator to avoid procedural variation.
Participants received a 2-month supply of medication and daily diaries at each visit to keep track
of their daily pill intake, sleep duration, physical activity and any other information about their
general well-being that the participant would feel was important to note. At visits 2-6, study
participants were asked to bring with them their pill bottles from the preceding two months to be
counted and the diary pages. Similar to initial visit form, month-specific visit forms were prepared
to keep track of all completed assessments and signed by the principal investigator. An
appointment card was given to each participant to carry with them during study visits so that it
could be updated with the next appointment date, even though the graduate student called each
participant to remind them about the visit at least a week prior to the appointment day. Usually the
bimonthly visits were short, around 15-20 minutes, except the ones held at months 6 and 12. These
two visits were long because blood samples were taken from the participants and participants were
asked to complete the psychological questionnaires. Treatment follow-up ensured that there was
no missing data for any participants. The study timeline is shown in Table 1.
2.1.5. Participants’ right and confidentiality of the study
Emphasis was placed on preserving the subject’s rights. For example, subjects could
withdraw from the study at any time without any obligation. Attrition from the MOTS was
minimized by having the study coordinator call each subject monthly to answer any questions or
concerns. Participants were also allowed to contact the study coordinator at any time. A clinician
in naturopathy, who was one of the co-investigators of this study, also reviewed the health record
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of each participant. Alongside the free health assessments and two DXA scans, participants were
also given a necessary compensation of $80 for their time to answer the questionnaires, for the
discomfort they experienced during the blood draws as well as to cover the costs for their
transportation.

Table 1: Experimental timeline of MOTS clinical trial

Participant confidentiality was highly preserved throughout the study and while publishing
the study data. A HIPAA compliant coding procedure was applied that provided for identification
coding on all data collection forms. Information gathered from the participants were only
accessible by the research team and were used for research purposes only. All written materials
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and consent forms were stored in a locked file cabinet in the principal investigator’s laboratory.
Only the participants’ responses but not their identity appeared in the statistical analysis as well as
in the published paper (Maria, Swanson et al. 2017). Following IRB instructions, all research
materials will be destroyed after 7 years following completion of the study.
2.1.6. Bone density measurement
Bone mineral density (BMD) was measured at baseline (month 0) and at month 12 in the
left femoral neck, total left hip and lumbar spine L1-L4 area via Dual-energy X-ray absorptiometry
(DXA). DXA is the most widely accepted and pain-free method for bone densitometry scanning
and gives the most accurate T-score reading (Imaging 2017). Participants were given necessary
instructions regarding where to go for their bone density assessments. DXA scans were performed
using Hologic bone densitometer (Weinstein imaging, PA, USA). Changes in BMD (g/cm2) from
baseline to month 12 were evaluated, compared between groups and reported as means ± S.E.M.
Participant’s calcaneus (heel) bone density T-scores were measured bimonthly using the
Achilles InSight Ultrasonometer (GE Healthcare, USA) to assess how this measurement correlated
with DXA. Achilles ultrasonography is a quick, comfortable and pain-free process in which the
participants were asked to place their non-dominant foot in between the two membranes of the
ultrasonometer. The membranes filled with warm water surrounding the foot and were then
subjected to ultrasound through the heel. Just prior to testing, the heel area was thoroughly wet
with ethanol spray to ensure proper signal transduction (Healthcare). The machine automatically
created a result sheet containing the T-scores for the ease of interpretation. Mean (± S.E.M.)
changes in heel T-score were calculated for each time point and compared within and between
groups.
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2.1.7. Fracture risk assessment
Fracture risk was assessed at months 0 and 12 using the FRAX®–a computer-generated
algorithm (http://www.shef.ac.uk/FRAX/). The FRAX® estimates the 10year probability of a
major osteoporotic fracture (clinical spine, forearm, hip or shoulder fracture) and a hip fracture in
men and women based on their current femoral neck bone density, body composition, previous
fractures, parental history of hip fracture and current risk factors (Kanis, McCloskey et al. 2010,
Kanis, Hans et al. 2011). A fracture assessment questionnaire (Figure 6) was prepared for
collecting information required to calculate FRAX® scores from participants and the scores were
calculated using the validated FRAX®- fracture risk assessment tool (Figure 7). Mean (± S.E.M.)
changes in fracture risk from month 0 to month 12 were calculated and compared between groups.
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Figure 6. Fracture risk (FRAX®) assessment questionnaire
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Figure 7. Fracture risk (FRAX®) assessment tool
2.1.8. Collection and storage of serum and urine samples
To assess bone turnover marker status (described in section 2.1.9. Biochemical assessments
and other hormones associated with bone health, participants’ serum samples were collected at
months 0, 6 and 12. Approximately 2mL of blood sample was taken via venous puncture using
BD Vacutainer® Safety-Lok blood collection set with a 23-gauge needle (BD, USA) and collected
in 8.5 mL BD Vacutainer® SSTTM Plus blood collection tubes (BD, USA). Blood collection was
performed by the registered nurse in the MOTS. Collected samples were allowed to clot for at least
30 min at room temperature. Serum was isolated by centrifugation (1200g for 25 min) and stored
at -20°C until the time of analysis. To maintain the integrity of the serum samples, small aliquots
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of each sample were frozen and stored. All samples were tested at the same time to minimize
analytical variation.
For the melatonin measurement, participants’ first morning urine were collected at the end
of the study (month 12). Participants were asked to collect all their urine samples between 10pm
and 6am the night preceding the day of their last visit and to freeze them. At their previous (month
10) visit, they were supplied two urine cups and ice packs to collect and store their urine and an
instruction sheet detailing how to collect, store and transport the sample to the Center for Pharmacy
Care.
2.1.9. Biochemical assessments
Bone markers. Bone marker turnover was assessed in serum sample at months 0, 6 and 12. Serum
bone formation markers, total procollagen type 1 amino-terminal propeptide (P1NP) and
osteocalcin (OC; both intact and N-terminal mid-fragments) were measured via sandwich enzyme
linked immunosorbent assay (ELISA) assay using the human total P1NP ELISA kit (CAT#
MBS2504819, Mybiosource, CA, USA) and osteocalcin (1-43/49) enzyme immunoassay assay kit
(CAT# 43-OSNHU-E01, ALPCO Diagnostic, NH, USA), respectively, according to the
manufacturer’s instructions. The serum bone resorption marker, collagen type I c-telopeptide
(CTx) was measured via sandwich ELISA assay using Human Cross-linked Carboxy-terminal
Telopeptide Of Type I Collagen (CTX-I) ELISA Kit (CAT# MBS700254, Mybiosource, CA,
USA) following kit instructions. In the sandwich ELISA assays, micro ELISA plates pre-coated
with an antibody specific to the desired bone marker (e.g. P1NP or OC or CTx) were used. When
serum samples were added to the plate, the bone marker present in the sample bound with that
specific antibody. Next, a biotinylated detection antibody, specific for the protein and AvidinHorseradish Peroxidase (HRP) enzyme conjugate, was added to the plate and incubated following
45

the removal of unbounded components from the plate via washing. The bone marker was
“sandwiched” between the two antibodies. Then substrate solution was added to initiate the
enzyme-substrate reaction. The absorbance (OD) was proportional to the concentration of the
desired bone marker present in the test sample. Absorbance readings of standards, controls and
test samples were measured spectrophotometrically at a wavelength of 450 nm using the Perkin
Elmer Victor 1420 Multilabel plate reader (Waltham, MA, USA). A standard curve was generated
from the OD values for each assay using the four-parameter logistic curve fit function.
Concentrations were then calculated from the generated standard curves using Workout 2.0
software (Waltham, MA, USA). Mean (± S.E.M.). Changes in the concentration of bone markers
P1NP (in pg/mL), OC (in ng/mL) and CTx (in ng/mL) were calculated for each time point and
compared within and between groups. Ratios of bone resorption to bone formation (i.e. CTx:P1NP
and CTx:OC) were calculated over time and compared within and between groups. All controls
contained within each of the kits were within normal ranges.
Melatonin. Participants’ nocturnal urinary melatonin levels were measured at month 12 to
investigate the therapeutic range of melatonin contained within MSDK required to attain an effect
on bone. Urinary melatonin levels (in ng/mL/hr) were calculated via sandwich ELISA using the
Melatonin-Sulfate Urine ELISA kit (CAT# RE54031, IBL International, Germany) per kit
instructions and then mean (± S.E.M.) concentrations were compared between groups.
Vitamin D3. Serum vitamin D3 levels were measured at months 0 and 12 by ELISA using the
25(OH) Vitamin D ELISA kit (CAT# ADI-900-215-0001, Enzo Life Science, NY, USA),
according to the manufacturer’s instructions. This kit offered a competitive ELISA assay which
detected the 25(OH) Vitamin D metabolite as an indicator for total Vitamin D concentration. Mean
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(± S.E.M.) concentrations of vitamin D3 (in ng/mL) were calculated for each time point and
compared between groups.
C-reactive protein (CRP). Serum CRP levels were measured at months 0 and 12 by sandwich
ELISA using the High sensitivity human C-reactive protein (hsCRP) ELISA kit (CAT#
EKD01009, Biomatik LLC., DE, USA), following kit instructions. Following the assessment of
absorbance (OD) values, mean (± S.E.M.) concentrations of CRP (in ng/mL) were calculated for
each time point and compared between groups.
2.1.10. Blood pressure and body composition
Participants’ blood pressure was measured at the initial visit (month 0) as a screening tool
for the inclusion criteria and then every two months until the end of the study to assess the effect
of MSDK on blood pressure. Systolic and diastolic blood pressure measurements were taken by
the MOTS nurse on three separate occasions from the right and left arms. Mean (± S.E.M.) blood
pressure readings at each time point were calculated and compared within and between groups. To
avoid experimental variation, the same blood pressure cuffs was used in all assessments.
To assess the effect of MSDK on body composition, morphometric analysis was carried
out at baseline (month 0) and at the end of the study (month 12) using TANITA body
composition analyzer (Model# TBF-215, IL, USA). Participants were asked to stand on the
analyzer and the machine automatically measure the participants’ height, weight, body mass index
(BMI), basal metabolic rate (BMR), fat percentage, fat mass (FM), lean body mass (FFM) and
total body water (TBW). Mean (± S.E.M.) changes in body composition from baseline to month
12 were calculated and compared within and between groups.
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2.1.11. Psychometric analyses
The effect of MSDK on subjective measures were assessed using four validated
questionnaires: Menopause Specific Quality of Life (MENQOL) (Lewis, Hilditch et al. 2005,
Hilditch, Lewis et al. 2008), Spielberger’s State-Trait Anxiety Inventory (STAI) (Spielberger,
Gorsuch et al. 1970, Yu and Ho 2010), Cohen’s Perceived Stress Scale (PSS) (Cohen, Kamarck et
al. 1983, Cohen 1988, Yu and Ho 2010) and the Center for Epidemiologic Studies Depression
(CES-D) (Radloff 1977). Questionnaires were administered to the study cohort at baseline and
then at months 6 and 12. A quiet and isolated environment was provided to the participants so that
they could fill out the questionnaires without any distraction. Participants were asked to complete
all questions so that there were no missing or incomplete data. Samples of psychometric
questionnaires are shown in Figures 8 and 9.
Menopausal quality of life: Menopause Specific Quality of Life (MENQOL) questionnaire
(Figure 8) is a widely used validated tool that measures self-perceived quality of life related to
menopausal health in middle aged women (Lewis, Hilditch et al. 2005, Hilditch, Lewis et al. 2008).
The concept of MENQOL relies on the fact that menopause brings a sudden change in a woman’s
life by producing symptoms that may disrupt her physical, emotional and social well-being.
MENQOL contains 32 menopausal symptoms- related items, which are sub-divided into four
domains: vasomotor (items no. 1-3), psychosocial (items no. 4-10), physical (items no. 11-26, 3032) and sexual (items no. 27-29). In the questioning process for MENQOL, participants first
identify if they have experienced a specific symptom (i.e. item) in the previous month by
answering “yes” or “no”. If they answer “no”, they then move to the next item. If they answer
“yes”, then they are further asked to rate the symptom on a scale of 0 to 6 based on how much they
were bothered by that item (0 means “not bothered” and 6 means “extremely bothered”).
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MENQOL scoring was performed according to the established guidelines (Lewis, Hilditch et al.
2005, Hilditch, Lewis et al. 2008). Briefly, the items were scored on a scale of 1 to 8—1
corresponded to answer “no”, 2 corresponded to answer “yes” but not bothered, and a score of 3
to 8 depending upon how bothered the women was by the item; a value to 8 corresponded to “yes”
with maximum botheration. Each domain was scored separately, and a high score indicates that
the item was bothersome to the participant. Mean (± S.E.M.) scores of MENQOL domains were
calculated for each time point and compared within and between groups.
Anxiety: Spielberger’s State-Trait Anxiety Inventory (STAI) is a widely used validated 40 item
questionnaire that assess the intensity of anxiety-related feelings (Spielberger, Gorsuch et al.
1970), and, more recently, may be helpful in detecting certain mental disorders such as depression
(Kvaal, Ulstein et al. 2005). The STAI questionnaire is sub-divided into two forms: form Y-1
measures state anxiety which refers to the short-term or transient level of anxiety (items no. 1-20)
and form Y-2 measures trait anxiety referring to the long-term or enduring level of anxiety (items
no. 21-40) (Spielberger, Gorsuch et al. 1970). Half of the items in each form indicate the presence
of anxiety symptoms and the other half indicates the absence of anxiety symptoms. Participants’
scores were rated on a scale of 1 to 4 depending on the intensity of anxiety; a high score indicates
more anxiety. For state form (Y-1), which measured how the participant was feeling at that
moment or felt at the recent past, a score of 1 corresponded to “not at all” whereas 4 corresponded
to “very much so”. For trait items (Y-2), which measured how the participant generally felt, the
response scale went from 1 to 4 (1= “almost never, 4= “almost always”). Items that indicated an
absence of anxiety were scored inversely. A total score ranging from 20-80 was obtained by
summing up the responses on all items (Spielberger, Gorsuch et al. 1970, Yu and Ho 2010). Mean
(± S.E.M.) scores of STAI were compared over time within and between groups.
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Stress: The Perceived Stress Scale (PSS) is another validated questionnaire (Figure 9) used to
predict the degree to which one perceives stressful life events (Cohen, Kamarck et al. 1983, Cohen
1988). The version utilized in this study had 10 questions measuring how often the participants
encountered psychological stress during the last month (i.e. “how often they felt that they were
unable to control any situation?”). There were some positive questions such as “how confidently
they overcame any situation in the last month?”(Cohen 1988). Participants were asked to rate the
stressful events based on a 5-point scale (0= “never” to 4= “very often”); a high score indicates
the presence of stress. Positive questions were scored inversely. Responses on all items were
summed up to obtain a total score ranging from 0 to 40 as described. (Cohen, Kamarck et al. 1983,
Yu and Ho 2010). Mean (± S.E.M.) scores of PSS were compared over time within and between
groups.
Depression: The Center of the Epidemiological Study of Depression Scale (CES-D) is a validated
20-item instrument that detects one’s current level of depressive symptoms including: depressed
mood, loss of appetite, feeling of guiltiness and failure, lack of hope and ambitions, and
forgetfulness in an adult community sample (Radloff 1977). Participants were asked to rate each
of these symptoms based on a 4-point scale depending on their frequency of occurrence (0 = “rarely
or none of the time or less than 1 day” and 3 = “most or all of the time: 5 to 7 days”). The severity
of the depressive state was measured based on their total scores ranging from 0 to 60 as described,
where the positive items were scored inversely (Radloff 1977, Yu and Ho 2010). Mean (± S.E.M.)
scores of CES-D were compared over time within and between groups.
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Figure 8. Menopause Specific Quality of Life (MENQOL) questionnaire
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Figure 8 (continued). Menopause Specific Quality of Life (MENQOL) questionnaire
MENQOL reprinted from Maturitas, 50(3), Lewis JE, Hilditch JR, Wong CJ, Further
psychometric property development of the Menopause-Specific Quality of Life
questionnaire and development of a modified version, MENQOL-Intervention
questionnaire, pp 209-221, copyright 2005, with permission from Elsevier.
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Figure 9. Perceived Stress Scale (PSS) questionnaire
PSS is available for free download from:
https://www.mindgarden.com/documents/PerceivedStressScale.pdf
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2.1.12. General well-being and treatment compliance as measured by daily diary
Participants’ feeling of well-being and compliance to the treatment were assessed using a
daily diary appropriate for the postmenopausal cohort (Error! Reference source not found.). The
diary utilized in this study was a modified version of the daily diary used in our previous MOPS
clinical trial (Kotlarczyk, Lassila et al. 2012). Participants were asked to record daily information
regarding their sleep duration and experience, use of any prescription and non-prescription
medications, exercise and general well-being. New diary pages were given to the participants at
their bimonthly visits after collecting the old diary pages. Comments written on the diary pages
were collated at the end of the study to see which themes emerged. In the MOTS, four categories
emerged that included comments made about sleep quality, general mood, GI symptoms and
general aches and pains (e.g. headache, ache in shoulder, ache in knees). Comments within each
category were then sub-stratified as positive, negative or neutral. Comments related to an
improvement in an existing physical condition or positive feelings were classified as positive;
whereas comments that indicated worsening of any condition, the emergence of a new health
problem, or negative (or sad) feelings were classified as negative. Comments that reflected
indifferent thoughts such as those made about their daily activities or weather, or that did not reveal
any health issue were classified as neutral. A study investigator blinded to the group assignments
coded the comments as neutral= 0, negative= -1 and positive= +1. These comments were then
summed up for each participant per group. Results for each category in each cohort (placebo and
MSDK) were reported as percent of total comments per type per category per cohort. For data
analyses, the positive and neutral comments made for each cohort (placebo vs. MSDK) were
combined as per category and then compared to the negative comments made under the same
category.
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Sleep duration was determined by averaging the number of hours each participant slept at
night. To assess if exercise had any confounding impact on participants’ bone health, exercise
intensity was determined according to the US Centers for Disease Control and Prevention (CDC)
guidelines (Medicine 2013). Based on the type and intensity of exercise, participants fell into four
different groups that were scored as: no exercise= 0; light exercise= 1; moderate exercise= 2; and
high intensity or vigorous exercise= 3. According to the CDC, examples of moderate intensity
exercise include brisk walking (3 miles per hour or faster, but not race-walking), water aerobics,
bicycling slower than 10 miles per hour, tennis (doubles), ballroom dancing, general gardening
etc. Examples of vigorous (high) intensity exercise include race walking (jogging or running),
swimming laps, tennis (singles), aerobic dancing, bicycling 10 miles per hour or faster, jumping
rope, heavy gardening (continuous digging or hoeing), hiking uphill or with a heavy backpack etc.
(Medicine 2013). Sleep hours and exercise scores were compared between study cohort (placebo
vs. MSDK) and reported as mean ± S.E.M. Use of multivitamins/herbal/OTC supplements were
also documented from their diary information and compared between groups. Other confounding
factors were also assessed from the diary log that included: safety, tolerability and compliance to
the treatment regimens. Compliance was also assessed at each visit through regular health
assessments by the MOTS nurse and by counting the number of pills remaining from the last study
visit.
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Figure 10. Daily diary
56

2.1.13. Statistical interpretations
To check if randomization was effective, a comparison of the baseline characteristics
between MSDK and placebo groups were performed using Student’s two-tailed t-test for
independent samples with Welch’s correction for unequal variances (continuous data) and Fishers
exact test (categorical data). Mean changes and percentage mean changes from baseline to month
12 in continuous variables were compared between treatment groups using Student’s one-tailed ttest for BMD measurements and Student’s two-tailed t-test for all other endpoints with Welch’s
correction. Longitudinal analyses were carried out for the continuous variables with repeated
measures (e.g. serum bone markers, vitamin D3 and CRP levels, questionnaires, blood pressure
and Achilles T-scores). Generalized linear mixed model (GLMM) approach was used to study the
groups, the times, and the interaction between groups and times. In this analysis, groups and times
were considered as fixed effects while subjects nested within the treatment groups were considered
random. Comparisons of the groups over time were studied using orthogonal contrast. Pearson
correlation was performed to analyze the correlation between age, melatonin, vitamin D3 and CRP
levels with the bone density, bone markers and morphometric changes. Dairy comments were
analyzed using two-tailed Fishers exact test for two categorical outcomes. All statistical testing
was carried out using JMP versions 12 (SAS Institute Inc., Cary, NC, USA) and GraphPad Prism
version 6 (GraphPad Software, San Diego, CA, USA) for Macintosh. Primary and secondary
endpoints were analyzed following the intention-to-treat (ITT) principle. Results were presented
as mean (± S.E.M.) with significance considered at p < 0.05.
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2.2. Results
2.2.1. Participant’s recruitment and enrollment
Nearly all recruitment strategies successfully generated interest among people from
different areas of Pittsburgh as well as its nearest cities. As shown in Figure 11. Responses to
recruitment strategies employed in the study (n=184), an article published in the Pittsburgh
Post-Gazette (PPG; see Appendix IIB) drew attention of nearly half of the women respondents.

Figure 11. Responses to recruitment strategies employed in the study (n=184)
The summary of participants’ screening and enrollment process is illustrated in Figure 12.
Flow diagram of study subjects’ recruitment and enrollment.. A total of 184 women responded
to our advertisements, of which 105 (57.1%) did not meet the inclusion and exclusion criteria.
Individuals were excluded due to having normal bone density T-score or not having a DXA scan
before (7.6%); being perimenopausal (2%); being osteoporotic with or without taking medications
(32.4%); or being osteopenic taking bisphosphonates or HT (7.6%). Other common reasons for
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exclusion included taking medications that would influence our outcome measures. These
included: use of blood pressure and cholesterol medications (25%) or medications for depression
or anxiety (17%). If the respondent had diseases such as ulcerative colitis, rheumatoid arthritis
(7.62%) or smoked (1%), then they were excluded as well. Among the 79 women invited to enroll
in the MOTS, 29 (37%) accepted our invitation and attended their initial appointment to the study
center, while another 50 individuals (63%) chose not to participate for their own reasons. These
reasons included: fear of being on placebo for one year (35%) or not being able to commit
bimonthly visits (25%). Fifteen women (31%) did not share their reasons for not participating in
the study and another 6 osteopenic women (12.2%) did not want to stop taking their bone loss
medications. At the initial visit and during the blood pressure screening, another 6 individuals were
excluded for having hypertension, which they were completely unaware. At the end of the
recruitment and screening process, 23 women were enrolled into the MOTS and randomized to
receive either placebo (n=11) or MSDK (n=12) via block randomization, as described previously.
One subject withdrew the day following enrollment and was not included in the overall analysis
because it had been determined that if a subject took <3 dosages of the medication, then they would
be replaced and not included in the analysis. Another two subjects withdrew (one from treatment
and one from placebo) at month 4 and month 6. They were included in the analysis following
intention-to-treat (ITT) principle. All women were self-identified as Caucasian.
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Figure 12. Flow diagram of study subjects’ recruitment and enrollment.
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2.2.2. Similar baseline characteristics between groups ensured efficient randomization
Our recruitment strategies resulted in a relatively healthy postmenopausal population
(other than having osteopenia) with an age range [58.6 yr. (49 -75)]. Their blood pressure and body
composition including height, weight, body mass index (BMI), basal metabolic rate (BMR), fat
mass (FM), fat percentage (Fat%), lean body mass (LBM) and total body water (TBW) are reported
in Table 2 and were normal for their age and physical status. The MOTS cohort had BMD and
FRAX scores representative of an osteopenic population with a moderate risk of fracture. Also,
both groups experienced almost an equal number of fractures. Each participant presented with
osteopenia in different parts of the body (e.g. lumbar spine, total hip and femoral neck); however,
these same regions are commonly affected as already discussed in the introduction. Although the
bone markers, vitamin D3 and CRP levels varied widely among subjects, these variations were
observed in both cohorts— placebo and MSDK. Psychological evaluation suggested that all
subjects had normal mental health with no significant anxiety, stress, depression or severe
menopause related symptoms. Nearly 87% subjects were taking either calcium/vitamin D3,
multivitamins and/or other dietary supplements. Almost all subjects were recognized as healthy
sleepers with an active lifestyle. Despite using a computer-generated block randomization scheme
for stratification, significant differences in serum CTx level and diastolic pressure were found
between MSDK and placebo groups, where baseline values for each were higher in the MSDK vs.
placebo. All other parameters did not differ between cohorts suggesting an overall and welladjusted randomization. Baseline characteristics of the cohort, both total and stratified are
illustrated in Table 2 and graphically represented as value per individuals at Figure 13.
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Table 2: Baseline characteristics of the study cohort un-stratified and stratified by treatment
(MSDK and placebo). n=11 per group and represented as mean ± S.E.M. (Range). BMI= body
mass index, BMR= basal metabolic rate, P1NP= total procollagen type 1 amino-terminal
propeptide, OC= osteocalcin, CTx= collagen type I c-telopeptide, MENQOL= menopause specific
quality of life, STAI= state and trait anxiety inventory, PSS= perceived stress scale, CES-D=
center for epidemiologic studies- depression. *p < 0.05 vs. placebo.
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Figure 13. Baseline characteristics of the study cohort stratified by treatment (MSDK and
Placebo). Each dot in the scatter plot represents the baseline parameters (age, blood pressure,
height, weight, body mass index, basal metabolic rate, fat mass and fat%) for placebo (open circle,
red) and treatment (closed circle, blue). *p ≤ 0.05 vs. placebo.
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Figure 13 (continued). Baseline characteristics of the study cohort stratified by treatment
(MSDK and Placebo). Each dot in the scatter plot represents the baseline parameters (lean body
mass, total body water, BMD, Achilles T-score, FRAX and P1NP) for placebo (open circle, red)
and treatment (closed circle, blue). *p ≤ 0.05 vs. placebo.
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Figure 13 (continued). Baseline characteristics of the study cohort stratified by treatment
(MSDK and Placebo). Each dot in the scatter plot represents the baseline parameters (bone
markers, vitamin D3, CRP, menopausal symptoms, anxiety, stress and depression) for placebo
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(open circle, red) and treatment (closed circle, blue). *p ≤ 0.05 vs. placebo.
2.2.3. MSDK improved bone health in postmenopausal women
To assess the effect of MSDK on bone health in MOTS cohort, three different parameters
of bone health were monitored over the course of the one-year study— BMD via DXA and heel
ultrasonography (Figure 14), fracture risk probability via FRAX (Figure 15) and serum bone
markers via ELISA (Figure 16).
MSDK increased bone density. As shown in Figure 14, the mean change in BMD (g/cm2) from
baseline to month 12 in the left femoral neck, total left hip, lumbar spine and heel, as revealed by
DXA scanning, increased in women taking MSDK. Specifically, in the femoral neck, women
taking MSDK had an average BMD change of +0.015 (2.2%), whereas participants in the placebo
group had an average BMD change of -0.023 (-3.6%) over one year. Data analysis showed
significant differences between groups (p = 0.021) (Figure 14). In the total left hip, the average
BMD change was +0.039 (5.03%) for women taking MSDK and +0.017 (2.2%) for placebo. Even
though analyses showed no significant difference in BMD between groups in this area, a trend (p
= 0.069) for an increase in total left hip BMD in the MSDK group was observed (Figure 14).
Women taking MSDK showed the most significant increase in BMD in the lumbar spine (L1-L4)
area (p < 0.001 vs. placebo) (Figure 14). Specifically, the mean BMD changes in lumbar spine for
MSDK was +0.035 (4.3%) and for placebo was -0.029 (-3.2%). Corresponding mean (± S.E.M)
changes in bone density T-scores following one-year of MSDK treatment are shown in Table 3
and their bone density T-scores are shown in Appendix V. Bimonthly investigation of heel bone
density T-scores revealed by Achilles ultrasonography showed high variability in T-scores within
groups and did not significantly differ between MSDK and placebo (Figure 14 and Table 3).
These findings suggest that this mode of bone measurement is relatively less reliable.
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Figure 14. Treatment effects on bone mineral density (BMD) in placebo and MSDK groups.
Bone mineral density (g/cm2) was assessed at baseline and month 12 via DXA. Each bar in the
column graph represents the mean (± S.E.M.) change in BMD (g/cm2) from baseline to month 12
in the (A) left femoral neck, (B) total left hip and (C) lumbar spine (L1-L4) area, respectively for
placebo (open bar) and MSDK (closed bars); n=11 per group. *p ≤ 0.05 and ***p ≤ 0.001 vs.
placebo, unpaired one tailed t-test with Welch’s correction. (D) Heel bone density T-score was
measured bi-monthly using Achilles ultrasonometer. Each point in the line graph represents the
mean (± S.E.M.) change in heel bone density T-scores at months 0, 2, 4, 6, 8, 10 and 12
respectively, for placebo (open circle, red) and MSDK (closed box, blue); n=11 per group.
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Longitudinal analysis for repeated measures using a generalized linear mixed model (GLMM)
approach, considering groups and times as fixed effects and subjects nested within the groups as
random.
MSDK decreased fracture risk probability. FRAX® assessment data, as shown in Figure 15A and
Table 3, indicated a significant and beneficial effect of MSDK treatment on the 10-year probability
of major osteoporotic fracture risks. Specifically, one-year MSDK treatment significantly reduced
the major vertebral and non-vertebral osteoporotic fracture risk by 6.48% from baseline compared
to the 10.82% increase in placebo (p = 0.008). A trend towards a decrease in hip fracture risk was
observed in women taking MSDK (p= 0.09 vs. placebo) (Figure 15B).

Figure 15. Treatment effects on fracture risk probability (FRAX) in placebo and MSDK groups.
Probability of (A) major osteoporotic and (B) hip fracture risks were measured via FRAX. Each
bar in the column graph represents the mean (± S.E.M.) change in FRAX scores from baseline to
month 12 for placebo (open bar) and MSDK (closed bars); n=11 per group. **p ≤ 0.01 vs. placebo,
unpaired two tailed t-test with Welch’s correction.
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MSDK decreased bone marker turnover. To identify potential mechanisms underlying MSDKmediated increases in bone density, serum bone formation markers, total procollagen type 1 aminoterminal propeptide (P1NP) and osteocalcin (OC) and the bone resorption marker, collagen type I
cross- linked telopeptide (CTx) were analyzed at baseline, month 6 and month 12 (Figure 16 and
Table 3). MSDK treatment significantly increased serum P1NP levels at month 6 (p = 0.023) and
month 12 (p = 0.004) compared to placebo (Figure 16A and Table 3). Serum P1NP levels varied
widely within each group, ranging from 2.75 to 48.14 pg/mL (average: 31.76 ± 4.75) in placebo
and 25.04 to 151.9 pg/mL (average: 66.62 ± 11.09) in MSDK at month 12. The analysis of P1NP
over time revealed that the mean increase in P1NP levels in the MSDK group occurred primarily
in the first six months of treatment (data shown in Appendix VIA). Serum osteocalcin (OC) levels
did not significantly differ between groups at any time point; however, a gradual decrease in OC
levels was observed in the placebo group, whereas levels remained steady in the MSDK group
(p=0.071 vs. placebo at month 12). At month 12, the average level of OC in women taking placebo
was 25.88 (± 2.5) ng/mL and 19.78 (± 1.21) ng/mL in women taking MSDK, respectively (Figure
16B and Table 3). Even though the serum bone resorption marker, CTx levels were significantly
higher in the MSDK group at baseline compared to placebo, it remained steady throughout the
study, suggesting that MSDK either had no intrinsic effects on CTx or the dose of MSDK was not
high enough to compensate for the higher baseline CTx levels in this group. Average CTx levels
at month 12 in women taking MSDK was 8.99 (± 1.01) ng/mL and in women taking placebo was
5.65 (± 0.42) ng/mL, respectively (Figure 16C and Table 3). The analysis of OC and CTx over
time are also portrayed graphically in Appendix VIB and C, respectively. Since osteoclast activity
is tightly coupled to osteoblast activity (Matsuo and Irie 2008), bone marker turnover was assessed
by calculating the ratio of bone resorption (CTx) to bone formation (P1NP or OC). Despite having
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higher baseline CTx level in the MSDK group (vs. placebo), the ratio of CTx:P1NP trended
towards a time-dependent decrease in women taking MSDK compared to the time-dependent
increase observed in women taking placebo (Figure 16). Although not significant, a similar trend
towards a time-dependent decrease in the ratio of CTx:OC was observed in women taking MSDK,
which was not observed in women taking placebo (Figure 16).

Figure 16. Treatment effects on serum bone markers turnover in placebo and MSDK groups.
Bone turnover markers were assessed at months 0, 6 and 12 using ELISA. Each point in the line
graph represents the mean (± S.E.M.) concentration of bone formation markers (A) total
procollagen type 1 amino-terminal propeptide (P1NP) and (B) osteocalcin (OC; both intact and Nterminal mid-fragments); and (C) bone resorption marker collagen type I c-telopeptide (CTx) at
months 0, 6, and 12, respectively for placebo (open circle, red) and MSDK (closed box, blue);
n=11 per group. Each point in the scatter plot represents the ratio of (D) CTx: P1NP and (E) CTx:
OC for each study subject, respectively at specific time point, where the solid line indicates the
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mean (± S.E.M.) for each group. *p ≤ 0.05 and **p ≤ 0.01 vs. placebo at similar time points.
Longitudinal analysis for repeated measures using a generalized linear mixed model (GLMM)
approach, considering groups and times as fixed effects and subjects nested within the groups as
random.
In summary, one-year supplementation with MSDK significantly increased bone density
in the left femoral neck and lumbar spine, with a trend towards an increase in the left total hip.
These increases in bone density were associated with a reduction in major osteoporotic fracture
risk probability. No such effect of MSDK on heel bone density T-score and hip fracture risk were
observed. MSDK treatment also showed a decrease in bone marker turnover (i.e. CTx:P1NP) over
the course of one year primarily through an increase in the bone formation marker, P1NP. Mean
(± S.E.M) changes of bone density T-score, FRAX score, and bone marker per group in one year
are stated in Table 3.
2.2.4. One-year MSDK supplementation increased nocturnal melatonin levels, but did not
change serum vitamin D3 levels in postmenopausal women
Figure 17A illustrates the nocturnal urinary melatonin sulfate level assessed at month 12.
Women taking MSDK had significantly higher levels of urinary melatonin-sulfate levels compared
to placebo (p= 0.0463). Urinary melatonin-sulfate levels in the placebo group ranged from 0.43 to
17.69 ng/mL/hr (average: 4.19 ± 1.83). Despite administering an equal nightly dose of melatonincontaining supplements for one year, participants in the MSDK group showed a wide variation in
their nighttime melatonin-sulfate levels ranging from 73.13 to 2883 ng/mL/hr (average: 586.4 ±
309.4). Melatonin levels were found to positively correlate with the annual changes in lumbar
spine BMD (p=0.029; correlation co-efficient, r= 0.487; R2= 0.24; 95% CI= 0.0566 to 0.7648),
supporting the requirement of daily melatonin for maintaining bone density.
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Participants’ serum vitamin D3 levels were assessed at month 0, 6 and 12 (Figure 17B).
Unlike melatonin, vitamin D3 levels did not differ between groups at baseline and over each time
point even though participants in either group could take an additional 1000IU of vitamin D3
supplement for ethical reasons. A wide variability in serum vitamin D3 levels occurred in both
groups ranging from 2.54 to 57.32 ng/mL (average: 20.19 ± 5.84) in MSDK and from 0.5 to 38.59
ng/mL (average: 13.71 ± 4.24) in placebo at month 12. Mean changes in vitamin D3 levels over a
year per group are shown in Table 3. Correlations between vitamin D3 levels and bone resorption
were performed since it was shown that low vitamin D3 levels are associated with high CTx levels
(Napoli, Strollo et al. 2014). Similar to past-published studies, serum D3 levels in MOTS
negatively correlated with the CTx levels (p=0.024; correlation co-efficient, r= -0.5011; R2= 0.25;
95% CI= -0.7723 to -0.0752).

Figure 17. Treatment effects on urinary nocturnal melatonin and serum vitamin D3 in placebo
and MSDK groups. (A) Nocturnal hourly melatonin secretion in urine was measured at month 12
via ELISA. Each point in the scatter plot represents an individual’s urine melatonin-sulfate level,
in placebo (open circle, red) and MSDK (closed circle, blue); (n=10 per group). Solid line indicates
mean (± S.E.M.) concentration per group. *p ≤ 0.05 vs. placebo at month 12; unpaired one-tailed
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t-test with Welch’s correction. (B) Serum levels of Vitamin D3 was measured at months 0, 6 and
12 via ELISA. Each point in the scatter plot represents the concentration for a single subject at a
specific time point, in placebo (open circle, red) and MSDK (closed circle, blue); (n=11 per group).
Solid line indicates mean (± S.E.M.) concentration per group. *p ≤ 0.05 vs. placebo at similar time
point; Longitudinal analysis for repeated measures using generalized linear mixed model (GLMM)
approach, considering groups and times as fixed effects and subjects nested within the groups as
random.
2.2.5. MSDK had possible declination effect on serum C-reactive protein (CRP)
The inflammatory marker, C-reactive protein (CRP), was measured in serum at months 0,
6 and 12 via ELISA. CRP levels varied widely within and between groups ranging from 124 to
1422 ng/mL (mean 573.1 ± 154.7) in MSDK and from 124.1 to 6023 ng/mL (mean 1513 ± 581.2)
in placebo at month 12. Mean changes in serum CRP levels over the course of the study per group
are shown in Table 3. As shown in Figure 18, serum CRP levels did not differ significantly within
or between groups; however, levels were lower in women taking MSDK at month 12— an effect
not seen in placebo. These findings may indicate a favorable effect of MSDK on inflammatory
status.
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Figure 18. Treatment effects on serum C-reactive protein (CRP) in placebo and MSDK groups.
Serum CRP levels were measured at months 0, 6 and 12 via ELISA. Each point in the scatter plot
represents the concentration for a single subject at a specific time point, in placebo (open circle,
red) and MSDK (closed circle, blue); n=11 per group. Solid line indicates mean (± S.E.M.)
concentration per group. *p ≤ 0.05 vs. placebo at similar time point; Longitudinal analysis for
repeated measures using generalized linear mixed model (GLMM) approach, considering groups
and times as fixed effects and subjects nested within the groups as random.
2.2.6. MSDK did not affect morphometric parameters and blood pressure, favoring bone
health in postmenopausal women
Morphometric changes from baseline (month 0) to month 12, as illustrated in Figure 19
and Table 3, revealed that MSDK treatment did not improve or worsen any of the parameters of
body composition. However, average height (cm) losses in the MSDK group were low (0.08)
compared to placebo (0.35 cm) (p= 0.38). Moreover, variance analysis via F-test showed that
participants in the MSDK group had less fluctuation in their weight change (F=4.248, DFn=10;
p= 0.032), BMI change (F=4.112, DFn=10; p= 0.036), BMR change (F=4.936, DFn=10; p= 0.019)
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and fat mass change (F=6.409, DFn=10; p= 0.007) from baseline to month 12 compared to placebo.
The lack of weight variation over time in women taking MSDK may produce favorable effects on
their bone mass (Labouesse, Gertz et al. 2014). An increase in lean body mass and total body water
may have occurred in response to MSDK, whereas an opposite trend was observed for placebo.
Mean changes in lean body mass in MSDK and placebo groups were 0.02 and -0.07, respectively.
Similarly, mean changes in total body water in MSDK and placebo groups were 0.02 and -0.07,
respectively.
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Figure 19. Treatment effects on body composition in placebo and MSDK groups. Body
compositions were measured at months 0 and 12 using TANITA body composition analyzer.
Each point in the scatter plot represents an individual’s change in a specific morphometric
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parameter; placebo (open circle, red) and MSDK (closed circle, blue); n=11 per group. Solid line
indicates mean (± S.E.M.) change per group from month 0 to month 12. *p ≤ 0.05, **p ≤ 0.01 and
***p ≤ 0.001 vs. placebo, unpaired two tailed t-test with Welch’s correction.
Bimonthly assessments of blood pressure, as shown in Figure 20, demonstrated that both
systolic and diastolic levels remained in the normal range throughout the study even though
baseline diastolic BP in the MSDK group was significantly higher compared to placebo. Mean (±
S.E.M) changes in blood pressure following one-year treatment can be found in Table 3.

Figure 20. Treatment effects on blood pressure in placebo and MSDK groups. Blood pressure
was measured bi-monthly. Each point in the line graph represents the mean (± S.E.M.) blood
pressure at a specific time point for placebo and MSDK (n=11 per group). (Systolic BP: solid line
graph; placebo= open circle, red; MSDK= closed circle, blue. Diastolic BP: break line graph;
placebo= open box, red; MSDK= close box, blue). *p ≤ 0.05 vs. placebo at similar time points.
Longitudinal analysis for repeated measures using a generalized linear mixed model (GLMM)
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approach, considering groups and times as fixed effects and subjects nested within the groups as
random.
2.2.7. MSDK had no worsening effect on psychometric parameters in postmenopausal
women
To determine if MSDK treatment impacted on our cohort’s menopausal quality of life, the
validated MENQOL-Intervention questionnaire was administered at baseline, month 6 and month
12. As illustrated in Figure 21(A-D), MSDK treatment showed no change in the vasomotor,
physical, psychosocial and sexual domain scores compared to placebo. However, MENQOL
scores in all domains were lower in both groups throughout the study suggesting that participation
in the MOTS produced positive effects. Interestingly, after six months of treatment, sexual domain
scores began to move in opposite directions for each group where a trend towards an improvement
was observed in women taking MSDK and a trend towards a worsening was observed in placebo
(Figure 21D). Participants’ serum vitamin D3 levels were found to positively correlate with their
MENQOL vasomotor domain scores (p=0.033; correlation co-efficient, r= 0.479; R2= 0.23; 95%
CI= 0.0459 to 0.7602). In addition, a negative correlation was observed between participants’ age
and annual changes in MENQOL psychosocial domain scores (p=0.014; correlation co-efficient,
r= -0.516; R2= 0.27; 95% CI= -0.7704 to -0.1213).
To determine if MSDK impacted on our cohort’s anxiety levels, the validated Spielberger’s
State-Trait Anxiety Inventory (STAI) questionnaire was administered at baseline, month 6 and
month 12. Analysis showed no significant difference in the state and trait anxiety levels between
MSDK and placebo (Figure 21E and F). At month 12, the average scores for state anxiety in
MSDK and placebo groups were 27.4 and 28.4, respectively; whereas the average scores for trait
anxiety was 31.3 in MSDK and 30.1 in placebo, respectively. These scores represented low state
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and trait anxiety levels (range: 20-39) in almost all participants.
To determine if MSDK impacted on our cohort’s perceived stress and depression status,
the validated Perceived Stress Scale (PSS) and Center of the Epidemiological Study of Depression
(CES-D) questionnaires were administered, respectively, at baseline, month 6 and month 12 and
revealed no significant difference between groups (Figure 21G and H). Average PSS scores at
month 12 were 10.7 in MSDK and 7.6 in placebo at month 12, reflecting a low stress level (score
< 20) in study population. Similarly, the average CES-D scores in MSDK and placebo groups were
5 and 5.2, respectively, suggesting the absence of depressive symptomatology (score <16) in the
study population.
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Figure 21. Treatment effects on the menopause quality of life, anxiety, stress and depression in
placebo and MSDK groups. Psychological assessments were carried out at months 0, 6 and 12
using validated questionnaires. Each point in the line graph represents the mean (± S.E.M.) score
for (A) MENQOL vasomotor, (B) MENQOL physical, (C) MENQOL psychosocial, (D)
MENQOL sexual, (E) STAI: State anxiety, (F) STAI: Trait anxiety, (G) PSS: Perceived stress
scores and (H) CES-Depression at specific time point, respectively for placebo (open circle, red)
and MSDK (close circle, blue); n=11 per group. *p ≤ 0.05 vs. placebo at similar time point.
Longitudinal analysis for repeated measures using generalized linear mixed model (GLMM)
approach, considering groups and times as fixed effects and subjects nested within the groups as
random.
In summary, MSDK treatment did not significantly improve or worsen the symptoms
associated with menopause, anxiety, stress, and depression. All participants remained in the
normal range for all psychological domains throughout the study. Corresponding mean (± S.E.M)
change per year of psychometric parameters are shown in Table 3.
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Table 3:Treatment effects on bone density (T-scores), fracture risk probability (FRAX), bone
marker, body composition and psychometric parameters. Mean (± S.E.M.). P1NP= total
procollagen type 1 amino-terminal propeptide; OC= osteocalcin; CTx= collagen type I ctelopeptide; CRP= c-reactive protein; BP= blood pressure; BMI= body mass index; BMR= basal
metabolic rate; MENQOL= menopause specific quality of life; STAI= state and trait anxiety
inventory; PSS= perceived stress scale; CES-D= center for epidemiologic studies depression. *p
< 0.05, **p < 0.01 and ***p < 0.001 vs. placebo (n=11 per group).
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2.2.8. MSDK improved general well-being and compliance in postmenopausal women
Diary comments were analyzed to assess if MSDK treatment affected our cohort’s general
well-being. As illustrated in Figure 22A, a total of 752 comments were written by women taking
MSDK, whereas women on placebo made 793 comments. Analysis of these comments revealed
an improvement in sleep quality in women taking MSDK, as indicated by 29% more
positive/neutral comments made in the MSDK group vs. placebo (p< .0001). The relative risk ratio
of a positive sleep statement for women taking MSDK was 2.5 (95% CI= 1.44 to 4.35), suggesting
that the likelihood of a positive sleep statement is 150% higher in MSDK group compared to
placebo. Regarding mood, the percentage of both positive and negative comments were high in
MSDK group as compared to placebo. However, analysis showed no correlation between MSDK
intake and mood change in this cohort. Interestingly, all (100%) comments made about GI
symptoms in the placebo group were negative whereas 87% were negative in the MSDK group—
a reduction of 13%. Women in the MSDK group made some positive comments perhaps indicating
improvements in GI upset. Regarding general aches and pains, the percentage of negative
comments made in the MSDK group was 79% compared to 84% comments recorded for placebo.
Statistical analyses revealed no significant impact of MSDK on GI symptoms and general
aches/pains. Most of what was reported, positive or negative, had to do with their overall general
well-being reported in their daily diaries. Although the women in MSDK group experienced an
improvement in sleep quality, their sleep duration remained similar to that of placebo (p= 0.55),
as determined from their diary log (Figure 22B and Table 4). The average sleep time (in hours)
for those taking MSDK or placebo was 6.85h and 7.06h, respectively. As shown in Figure 22C
and Table 4, analysis of exercise intensity showed no significant differences between groups
(p=0.23); however, most participants in the placebo group were involved with high intensity
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exercises whereas almost all MSDK group participants were exercised with light to moderate
intensity. Both groups had an equal intake of multivitamins/herbal supplements/OTC products
(81.82%). Analysis of confounders revealed no significant differences between groups (Table 4).
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Figure 22. Treatment effects on participants’ (A) sleep quality, mood, GI upset and general
aches/pains; (B) sleep duration and (C) exercise intensity in placebo and MSDK groups. (A) To
assess the effect of MSDK on the general well-being of the MOTS cohort, total diary comments
made by the participants in each group throughout the study were stratified into four categories:
sleep, mood, GI upset and general aches/pains, as illustrated by the four segments in the pie
diagram. Each category was sub-stratified as positive (pink), neutral (yellow) and negative (green)
comments. Each portion represents the percent of total comments made under each category. *p ≤
0.05 vs. placebo; two-tailed Fishers exact test for two categorical outcomes. (B, C) Sleep duration
and exercise intensity was assessed from the diary log. Each point in the scatter plot represents the
scores of (B) sleep duration (in hour) and (C) exercise intensity for each participant in placebo and
MSDK respectively (n=11 per group); where the solid line indicates the mean (± S.E.M.) score
per group. *p ≤ 0.05 vs. placebo; unpaired one tailed t-test with Welch’s correction.
Compliance was measured from the daily diary logs as well as from bimonthly pill
counting and health assessments. No incidence of adverse effects was reported from participants
in either group during their bimonthly general health checkups at the Center of Pharmacy Care at
Duquesne University or through their diary logs. The fact that MSDK treatment did not worsen
any of the subjective measures assessed may have impacted positively on compliance, which was
high in the MOTS (Placebo=90.03% and MSDK = 92.4%; Table 4).
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Table 4: Sleep duration, exercise intensity and pill intake in placebo and MSDK groups. Mean
(± S.E.M.) for sleep duration and exercise intensity (n=11 per group).

2.3. Discussion
Our study is one of the firsts addressing the need for starting earlier intervention therapy to
reverse bone loss and normalize bone density in postmenopausal women with osteopenia. This is
important because studies have shown that osteopenia is the primary accountable factor for the
population burden of fracture as earliest fractures predominantly arise in the osteopenic population
(Siris, Chen et al. 2004, Pasco, Seeman et al. 2006). Therefore, this shift to earlier intervention
starting with osteopenia rather than osteoporosis may lead to the prevention of most fractures
observed worldwide. To the best of our knowledge, this is also the first randomized, double-blind,
placebo-controlled study focusing on the efficacy of a timed combination therapy consisting of
melatonin and micronutrients (strontium citrate, vitamin D3 and vitamin K2) intended to reverse
osteopenia while improving compliance in postmenopausal women. The choice of supplements
were all natural and over-the-counter remedies known to benefit bone.
The inclusion and exclusion criteria of this study aimed to minimize the presence of any
additional positive and/or negative effects on bone, rather than the treatment effects. Avoiding
alcohol intake while taking the medication was one inclusion criterion, since alcohol consumption
in the evening may suppress salivary melatonin levels (Rupp, Acebo et al. 2007). Women taking
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bisphosphonates were excluded even though many of them were ready to discontinue before
joining the study. This is because it takes at least 6 months to 2 years after stopping
bisphosphonates to clear out of the system so not to blunt strontium’s effects (Middleton, Steel et
al. 2010). Selective serotonin reuptake inhibitors (SSRIs) increase osteoporosis and fracture risk,
which could affect one of the primary outcome measures (Chau, Atkinson et al. 2012) and
therefore was one of the reasons for being an exclusion criterion. In addition, MSDK effects on
depression status was a secondary outcome measure and SSRIs could have influenced that as well.
Finally, concomitant use of melatonin and Zoloft (an SSRI antidepressant also known as
Sertraline) has been shown to produce an adverse drug interaction exhibiting as toxic optic
neuropathy due to a melatonin/dopamine imbalance in the retina (Lehman and Johnson 1999).
Gastrointestinal (GI) diseases such as inflammatory bowel disease (IBS) and celiac disease could
trigger osteoporosis in many ways primarily by affecting the absorption and metabolism of calcium
and vitamin D3 (Katz and Weinerman 2010). Women with ulcerative colitis and other severe GI
disorders were not included in the study. Even though strontium ranelate is known to occasionally
cause diarrhea (Reginster, Seeman et al. 2005), which may worsen IBS flare-ups in ulcerative
colitis, no such data was reported for the strontium citrate at the time of the study. Women taking
proton pump inhibitors (PPIs) regularly were excluded because use of PPIs is modestly associated
with fractures of the spine, forearm or wrist and increased the risk of total fractures with a hazard
ratio of 1.47, 1.26 and 1.25, respectively (Gray, LaCroix et al. 2010). Another study found a
potential impact of PPIs on increasing the risk of hip fractures among patients already at-risk
possibly by decreasing calcium absorption (Corley, Kubo et al. 2010). Participants in the MOTS
were told to restrain from using PPIs while in the study. Current smokers were excluded because
smoking is associated with a decrease in BMD and a prolonged history of smoking significantly
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increases the risk of fractures (Kanis, Johnell et al. 2005). Hyperparathyroidism accelerates bone
loss in postmenopausal women and significantly affects bone turnover by increasing bone
resorption (Guo, Thomas et al. 1996). Multiple myeloma and other cancers that metastasize to
bone could also adversely affect bone metabolism and bone turnover (Simko and Paulis 2007);
and sleep apnea that disturbs one’s circadian rhythm can trigger bone loss in women via various
mechanisms including altered glucocorticoid regulation (Chakhtoura, Nasrallah et al. 2015, Maria
and Witt-Enderby 2017). Therefore, women with any of these diseases were excluded from the
MOTS. Furthermore, COPD-related systemic inflammation, vitamin D deficiency as well as use
of systemic corticosteroids can significantly contribute to bone loss (Lehouck, Boonen et al. 2011).
Women having hepatic and renal impairment were excluded because these conditions could
interfere with the bioavailability of orally administered components of MSDK. The total amount
of calcium and vitamin D3 allowed in the MOTS including calcium and vitamin D3 coming from
supplements and multivitamins was up to 600 mg of calcium and 1000 IU of vitamin D3 per day;
since these amounts were found to not interfere with strontium effects (Reginster, Seeman et al.
2005).
The primary endpoints in this study were the assessments of bone health in response to
nightly MSDK supplementation compared to placebo. Bone health was examined by measuring
bone density changes before and after one-year of treatment, and bone marker status every six
months over one year. The one-year timeline for bone density assessment was chosen based on
former bone density studies demonstrating the requirement of at least one year to observe any
changes in bone density. Osteopenic women taking MSDK for one year had significant
improvements in their left femoral neck and lumbar spine BMD with a trend (p= .069) towards an
increase in the total left hip BMD compared to women taking placebo. Both MSDK and placebo
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group showed an improvement in their hip BMD, perhaps due to the kinetics of bone remodeling
in long vs. flat bones. Vertebral and femoral neck contain mostly the trabecular bones, which goes
more readily into bone remodeling and endure more wear and tear as compared to cortical bones.
Therefore, changes in bone density in these areas are more pronounced (Clarke 2008). In contrast
to osteoporosis, an osteopenic population is expected to demonstrate a longer change in BMD
improvement in response to treatment because their BMD status was better (or denser) than the
BMD status in an osteoporotic population. In keeping, our findings are consistent with respect to
the magnitude of the BMD change and the tissues being most affected (i.e. spine> femoral neck>
total hip) to the previous postmenopausal health studies. In these studies, it is shown that the most
significant increase in BMD following one treatment with strontium citrate, vitamin D3 and
vitamin K2 and other micronutrients occurs in the spine (6 to 8%) followed by femoral neck (4%)
and total hip (3%) BMD (Genuis and Bouchard 2012) or in spine BMD following treatment with
vitamin D3 and vitamin K2 (Ushiroyama, Ikeda et al. 2002, Kanellakis, Moschonis et al. 2012).
Another study with strontium ranelate demonstrates similar increases in spine bone density in
26.4% postmenopausal osteopenic women after one year, while the number increases up to 58.2%
after three years. The percentage of patients with renormalized hip bone density increases up to
5.4% after one year and 19.6% after three years of treatment (Malaise, Bruyere et al. 2007). A
recent randomized control trial by Amstrup et al demonstrates a similar outcome where 3 mg/day
melatonin supplementation for one year results in a 1.4% increase in femoral neck BMD in
postmenopausal osteopenic women, whereas no significant improvement occurs at other areas
(Amstrup, Sikjaer et al. 2015).
Consistent with the BMD data, women taking MSDK had a lower risk for a major
osteoporotic fracture with no significant effect on hip fracture, as revealed by FRAX®. Little is
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known about the effect of melatonin and other micronutrients in preventing osteoporotic fractures.
Strontium ranelate is found to be effective against fractures in postmenopausal population. In the
Spinal Osteoporosis Therapeutic Intervention (SOTI) trial, strontium ranelate (2 g/day) shows a
49% reduction in new vertebral fractures after one year and a 41% reduction in vertebral fracture
risk after three years in postmenopausal women with mean age 70, (Meunier, Roux et al. 2004).
The Treatment of Peripheral Osteoporosis (TROPOS) trial demonstrates similar results with a 16%
reduction in overall non-vertebral fractures after three years treatment with strontium ranelate (2
gm/day), and a 36% reduction in hip fractures for high risk subgroups (Reginster, Seeman et al.
2005). Extensive studies reveal that vitamin D3 (minimum 800 IU per day), when taken with
calcium, effectively reduces the risk of hip fracture in both high and low risk populations while
showing inconsistent effects against vertebral fracture. These studies also demonstrate that even
though vitamin D3 deficiency increases fracture risk, supplementation with vitamin D alone is
ineffective in fracture prevention (Avenell, Mak et al. 2014). As shown in the MOTS, vitamin D
combined with other bone-tropic agents aids in reversing bone loss in an osteopenic population of
women who have gone through menopause.
Bone markers are independent fracture risk predictors, mainly used to monitor treatment
efficacy. The bone formation marker, P1NP, and the bone resorption marker, CTx, were assessed
in this study based on the recommendations of the Bone Marker Standards Working Group, the
International Osteoporosis Foundation (IOF) and the National Bone Health Alliance (NBHA) as
being the gold standard reference analytes in clinical studies. Even though intact P1NP is the
preferred analyte to be measured, total serum P1NP level was measured because all our
participants had normal renal function (Wheater, Elshahaly et al. 2013). Serum P1NP levels
significantly increased with MSDK treatment vs. placebo throughout the course of the study. Two
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randomized controlled trials with strontium ranelate found a link between short term (3-month)
changes in the bone formation markers (bone-specific alkaline phosphatase, BSAP and C-terminal
propeptide of type I procollagen, PICP) with a prospective 3-year change in BMD (Bruyère,
Collette et al. 2010). These findings suggest that an increase in the bone formation marker, P1NP,
may underlie the increases in BMD in the MOTS. Another bone formation marker, OC, was
measured but its level did not increase significantly with MSDK treatment. Rather, a steady level
was maintained throughout the study as compared to placebo. This is consistent with the MOPS
and MelaOst demonstrating that melatonin alone (3mg) did not induce serum OC or P1NP levels
in perimenopausal or postmenopausal women (Kotlarczyk, Lassila et al. 2012, Amstrup, Sikjaer
et al. 2015).
To our knowledge, no data is yet available on the effect of strontium citrate, vitamin D3
and vitamin K2 on the bone marker, P1NP. However, strontium ranelate, is shown to enhance other
bone formation markers (e.g. bone-specific alkaline phosphatase, BSAP; Procollagen I
carboxyterminal propeptide, PICP) (Meunier, Roux et al. 2004, Bruyère, Collette et al. 2010). With
respect to vitamins K2 and D3, vitamin K2 shows enhancing effects on serum OC (Tsukamoto,
Ichise et al. 2000) whereas low levels of vitamin D3 (<20ng/mL) produce a suppressive effect on
P1NP (Bacon, Gamble et al. 2009). Although these compounds alone have little or variable effects
on bone formation markers, their combination in MSDK produced a significant inductive effect
on P1NP in the present study, which is consistent with MSDK’s inductive effect on BMD.
In our study, even though MSDK group had a higher CTx level at baseline, MSDK was
without effect on serum CTx levels at each time point tested. It was not clear what the effect of
MSDK would have on CTx levels because the studies are mixed. For example, increases in bone
resorption occur in response to low vitamin D3 levels (Napoli, Strollo et al. 2014) or after removal
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of the melatonin source via pinealectomy as reviewed (Maria and Witt‐Enderby 2014). Strontium,
in the form of ranelate, produces a reducing effect on CTx (Meunier, Roux et al. 2004); however,
no effect was evaluated with citrate form. Melatonin alone (Amstrup, Sikjaer et al. 2015), vitamin
D3 alone (Kuchuk, van Schoor et al. 2009), or vitamin K2 (MK4) alone (Kim, Na et al. 2013)
produces little or no effect on serum CTx levels. These mixed effects on serum OC and CTx levels
may be explained by the fact that, unlike P1NP, both OC and CTx display a circadian rhythm and,
particularly for CTx, it is best to use a morning fasting sample for an accurate reading (Wheater,
Elshahaly et al. 2013), which was not followed in the MOTS due to technical limitations. However,
in our study, circadian variation was minimized by collecting serum samples at regular time
intervals (between 4pm-5:30pm) for each participant throughout the study. Interestingly, when
ratios of bone resorption to bone formation (i.e., CTx:P1NP or CTx:OC) were calculated per
person and then compared within and between groups, time-dependent decreases in both occurred
even though the decreases for CTx:OC were less pronounced compared to CTx:P1NP.
The effect of MSDK on decreasing the ratio of CTx:P1NP or CTx:OC was primarily
mediated via increasing the bone formation marker (i.e. P1NP) or keeping them at a steady level
(i.e. OC), rather than by decreasing the bone resorption marker, CTx. This mechanism of MSDK
to regulate bone turnover differs from the mechanisms of most current antiresorptive therapies
where both formation and resorption markers decrease proportionally. The pattern of MSDK
matches, in part, with what was seen for strontium ranelate or teriparatide, particularly with respect
to the bone formation marker, P1NP. Strontium ranelate regulates bone marker changes in a way
that would support more balanced bone remodeling, with an approximate 8% increase in bone
formation and 12% decrease in bone resorption. Teriparatide, on the other hand, induces both bone
formation and resorption markers (Meunier, Roux et al. 2004). (Bruyère, Collette et al. 2010). The
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changes in serum P1NP is most likely due to the strontium citrate component of MSDK since
strontium ranelate increases bone-specific alkaline phosphatase (BSAP) by 8.1% (Meunier, Roux
et al. 2004) and in the MOPS or MelaOst RCTs, melatonin alone did not affect individual bone
marker levels (Kotlarczyk, Lassila et al. 2012, Amstrup, Sikjaer et al. 2015). In the MOTS,
decreases in the ratio of bone resorption to bone formation (i.e., CTx:P1NP) occur suggesting
that MSDK may be renormalizing bone marker turnover towards equilibrium resulting in an
increase in BMD and, if taken for extended periods of time, may continue to reverse bone loss
through the aging process. These data also suggest that MSDK may be superior to melatonin alone
since the findings from the MelaOst study suggest that the mechanism for melatonin-induced
increases in BMD may be through calcium-mediated bone mineralization, which may produce a
ceiling effect of melatonin alone on improving bone health if taken for long periods of time
(Amstrup, Sikjaer et al. 2015).
In addition to this, the major increase in serum P1NP levels occurred during the first six
months of treatment in the MOTS (graph shown in Appendix VI) which may indicate that MSDK
is initiating bone formation in the first six months of treatment resulting in increases in BMD; and
once bone mass is achieved to homeostatic levels, MSDK then begins to regulate bone remodeling
to maintain equilibrium. This is important because too much bone growth may lead to osteopetrosis
or an overgrowth of bone. MSDK-mediated increases in bone density and P1NP along with
decreases in CTx indicate a dual anabolic and possibly antiresorptive effect of MSDK, making it
unique with respect to current osteoporosis therapies.
Currently, no data exist with respect to therapeutic levels of melatonin on bone. Because
of this, nocturnal urinary melatonin levels were assessed in both groups. Women taking MSDK
(which contained 5mg melatonin) at night had ~140 times more nocturnal melatonin than women

93

taking placebo. In fact, women in the placebo group had very low endogenous nocturnal urinary
melatonin-sulfate levels consistent with reports showing low melatonin levels in aged and
menopausal population (Bellipanni, Bianchi et al. 2001, Witt‐Enderby, Radio et al. 2006). Even
though women in the MSDK group took supplements for a year, their melatonin levels varied
widely possibly due to bioavailability differences between women similar to what is seen in males
(range: 10%-56% in men; mean 33%) (Di, Kadva et al. 1997). In the MOTS, a direct relationship
between melatonin levels and lumbar spine BMD was observed and is consistent with the findings
of Amstrup et al. that demonstrates a dose-dependent effect of melatonin on femoral neck BMD
(Amstrup, Sikjaer et al. 2015). Therefore, exogenous melatonin supplementation alone or in
combination with other bone-tropic agents like SDK may play an important role in maintaining
bone density in postmenopausal osteopenic women.
Even though all MOTS participants could take up to 1000 IU of vitamin D3 daily, serum
vitamin D3 levels were assessed to ascertain if the MSDK-mediated increases in BMD and P1NP
were due to differences in vitamin D3 levels between the groups. Surprisingly, serum vitamin D3
levels in women taking MSDK did not differ significantly when compared to placebo, despite the
fact that women taking MSDK would have a higher intake of vitamin D3 over the course of one
year. In fact, many of our MOTS participants still remained below the sufficient level (30100ng/mL) according to the Endocrine Society Clinical Practice Guidelines (Holick, Binkley et
al. 2011). This, perhaps, is due to variable bioavailability in women with respect to vitamin D3.
Because it has been shown that low vitamin D3 status is associated with high serum CTx levels
(Napoli, Strollo et al. 2014), we wanted to determine if this same negative correlation occurred in
our study. Consistent with (Napoli, Strollo et al. 2014), a negative correlation between vitamin D3
and CTx was also observed in our cohort. Perhaps the wide variations in vitamin D3 levels in our
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study contributed, in part, to the lack of MSDK’s effect on CTx levels.
C-reactive protein (CRP) levels were measured to assess if MSDK could lower CRP levels
as another mechanism to explain its inducing effects on BMD. Levels of CRP are inversely
correlated with vitamin D levels (De Vita, Lauretani et al. 2014) and BMD (de Pablo, Cooper et
al. 2012). Human serum CRP (hsCRP) levels are significantly higher in lumbar spine osteoporotic
women than in normal women (Lee, Kim et al. 2011); high circulating hsCRP levels (>1.8mg/L)
are associated with postmenopausal osteopenia and/or osteoporosis (Koh, Khang et al. 2005); and
fracture risk has been shown to occur in perimenopausal women who have CRP levels ≥ 3mg/L
(Ishii, Cauley et al. 2013). After one year of MSDK treatment, CRP levels of the MOTS
participants dropped below 1.4mg/L with a mean group value of 0.57mg/L compared to the
placebo mean value of 1.5mg/L. A reduction in CRP levels by MSDK could imply a possible antiinflammatory role of MSDK, aiding in the bone health and other diseases such as cardiovascular
and metabolic disorders.
Morphometric analyses were conducted to determine if any changes in body morphometry
occurred in response to MSDK. No significant changes occurred in response to MSDK treatment
when compared to placebo; however, there were two interesting observations regarding height and
weight. Historical height loss greater than 6 cm is associated with the likelihood of vertebral
fracture (Siminoski, Warshawski et al. 2006). In keeping with this, both MSDK and placebo
groups experienced height loss (albeit at a much lower extent than 6cm) where women in the
MSDK group lost 0.05% of their height while those in the placebo group had a height loss of
0.21%. Perhaps the gain in lumbar BMD in the MSDK group prevented loss of height and, if taken
for longer periods of time, may lead to a decrease in vertebral fractures. Dramatic changes in
weight could also contribute to increases in bone turnover and decreases in bone mass (Labouesse,
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Gertz et al. 2014). Also, mature women with a BMI lower than 18kg/m2 are estimated to have
more than 30% bone loss than normal women of same age (Emaus, Wilsgaard et al. 2014). In our
study, we observed no significant changes in mean weight within and between groups over the
course of one year; however, there was more variance of weight change within the placebo group
compared to the MSDK group (p= 0.032). Perhaps MSDK, most likely through melatonin,
stabilized weight fluctuation and provided some bone protection. Melatonin’s effects on body
weight has been reported in the MelaOst study where postmenopausal osteopenic women taking
melatonin have a decrease in total fat mass and trended towards an increase in lean body mass
(Amstrup, Sikjaer et al. 2015). Also, in Maria et al 2017, melatonin modulates the metabolic
proteins, PPARγ and GLUT4, in a manner that would result in a lowering of fat production in the
body (including bone marrow) while inducing osteoblast differentiation (Maria, Samsonraj et al.
2017). This shifting away from adipogenesis (i.e., decreased PPARγ and GLUT4 levels) towards
osteogenesis may explain, in part, MSDK’s actions on bone, which is supported in the co-culture
studies (to be discussed in the next chapter) using human mesenchymal stem cells and peripheral
blood monocytes and also in monocultures of mesenchymal stem cells derived from human
adipocytes. Similar to melatonin, MSDK, in combination with osteogenic medium, significantly
reduced PPARγ and GLUT4 expression consistent with MSDK’s stimulatory effect on
osteoblastogenesis and inhibitory effect on adipogenesis. These mechanisms and more are
discussed later in the in vitro chapter.
Cardiovascular parameters, specifically blood pressure, was monitored during the
recruitment process but also throughout the MOTS because the individual components of MSDK
have been shown to produce differential effects on cardiovascular health. For example, strontium
ranelate is associated with a risk of myocardial infarction (relative risk 1.6 vs. placebo) (Bolland
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and Grey 2013). For the sake of comparison, this risk is lower than that of calcium (HR= 1.86 for
dietary calcium and 2.39 for calcium only supplements (Li, Kaaks et al. 2012). Also, compared to
bisphosphonates, strontium is not significantly associated with risk of acute coronary syndrome
(rate per 1000 person-years 5.7 for strontium vs. 6.3 for alendronate/risedronate; adjusted HR 0.89,
95% CI 0.52 to 1.55) or any-cause mortality (adjusted HR 0.96, 95% CI 0.76 to 1.21) (Svanström,
Pasternak et al. 2014). Melatonin and vitamin K2 also have cardioprotective roles in the body
(Geleijnse, Vermeer et al. 2004, Paradies, Paradies et al. 2015). Besides, osteopenic patients tend
to have less cardiovascular risk than osteoporotic patients, as observed in a study with Japanese
postmenopausal women, where osteoporotic women have impaired endothelial function in their
forearm resistance arteries compared to osteopenic women (Sanada, Taguchi et al. 2004, Farhat
and Cauley 2008). However, because of the lack of adverse reporting studies using strontium
citrate, we could not exclude the possibility of having cardiovascular events with strontium citrate
and therefore only recruited those women in the study who had normal blood pressure (BP). In
addition to excluding women with elevated blood pressure level during the screening process,
bimonthly BP assessments were performed in our study participants to detect any change in their
BP while taking this therapy. No worsening effect of MSDK on blood pressure was observed
throughout the study. Even though the baseline diastolic BP in the MSDK group was higher
compared to placebo, their BP level remained steady and within the normal range throughout the
study. MSDK did not affect systolic and diastolic BPs in our study throughout the treatment,
making it potentially safe for use in the elderly population.
The second endpoint in this study was to assess MSDK’s effects on the health-related QOL
using validated questionnaires measuring menopausal symptoms, anxiety, stress and depression;
and daily diaries. These parameters were measured because health related QOL becomes greatly
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hampered in women transitioning through menopause. Studies showed that more than 60%
postmenopausal women suffer from three or more menopausal symptoms, among which sleep
disturbance, vaginal dryness and anxiety have the highest impact on their QOL. (Greenblum, Rowe
et al. 2013). Unlike the MOPS (Kotlarczyk, Lassila et al. 2012), which shows an improved
MENQOL physical domain score in perimenopausal women following 3 mg melatonin nightly for
6 months, a one-year MSDK supplementation did not significantly improve the physical symptoms
associated with menopause and did not improve any of the other menopausal domains:
psychosocial, vasomotor or sexual. These differences could be attributed to the fact that the study
populations between the MOPS (perimenopausal) and the MOTS (postmenopausal) were quite
disparate with respect to the menopausal transition. The prevalence of menopausal symptoms as
well as physiologic distress associated with menopause is reportedly higher in perimenopause than
postmenopause (McKinlay, Brambilla et al. 1992, Bromberger, Meyer et al. 2001). This was also
supported in our study where an improvement in participants’ MENQOL psychosocial symptoms
were significantly associated with an increase in their ages, indicating the women who are in
postmenopausal state for a longer period compared to those who just entered postmenopause. This
could possibly explain why we did not see significant QOL changes in these aspects in our
postmenopausal cohort. Also, as discussed previously, vitamin D3 supplementation may have
prevented any vasomotor symptoms from surfacing since a negative correlation exists between
vitamin D3 and vasomotor symptoms. Though not significant, the sexual domain is the only
domain that showed a splitting off into opposite directions for placebo (positive direction) and
MSDK (negative direction); a more negative number indicates improvement. Items included in the
sexual domain include: decrease in sexual desire, vaginal dryness, and avoiding intimacy.
Participants in both groups maintained normal and/or healthy psychological states throughout the
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study indicating that one-year MSDK treatment did not worsen their health-related QOL.
Daily dairy information revealed additional treatment effects of MSDK on general wellbeing, which were not possible to capture from the specific questionnaires. A positive relationship
between MSDK treatment and sleep quality occurred. This is an important finding considering that
poor sleep quality, specifically going to bed at a later bedtime, sleeping late into the morning and
frequent daytime napping is associated with low BMD in postmenopausal women (Chen, Chen et
al. 2014). Also, disrupted sleep rhythms, as seen in shift workers, has also been shown to decrease
BMD and increase one’s risk of hip and wrist fracture (Feskanich, Hankinson et al. 2009, Quevedo
and Zuniga 2010, Kim, Choi et al. 2013, Wang, Wu et al. 2015). Another study shows an
independent association between nighttime sleep problems with an increase in fall risk in an
elderly population (aged 64-99 years) (Brassington, King et al. 2000). Therefore, an improvement
in their sleep quality by MSDK may also contribute to the positive effects of MSDK on their bone
health and fracture risk.
The melatonin component in MSDK is an efficacious agent for entraining sleep rhythms
and this important fact may be improving bone health by regulating sleep quality and bone rhythms
but also by improving compliance (Maria and Witt-Enderby 2017). Melatonin contained within
MSDK may improve compliance due to its positive reinforcing effects on sleep quality and mood
(Maria, Samsonraj et al. 2017). Because bone resorption (N-terminal peptide) follows a circadian
rhythm that parallels melatonin’s endogenous rhythm, as shown in premenopausal women (St
Hilaire, Rahman et al. 2018), the preservation of the circadian rhythm by nocturnal exogenous
melatonin supplementation may prevent the disruption of bone marker rhythms due to lifestyle
(i.e., light at night, shift work, stress) and maintain balanced bone remodeling; this would keep
one’s sleep rhythms entrained to the light/dark cycle and produce benefits to bone and overall well-
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being. This is supported in the MOTS and MelaOst trials where 29% more positive/neutral
comments about sleep and 14% more positive comments about mood were made by women taking
MSDK compared to placebo (MOTS) and a borderline significant improvement in sleep quality
occurs after 1 year of melatonin treatment in a subgroup of postmenopausal osteopenic women
with poor sleep quality (Amstrup, Sikjaer et al. 2015). Like melatonin, the strontium citrate
component in MSDK may be contributing to improvements in QOL as well. In the SOTI trial,
QOL was measured using the Quality of Life questionnaire in Osteoporosis (QualiOst), which is
a validated disease-specific 23 items questionnaire measuring the effect of osteoporosis on the
health-related QOL. Strontium ranelate treatment slightly improves the QOL in their
postmenopausal osteoporotic cohort, which persisted for up to 4 years as reviewed (Roux 2008).
Improvements in sleep duration cannot be factored into the improvement in QOL because both
groups averaged ~7h of sleep per night throughout the study. This could be because almost all our
participants were working women with a scheduled lifestyle and used alarm clocks to wake up in
the morning.
Besides sleep, there were a high number of comments (both positive and negative) made
about mood in both groups making it difficult to provide a satisfactory conclusion about MSDK’s
effect on general mood in this cohort. What is interesting to note, though, was that more positive
comments were made in the MSDK group compared to placebo when neutral comments were
excluded. Perhaps the improvement in sleep quality observed in the MSDK group translated to
improvements in mood. In another study, melatonin shows general improvements in mood and
depressive states in postmenopausal women (Bellipanni, Bianchi et al. 2001). Treatment effects
on the GI tract were also evaluated because GI disorders, particularly nausea and diarrhea, are
found to be associated with strontium ranelate usage in postmenopausal women (Reginster,
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Seeman et al. 2005). In the MOTS, no effect of MSDK on GI symptoms occurred and, in fact,
women taking MSDK, to some extent, demonstrated an improvement in GI-related matters. This
was revealed by the number of positive comments made by women taking MSDK compared to all
of the negative comments made by placebo group. A similar trend towards an improvement was
observed in the general aches/pain category where MSDK produced minimal, if any, effects. These
findings underscore the fact that MSDK is safe to use with respect to these aspects in
postmenopausal women with osteopenia.
Treatment compliance has a great influence on the overall QOL. Bone loss therapies often
fail to produce their desired effect because of the poor compliance and limited adherence to the
treatments. One study shows that the compliance rate for taking osteoporosis medications is <80%
as measured by the medication possession ratio (MPR) and this is associated with a 17% increase
in fracture rate (Silverman and Gold 2010). Women taking MSDK were highly compliant
throughout the study (92.4%) with no reported adverse events. Two of the participants dropped
out from the study—one from placebo group due to having a problem with the pill size and another
from the MSDK group due to general illness unrelated to the study supplement. Improved
treatment compliance is expected to improve bone health outcomes in postmenopausal women
with osteopenia.
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Chapter 3: Assessment of mechanisms underlying the effect of melatonin, strontium
citrate, vitamin D3 and vitamin K2 (MSDK) on human adult mesenchymal stem cells
and human peripheral blood monocytes grown as co-cultures

3.1. Materials and Methods
3.1.1. In vitro treatment preparation
In vitro MSDK treatment concentrations were calculated based on the doses used in the
MOTS clinical trial. Hence, 50 nM melatonin (M), 191.5 μM strontium citrate (S), 26 nM vitamin
D3 (D) and 18.5 nM vitamin K2 (K) were prepared and dissolved into 100% pure ethanol to achieve
the final concentration of MSDK per well. All study drugs were generously provided by Pure
Encapsulations, Inc. (Sudbury, MA, USA).
3.1.2. Osteoblast/Osteoclast co-cultures and hMSC mono-cultures
Two bone cell co-culture model systems (transwell and layered) were developed using
undifferentiated forms of osteoblasts and osteoclasts—multipotent human adult mesenchymal
stem cells were used to study osteoblastogenesis and human peripheral blood monocytes, isolated
from freshly drawn human blood, were used to study osteoclastogenesis.
Initiation of hMSCs culture. Human adult mesenchymal stem cells (hMSCs) (CAT# PT-2501,
Lonza, MD, USA) were grown in 75 cm2 cell culture flasks using mesenchymal stem basal cell
growth medium (Os-) (CAT# PT-3001, Lonza, USA) and cells were maintained at 37°C, 5% CO2
and 90% humidity. When 80% confluence was achieved, cells were passaged following
detachment from the flask surface by trypsinization and transfer into other tissue culture plates or
flasks. Cells were then seeded (at passage 3-5) at an initial density of 3 × 103 cells/cm2 at the
bottom chamber of CorningTM transwell permeable support 6 well plates (Cat# 07-200-165; pore
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size 0.4µm, 24.5mm Diameter, 4.7cm2 Growth Area; Corning, USA) or on typical 6-well cell
culture plates (Corning, NY, USA). On day 1 of the 21-day co-culture period, cells were treated
with either basal growth media (Os-) or osteogenic media (Os+) (CAT# PT-3002, Lonza, USA)
and then with 0.01% ethanol as vehicle (Veh) or melatonin (Mel), strontium citrate (Sr), vitamin
D3 (D3) and vitamin K2 (K2) alone or in combination with MSDK. Ascorbate, dexamethasone and
β-glycerophosphate were added to basal growth medium, referred to as osteogenic media (Os+),
to induce the differentiation of hMSCs into osteoblasts (Langenbach and Handschel 2013). Full
media exchanges occurred every four days.
Isolation of hPBMCs from blood sample. On day 13, a blood sample (approx. 2mL) was taken
from a young consenting healthy volunteer unrelated to the MOTS clinical trial via venous
puncture using BD Vacutainer® Safety-Lok blood collection set with a 23-gauge needle (BD,
USA) and collected in 8.5 mL BD Vacutainer® SSTTM Plus blood collection tubes with
anticoagulant (BD, USA). To isolate peripheral mononuclear cells, anticoagulant-treated blood
was mixed with an equal volume of balanced salt solution (e.g. PBS). The blood/PBS solution
(1:1) was then carefully layered on top of the Ficoll-PaqueTM Plus solution (Amersham Pharmacia
Biotech, Sweden) without disturbing that layer. After two repeated centrifugations at 400g for 3040 min at 18-200C without brake, mononuclear cells were visible as a yellowish layer in the middle.
They were then isolated from the multiple layers of centrifuged blood using a long sterile pipette
tip and re-suspended in RobosepTM buffer (CAT# 20104, Stemcell technologies, USA). Magnetic
separation of pure peripheral blood monocytes (hPBMCs) from the fresh mononuclear cells
mixture was performed using the EasySep™ negative selection human monocyte enrichment kit
without CD16 depletion (CAT# 19058, Stemcell technologies, USA) and purple EasySep™
magnet (CAT# 18000, Stemcell technologies, USA), following manufacturer’s instructions.
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Briefly, mononuclear cell suspensions (~5 x 107 cells/mL) in 2mL RoboSep buffer media were
placed in a 5mL polystyrene tube (CAT# 352058, BD Bioscience, USA). Next, the tube was
inserted into a magnet and the suspension was treated with EasySepTM human monocytes
enrichment antibody cocktail without CD16 Depletion (50uL/mL cells) and incubated at 2-80C for
10 min. Following antibody treatment, the mixture was treated with the magnetic particles
(50uL/mL cells) and incubated for another 5 min at 2-80C. The antibody cocktail provided with
the kit bound to all mononuclear cells except CD16-specific monocytes. This complex also
recognized dextran-coated magnetic particles provided with the kit. When the tube was placed
inside the EasySepTM magnet and set aside for 2.5 min at room temperature, the magnetically
labeled unwanted mononuclear cells remained bound to the inside wall of the tube, leaving only
pure monocytes into the solution. Human peripheral blood monocytes (hPBMCs) in solution were
then carefully poured into another tube. To avoid contamination of other cells, the tubes were not
allowed to shake and the top of two tubes were not to touch each other. A schematic representation
of this procedure is shown in Figure 23.
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Figure 23. Isolation of monocytes (hPBMCs) from blood sample
Initiation of hMSCs/hPBMCs co-culture. Human PBMCs were added to osteoblastic cultures on
day 13 because past studies using osteogenic medium have shown that hMSCs start to differentiate
into mature osteoblasts between 14 to 21 days (Sethi, Radio et al. 2010) and begin producing
substantial amounts of RANKL, M-CSF and/or OPG (Atkins, Kostakis et al. 2003) to modulate
osteoclastogenesis (Atkins, Kostakis et al. 2003, Boyce and Xing 2008). Monocytes were seeded
(5 × 103 cells/cm2) in the top chamber of the transwell plate to initiate the “transwell” co-culture
or layered directly on top of the hMSC culture to initiate “layered” co-culture. The permeable
polycarbonate membrane present between the two chambers of the transwell allowed for the
MSCs/osteoblasts and PBMCs/osteoclasts to communicate via passage of factors released into the
media and not through contact whereas in the layered co-culture, MSCs/osteoblasts and
PBMCs/osteoclasts could communicate via both means. Full media exchange was continued for
once every four days until day 21.
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Initiation of hMSCs mono-culture. The hMSC mono-cultures were cultured exactly as the cocultures except that the hMSCs were grown in the absence of hPBMCs to determine how
hPBMCs/osteoclasts influence MSDK-mediated osteoblast differentiation. The development and
treatment paradigm of co-culture is shown in Figure 24.

Figure 24. Development of hMSCs/hPBMCs transwell (indirect) and layered (direct) cocultures. DIV=Day in vitro.
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3.1.3. Osteoblast differentiation and mineralization
On day 21, calcium mineralization by matured, differentiated osteoblasts was measured via
alizarin red staining assay— this time period was chosen based on past published studies using
melatonin to induce differentiation of hMSCs into osteoblasts (Sethi, Radio et al. 2010). Alizarin
red staining was performed on the bottom chamber (hMSCs portion) of transwell co-culture and
directly on 6-well plates (both hMSCs and hPBMCs) of the layered co-culture using the
commercially available osteogenesis quantification kit (CAT# ECM815, EMD Millipore, MA,
USA) as per manufacturer’s instructions. Briefly, the bottom chamber cells were washed with PBS
and fixed with 10% formaldehyde and 15 min incubation at room temperature. Then alizarin red
stain was applied to each well (0.5-1mL/well). Following 20 min incubation at room temperature
and extensive washing (three times, 5 min, gentle rocking) with deionized water, differentiated
osteoblasts containing mineral deposits were visualized using Vistavision microscope (VWR
international) with progress C3 camera (Zenoptik).
Osteogenesis was also quantified by extracting the mineral deposits released by osteoblasts
using the Osteogenesis Assay Kit (CAT# ECM815, EMD Millipore, MA, USA).
Spectrophotometric quantification was performed at 405 nm using the Perkin Elmer Victor 1420
Multilabel plate reader (Waltham, MA, USA). A standard curve was generated from the
absorbance (OD) readings of standards. Concentrations of alizarin red of the samples were
calculated from the generated standard curve using Workout 2.0 software (Waltham, MA, USA),
normalized against Os-/Veh and compared between groups. Osteoblastic mineralization activity
was proportional to the concentration of alizarin red in this assay.
3.1.4. Osteoclast differentiation and resorption pit formation
On day 21, tartrate resistant acid phosphatase (TRAP) assays were carried out on the top
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chamber of transwell co-culture or directly on the 6-well plate (layered co-culture) to measure
osteoclastic differentiation and TRAP releasing activity. Qualitative analysis was performed using
the commercially available Acid Phosphatase Leukocyte assay kit (CAT# 387A, Sigma, USA) per
manufacturer’s instructions. Briefly, recommended reagents supplied in the assay kit were added
to the cells (1mL/well) per kit instructions and incubated for 1h in a water bath at 37ºC in the
absence of light. The cells were then counterstained with hematoxylin for 2 min and rinsed
thoroughly in alkaline tap water, resulting in the visualization of blue nuclei of osteoclasts.
Microscopic assessment of the stained osteoclasts was performed using Vistavision microscope
(VWR international) with progress C3 camera (Zenoptik) under grey setting. Purple staining
indicated TRAP deposition by osteoclasts where the amount of TRAP deposition was proportional
to the differentiation of osteoclasts.
Quantitative analysis of the total TRAP was performed according to the protocol
previously explained by Janckila et al., with modifications (Janckila, Takahashi et al. 2001).
Briefly, Naphthol-ASBI phosphate (N-ASBI-P) was used as a substrate for TRAP. TRAP buffer
was prepared by dissolving N-ASBI-P (2.5mM) in a solution containing 1% ethylene glycol
monomethyl ether (EGME), 2% NP40, Na-acetate (100mM) and Na-tartrate (50mM) with pH
adjusted at 5.5-6.1. Cells were lysed with 50mM TRIS and treated with TRAP buffer (1mL/well).
Cells were also treated with a blank solution containing100 µL TRIS and 1 mL TRAP buffer only.
Cells were then scraped and then placed in a 5mL tube along with the buffer and incubated at 37°C
for 30 min. Reactions were stopped upon the addition of 2.5 mL 0.1 M NaOH containing 0.05%
NP-40. Fluorescence readings were taken at 405nm excitation and 515nm emission wavelength
using a Perkin Elmer Victor 1420 Multilabel plate reader. Data were normalized against Os-/Veh
and compared between groups. All reagents were bought from Sigma, USA. Osteoclastic
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resorption pit formation activity was also performed by manually counting the number of
resorption pits formed by the differentiated osteoclasts in the layered co-culture using a Vistavision
microscope.
3.1.5. Western blot
Western blotting was performed to measure protein expression of osteoprotegerin (OPG),
receptor activator of nuclear factor kappa-B ligand (RANKL), extracellular signal-regulated
protein kinases 1 and 2 (ERK1/MAPK3 and MAPK1/ERK2), extracellular signal-regulated
protein kinase 5 (ERK5/MAPK7), runt-related transcription factor 2 (RUNX2), integrin β1
(ITGB1), nuclear factor kappa B (NFκB), peroxisome proliferator-activated receptors gamma
(PPARγ), glucose transporter type 4 (GLUT4/SLC2A4) and beta subunit of insulin receptor (IRβ);
using the Odyssey® Western Blotting Kit IV RD (CAT# 926-31084, Licor bioscience, USA).
Primary antibodies included rabbit anti-OPG/TNFRSF11B (ab73400, Abcam, USA), rabbit antiRANKL/TNFSF11 (ab9957, Abcam, USA), rabbit anti-phospho ERK1/2 (9101, Cell Signaling,
USA), rabbit anti-total ERK1/2 (9102, Cell Signaling, USA), rabbit anti-phospho ERK5 (3371,
Cell Signaling, USA), rabbit anti-total ERK5 (3372, Cell Signaling, USA), rabbit anti-RUNX2
(sc10758, Santa Cruz Biotech, USA), rabbit anti-Integrin β1 (sc8978, Santa Cruz Biotech, USA),
rabbit anti-NFκB (sc298, Santa Cruz Biotech, USA), rabbit anti-PPARγ (sc7196, Santa Cruz
Biotech, USA), rabbit anti-GLUT4 (sc7938, Santa Cruz Biotech, USA), rabbit anti-IRβ (sc711,
Santa Cruz Biotech, USA) and mouse anti-β-actin (926-42212, Licor, USA). Secondary antibodies
against appropriate IgG included goat anti-rabbit (800nm) and goat anti-mouse (680nm), which
were supplied with the Licor western blotting kit.
Cell lysate preparation. On day 21, osteoblast and osteoclast cell lysates each were prepared from
the bottom and top chambers of the transwell co-culture, respectively. Whole cell lysates
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containing both osteoblasts and osteoclasts were prepared from the layered co-culture. Following
aspiration of culture media, cell lysates were prepared by adding 2X Laemmli sample buffer
(CAT# 161-0737, BioRad, USA) and β-mercaptoethanol (CAT# 161-0710, BioRad, USA) at a
ratio of 19:1 onto each well and then gently scraping the cells. Cell lysates were then heated for 5
min at 95oC, cooled down and stored at -20oC until use.
SDS-PAGE. Thirty microliters of cell lysates and 10 µL of the molecular weight marker (Precision
Plus ProteinTM, CAT# 161-0373, BioRad, USA) were added to wells and then separated using
10% SDS-polyacrylamide gel electrophoresis. Proteins were then transferred to nitrocellulose
membranes and placed in blocking buffer for 1h with gentle rocking to reduce non-specific
staining. Membranes were then incubated with the respective primary antibodies and anti-β-actin
antibodies to visualize the proteins of interest and to normalize protein load overnight at 4°C with
gentle rocking. Following incubation with the antibodies, blots were washed with PBS-tween and
incubated with two different secondary antibodies with different infrared spectra (800nm and
680nm) for 45min to 1 hour at room temperature. Protein bands were then visualized in Odyssey
Infrared Imager and quantified using Odyssey software (Licor bioscience, USA). Proteins were
normalized against β-actin to control for variations in protein loading between treatment groups.
Protein levels were then normalized against Os-/Veh or Os-/MSDK and compared between groups.
3.1.6. Measurement of secreted OPG and RANKL
Concentrations of osteoblast-secreted osteoprotegerin (sOPG) and receptor activator of
nuclear factor kappa-B ligand (sRANKL) in culture media were measured via Sandwich enzymelinked immunosorbent assay (ELISA using Osteoprotegerin Human ELISA kit (CAT# ab100617,
Abcam, USA) and total sRANKL (human) ELISA kit (CAT# ALX-850-019, Enzo Life Science,
USA), respectively, following manufacturer’s instructions. Culture media was collected before
110

preparing the cell lysates from the bottom chamber of the transwell plate (contains hMSCs) or
from the layered or hMSC mono-cultures and stored at -20oC until use. Absorbance readings of
standards, controls and samples were measured at 450 nm using the Perkin Elmer Victor 1420
Multilabel plate reader (Waltham, MA, USA). A standard curve was generated for each assay
using the four-parameter logistic curve fit function and concentrations of sOPG and sRANKL were
calculated using Workout 2.0 software (Waltham, MA, USA). Mean concentration changes of
sOPG (in pg/mL) and sRANKL (in pg/mL) were calculated, normalized against Os-/MSDK
groups and compared between groups. Ratios of sOPG to sRANKL were calculated, normalized
against Os-/MSDK and then compared between groups.
3.1.7. Statistical interpretation
For in vitro assays, all data were normalized against either Os-/Veh or Os-/MSDK and
analyzed by one-way ANOVA followed by Bonferroni’s post-hoc multiple comparison t-test,
where significance was defined as p < 0.05.

3.2. Results
3.2.1. MSDK increased osteoblastogenesis and decreased osteoclastogenesis in co-cultures of
hMSCs and hPBMCs
Both alizarin red staining and TRAP assays indicated successful differentiation of hMSCs
into osteoblasts and hPBMCs into osteoclasts when grown together as co-cultures in the presence
of osteogenic (Os+) media. Figure 25A represents calcium mineralization activity of mature,
differentiated osteoblasts grown in a transwell co-culture as measured after 21 days of exposure to
MSDK and other treatments. Human adult MSCs grown in growth media alone (Os-/Veh) or in
presence of MSDK (Os-/MSDK) did not differentiate into osteoblasts as revealed by the absence
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of alizarin red staining. As expected, hMSCs exposed to osteogenic media alone (Os+/Veh)
differentiated into osteoblasts (p< .01 vs. Os-/Veh). The addition of MSDK to osteogenic media
(Os+/MSDK) enhanced osteoblast mineralization to the greatest extent (p< .0001 vs. all groups).
We next investigated if the individual components of MSDK were capable of inducing osteoblast
differentiation beyond that of Os+ alone. Therefore, melatonin (Mel), strontium citrate (SC),
vitamin D3 (D3) or vitamin K2 (K2) each were added to Os+ media. Melatonin was the only
component that increased transwell osteoblast differentiation vs. Os+/Veh (Figure 24A inset).
Similar treatment effects on osteoblast differentiation were observed in the layered coculture except that the extent of MSDK-mediated osteoblast differentiation was less compared to
the transwell osteoblasts (Figure 25B). However, both melatonin and strontium citrate induced
osteoblast differentiation alone when compared to Os+/Veh in this co-culture system (Figure 25B
inset). Qualitative alizarin red staining analyses showing the extent of calcium deposition further
demonstrated the effects of MSDK and other treatments on transwell co-culture (Figure 25C) and
layered co-culture (Figure 25D).
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Figure 25. Effect of MSDK on osteoblast-mediated calcium mineralization. Following 21 days
of exposure to MSDK and other treatments, calcium deposition by differentiated, matured
osteoblasts was evaluated by alizarin red staining on (A) bottom chamber cells of the transwell coculture or (B) in the layered co-culture. Each bar represents the mean (± S.E.M.) concentration of
alizarin red (M) for the respective group normalized against Os-/Veh. Inset graph represents
similar analysis in the absence of Os+/MSDK. One-way ANOVA followed by Bonferroni’s posthoc multiple comparison t-test (n=3 per group). Transwell co-culture: ****=p<.0001 vs. all
groups, a=p<.01 vs. Os-/Veh, b=p<.05 vs. Os-/MSDK, c=p<.05 vs. Os+/Veh. Layered co-culture:
****=p<.0001 vs. all groups, a=p<.01 vs. Os-/Veh, b=p<.01 vs. Os-/MSDK, c=p<.01 vs. Os/Veh). Representative images obtained from the qualitative assessment of osteoblast
mineralization performed on the (C) bottom chamber cells of transwell co-culture and (D) layered
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co-culture via qualitative alizarin red staining. Red color indicates calcium deposition by
osteoblasts. Os- =basal media, Os+ =osteogenic media, Veh= vehicle, Mel= melatonin, SC=
strontium citrate, D3= vitamin D3 (Cholecalciferol), K2= vitamin K2 (MK7).
The effect of MSDK on TRAP levels was measured since TRAP is an well-known marker
for terminally differentiated osteoclasts and their bone resorption activity (Angel, Walsh et al.
2000, Halleen, Tiitinen et al. 2006). Figure 26A demonstrates treatment effects of MSDK and its
individual components on TRAP releasing activity of the osteoclasts grown as transwell cocultures. Although osteogenic media (Os+) favored transwell osteoblast formation, it did not have
any effect on transwell osteoclast activity. However, the addition of MSDK to osteogenic media
(Os+/MSDK) significantly inhibited TRAP expression, suggesting an inhibitory role of MSDK on
osteoclast differentiation and activity. The individual components did not inhibit TRAP expression
in this co-culture. Figure 26B illustrated treatment effects on TRAP expression in layered cocultures. Os+ was the only culture condition that inhibited TRAP expression. The addition of
melatonin, strontium citrate, vitamin D3 and vitamin K2 to Os+ media either alone or in
combination as MSDK did not have any enhancing or inhibitory effects on TRAP expression.
Qualitative TRAP expression by differentiated osteoclasts, as performed via Acid Phosphatase,
Leukocyte assay (TRAP staining assay) in transwell and layered co-cultures are shown in Figure
26C and D, respectively. Qualitative illustrations matched to what was obtained from the
quantitative analysis. Resorption pit number, as measured in the layered co-culture, significantly
decreased in Os+ culture treated with MSDK (Figure 26E), indicating an inhibitory effect of
MSDK on osteoclastic pit forming activity.
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Figure 26. Effect of MSDK on osteoclast differentiation and resorption pit formation. Following
21 days of exposure to MSDK and other treatments, TRAP releasing activity by differentiated,
mature osteoclasts were evaluated by quantitative TRAP assays on (A) the top chamber of cells
from the transwell co-cultures or (B) in the layered co-cultures. Each bar represents the mean (±
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S.E.M.) fluorescence reading of TRAP (at 405nm ex, 515nm em) for the respective group
normalized against Os-/Veh. One-way ANOVA followed by Bonferroni’s post-hoc multiple
comparison t-test (n=3 per group). Transwell co-culture: **=p<.01 vs. Os-/Veh. Layered coculture: *=p<.05 vs. Os-/Veh). Representative images obtained from the qualitative assessment of
osteoclast differentiation performed on the (C) top chamber cells of transwell co-culture and (D)
layered co-culture via qualitative Acid Phosphatase, Leukocyte assay (TRAP staining assay). The
purple color indicates TRAP deposition by matured osteoclast which was further observed by blue
nuclei of osteoclasts. Os- =basal media, Os+ =osteogenic media, Veh= vehicle, Mel= melatonin,
SC= strontium citrate, D3= vitamin D3 (Cholecalciferol), K2= vitamin K2 (MK7). (E) Resorption
pit number counted in layered co-cultures as a measure of osteoclast-mediated resorption pit
formation activity. Each bar represents the number of resorption pit in the respective group. Oneway ANOVA followed by Bonferroni’s post-hoc multiple comparison t-test (n=3; *=p<.05 vs. Os/MSDK).
In summary, 21 days of MSDK treatment significantly enhanced osteoblast differentiation
and mineralization in both transwell and layered co-cultures. MSDK treatment showed a parallel
decrease in osteoclast differentiation and TRAP releasing activity in the transwell co-cultures. No
additional inhibitory effect of MSDK on osteoclast differentiation was observed in layered cocultures because Os+ alone produced substantial inhibition. Nonetheless, the manner in which
osteoblasts and osteoclasts are cultured influences mostly the magnitude of osteoblast or osteoclast
differentiation.
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3.2.2. MSDK modulates OPG and RANKL levels in co-cultures of hMSCs and hPBMCs
dependent upon the type of culturing condition—layered or transwell
Figure 27 illustrates the effect of MSDK on osteoprotegerin (OPG) and receptor activator
of nuclear factor kappa-B ligand (RANKL)—signaling proteins known to modulate osteoclast
activity and differentiation. As shown in Figure 27Ai, Os+ media alone significantly increased
OPG and decreased RANKL expression in transwell osteoblasts, which also resulted in an increase
in the OPG: RANKL ratio, as compared to growth media (Os-). The presence of MSDK in Os+
media (Os+/MSDK) further enhanced the ratio of OPG: RANKL (p< .001 vs. Os-/MSDK and p<
.05 vs. Os+/Veh), by increasing OPG (Figure 27Aii) and concomitantly decreasing RANKL
(Figure 27Aiii) expression of transwell osteoblasts. Similar effects were observed when hMSCs
were grown as mono-cultures (Figure 27Ci and Cii) in the absence of hPBMCs except that
RANKL remained unchanged (Figure 27Ciii) at levels similar to control. Interestingly, when
hMSCs were cultured in direct contact with hPBMCs (layered co-culture), no further enhancement
of OPG (Figure 27Bii) or decrease in RANKL (Figure 27Biii) occurred with MSDK treatment
vs. Os+/Veh, resulting in no MSDK-mediated increases in the ratio of OPG:RANKL (Figure
27Bi).
Figure 27D illustrates the effect of MSDK on OPG and RANKL secreted from transwell
osteoblasts into the culture media, as measured via ELISA. The ratio of sOPG: sRANKL decreased
in both Os+/Veh and Os+/MSDK treated co-cultures as compared to Os-/MSDK mostly due to
significant increases in sRANKL. Similar patterns in sOPG: sRANKL levels were also observed
in hMSC mono-cultures (Figure 27E) due to increases in sRANKL levels and decreases in sOPG
levels. High levels of sRANKL (Figure 27Diii and Eiii) was expected to increase
osteoclastogenesis, but this did not occur as shown in Figure 26. In fact, osteoclastogenesis was

119

inhibited in both co-cultures in the presence of osteogenic (Os+) medium and, even more so, in
transwell co-cultures containing MSDK. The fact that OPG was the only protein modulated by
MSDK and that its level correlated with osteoclastogenesis suggests that sOPG and not sRANKL
was modulating osteoclastogenesis. Therefore, the attenuation of osteoclastogenesis in transwell
co-cultures vs. layered may be due to the secretory pattern of OPG (sOPG) from the osteoblast
rather than sRANKL (Figure 27D and E). Moreover, the decreased sOPG level in hMSC monocultures and the unchanged sOPG level in transwell co-cultures in response to MSDK suggest that
the presence of osteoclast in the transwell co-culture is probably modulating sOPG release from
the osteoblast. The inhibition of osteoclastogenesis observed in transwell co-cultures was possibly
due to OPG-mediated decreases in free RANKL; this would decrease RANK activation on
osteoclasts resulting in the decreases in osteoclastogenesis and activity. Another possibility is that
differential processing of RANKL by proteinases located on the osteoblasts created soluble
RANKL products, which were less capable of generating osteoclasts (Nakashima, Kobayashi et
al. 2000). This was supported in Figure 27F and G, which demonstrated that MSDK uniquely
modulated the expression of different RANKL peptide fragments in transwell and layered
osteoblasts. The RANKL fragments, 25kDa (Figure 27Fi and G) and 24kDa fragments (Figure
27Fii), also referred to as “shredded fragments” indicate ectodomain shedding by A disintegrin
and metalloproteinase domain-containing protein (ADAM) 10 or Matrix metalloproteinase
(MMP) 14 (Hikita, Yana et al. 2006).
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Figure 27. Effect of MSDK on OPG and RANKL expression of osteoblasts in transwell cocultures, layered co-cultures and hMSCs mono-cultures. Following 21 days of MSDK exposure,
(A-C) treatment effects on the OPG and RANKL expression of osteoblasts was measured via
western blot in (A) transwell co-cultures, (B) layered co-cultures and (C) hMSC mono-cultures.
Cell lysates were prepared on day 21 from the bottom (osteoblasts) chamber in the transwell coculture or from the whole plate (both osteoblasts and osteoclasts) in the layered co-culture. Protein
levels were normalized against β-actin and then to Os-/MSDK. Each bar represents the mean (±
S.E.M.) expression of (i) OPG: RANKL, (ii) OPG and (iii) RANKL for respective cultures. (D,
E) Treatment effects on osteoblast-mediated secretion of OPG (sOPG) and RANKL (sRANKL)
were measured by ELISA in (D) transwell osteoblasts and (E) hMSC mono-cultures. Following
21 days of MSDK exposure, protein concentrations (in pg/mL) were analyzed in culture media
and then normalized against Os-/MSDK. Each bar represents the mean (± S.E.M.) concentrations
of (i) sOPG: sRANKL, (ii) sOPG and (iii) sRANKL for respective cultures. (F, G) Treatment
effects on the extracellular portion of RANKL in osteoblasts were detected via western blot by
measuring mean osteoblastic expression of the (i) 25 KDa and (ii) 24 KDa RANKL fragments in
(F) transwell co-cultures; and (G) the 24 KDa RANKL fragment in layered co-cultures. *=p< .05,
**=p< .01 and ***=p< .001; One-way ANOVA followed by Bonferroni’s post-hoc multiple
comparison t-test (n=6 per group).
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3.2.3. MSDK modulates pERK1/2 and pERK5 levels in co-cultures of hMSCs and hPBMCs
dependent upon the type of culturing condition—layered or transwell
Studies done in our lab and others (Radio, Doctor et al. 2006, Ge, Xiao et al. 2007, Ge,
Xiao et al. 2009, Matsushita, Chan et al. 2009, Maria, Samsonraj et al. 2017), reveal that melatonin
induces osteoblast differentiation through MEK1/2. In hMSC mono-cultures, melatonin enhances
their differentiation into osteoblasts by activating the ERK1/2 pathway because inhibition of
MEK1/2 by PD98059 during the melatonin exposure period blocks these effects (Radio, Doctor et
al. 2006, Sethi, Radio et al. 2010). Since melatonin is one of the four components of MSDK, we
examined whether ERK1/2 was regulated by MSDK in a manner like that of melatonin to make
an association between ERK1/2 activity and expression to MSDK-mediated increases in
osteoblastogenesis. Figure 28A represents the effect of MSDK on ERK1/2 activity and expression
in osteoblasts grown as transwell co-cultures. The presence of MSDK in the Os+ medium primarily
enhanced ERK1/2 activity (phospho ERK1/2) and down-regulated total ERK1/2 (tERK1/2) in
osteoblasts. This is consistent with previous data showing that ERK1/2 is associated with an
increase in cellular differentiation (Ge, Xiao et al. 2007, Ge, Xiao et al. 2009, Matsushita, Chan et
al. 2009), or, in this case, mesenchymal stem cell differentiation into osteoblasts. As shown in
Figure 28B, MSDK produced a similar increase in ERK1/2 activity by both increasing phosphoERK1/2 and decreasing total ERK1/2 expression which could be due to increases in phosphoERK1/2 activity in osteoblasts, osteoclasts or both. In another study, ERK1/2 is also expressed in
osteoclasts and plays a significant role in osteoclast differentiation (Matsushita, Chan et al. 2009).
Therefore, it was not possible to conclude that MSDK was mediating ERK1/2 expression solely
in osteoblasts in this co-culture. This could explain the difference in ERK1/2 expression between
co-cultures with respect to MSDK.
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Previous studies have shown that ERK5 also plays a role in both osteoblast and osteoclast
function and, possibly, differentiation (Li, Ma et al. 2012, Kaneshiro, Otsuki et al. 2015, Bo, Bin
et al. 2016). However, a recent study has shown that PD98059 and U0126, purported selective
inhibitors of MEK1/2, also can inhibit MEK5 (Drew, Burow et al. 2012). These findings suggest
that use of PD98059 or U0126 to assess the role of ERK1/2 in osteoblast proliferation and
differentiation may have inadvertently inhibited both ERK1/2 and ERK5. Therefore, MSDK
effects on ERK5 in all three-cell culture models—transwell, layered and monolayers—were
assessed. Figure 28C illustrates the effect of MSDK on ERK5 expression in osteoblasts grown as
transwell co-cultures. As shown, hMSCs exposed to Os+ media alone decreased ERK5 activity
(pERK5) (p< .001 vs. Os-/MSDK), which was not due to decreases in total ERK5 (tERK5) levels.
The addition of MSDK to the Os+ media produced an increase in pERK5 relative to Os+/Veh (p<
.05 vs. Os+/Veh); however, this may be due to decreases in tERK5 since levels decreased when
compared to Os-/MSDK (p< .01 vs. Os-/MSDK). This finding is consistent with the role of ERK5
in osteoblasts (Li, Ma et al. 2012, Kaneshiro, Otsuki et al. 2015, Bo, Bin et al. 2016). Because
ERK5 is a prosurvival kinase, decreases in its expression following Os+/Veh or Os+/MSDK
exposure occurs to possibly allow for hMSCs to switch from a proliferative state towards a
differentiation state as shown in Figure 25. Interestingly, when hMSCs were cultured in direct
contact with hPBMCs (layered), no changes in pERK5 or tERK5 occurred (Figure 28E). Perhaps,
MSDK exerted variable effects on pERK5 expression in hPBMCs and hMSCs resulting in a net
zero effect because layered co-cultures contain both osteoblasts and osteoclasts. This idea is
supported in Figure 28D demonstrating a trend (p= 0.19) towards an increase in transwell
osteoclastic pERK5 in response to MSDK. Another alternative could be that that the presence of
osteoclasts exert an inhibitory influence over osteoblastic pERK5 because when hMSCs were
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grown in the absence of osteoclasts or as mono-cultures, MSDK increased both pERK5 and tERK5
(Figure 28F).
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Figure 28. Effect of MSDK on MAPK (ERK1/2 and ERK5). After 21 days of MSDK exposure,
western blot was performed to determine (A) ERK1/2 expression of osteoblasts grown as a
transwell co-culture, (B) ERK1/2 expression of osteoblasts and osteoclasts grown as a layered coculture, (C) ERK5 expression of osteoblasts grown as a transwell co-culture, (D) phospho-ERK5
expression of osteoclasts grown as a transwell co-culture, (E) ERK5 expression of osteoblasts and
osteoclasts grown as a layered co-culture, and (F) ERK5 expression of osteoblasts grown as hMSC
mono-cultures. Cell lysates were prepared on day 21 from the bottom (osteoblasts) or top
(osteoclasts) chambers of transwells and from the whole plate (both osteoblasts and osteoclasts) in
the layered co-culture. Protein levels were normalized against β-actin and against Os-/MSDK.
Each bar represents the mean (± S.E.M.) expression of (i) phospho-ERK: total-ERK, (ii) phosphoERK and (iii) total-ERK for ERK1/2 and ERK5 in each respective co-culture. *=p<.05, **=p<.01
and ***=p<.001; One-way ANOVA followed by Bonferroni’s post-hoc multiple comparison ttest (n=6 per group).

126

In summary, MSDK treatment for 21 days significantly enhanced ERK1/2 activation in
osteoblasts grown as transwell co-cultures primarily by decreasing total ERK1/2. Although a
similar pattern of ERK1/2 expression was observed in layered co-cultures, no such conclusion
could be drawn as both osteoblasts and osteoclasts were present together in this co-culture. MSDK
decreased total ERK5 expression in transwell osteoblasts and was without effect in layered cocultures. Human MSCs grown as monolayers demonstrated increases in pERK5 and tERK5 in
response to MSDK suggesting possible inhibitory influence of osteoclasts on osteoblastic ERK5
expression.
3.2.4. MSDK modulates RUNX2 level in co-cultures of hMSCs and hPBMCs dependent upon
the type of culturing condition—layered or transwell
MSDK effects on runt-related transcription factor 2 (RUNX2) was examined because
RUNX2 is a master regulator of osteogenesis (Ge, Xiao et al. 2007, Ge, Xiao et al. 2009) and it is
regulated by MAPKs (Ge, Xiao et al. 2007, Ge, Xiao et al. 2009). Melatonin induces RUNX2
expression in osteoblasts differentiated from hMSCs (Sethi, Radio et al. 2010) and in bone
(Koyama, Nakade et al. 2002, Witt‐Enderby, Slater et al. 2012). Like many of the other proteins
studied, the type of co-culture dictated their response to MSDK. For example, MSDK enhanced
RUNX2 expression in transwell osteoblasts beyond that induced by Os+/Veh (p< .05) (Figure
29A). However, in layered osteoblasts, MSDK did not further enhance RUNX2 expression
induced by Os+/Veh (Figure 29B). The latter may be due to the possibility that maximal levels of
RUNX2 expression may already have been attained.
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Figure 29. Effect of MSDK on RUNX2. After 21 days of MSDK treatment, western blot was
performed to determine RUNX2 expression of osteoblasts grown in (A) transwell co-cultures and
(B) layered co-culture, respectively. Cell lysates were prepared on day 21 from the bottom chamber
(osteoblasts) in the transwell co-culture and from the whole plate containing both osteoblasts and
osteoclasts (layered co-culture). Protein levels in each co-culture was analyzed, normalized against
β-actin followed by normalization against Os-/MSDK and represented as mean (± S.E.M.).
*=p<.05, **=p<.01 and ***=p<.001; One-way ANOVA followed by Bonferroni’s post-hoc
multiple comparison t-test (n=6 per group).

3.2.5. MSDK did not modulate INTEGRIN β1 level in co-cultures of hMSCs and hPBMCs
Integrins regulate the interaction between bone cells and the extracellular matrix and thus
control different aspects of bone cell growth and activity (Mizuno, Fujisawa et al. 2000). The use
of these two different co-culture models permitted exploration of the roles of MSDK on this
important class of cell matrix proteins, especially in the layered co-culture where osteoblasts and
osteoclasts are in direct contact with each other during their differentiation. As shown in Figure
30C and D, the effect of Os+ media alone on INTEGRIN β1 expression was opposite in effect
depending on the type of co-culture; Os+/Veh decreased INTEGRIN β1 level in transwell
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osteoblasts (Figure 30A) but increased in layer co-culture where both cells are present. (Figure
30B). The addition of MSDK to Os+ did not further decrease or increase INTEGRIN β1 levels in
either co-culture.

Figure 30. Effect of MSDK on INTEGRIN β1. After 21 days of MSDK treatment, western blot
was performed to determine INTEGRIN β1 expression of osteoblasts grown in (A) transwell cocultures and (B) layered co-cultures, respectively. Cell lysates were prepared on day 21 from the
bottom chamber (osteoblasts) in the transwell co-culture and from the whole plate of the layered
co-culture. Protein levels in each co-culture was analyzed, normalized against β-actin followed by
normalization against Os-/MSDK and represented as mean (± S.E.M.). *=p<.05, **=p<.01 and
***=p<.001; One-way ANOVA followed by Bonferroni’s post-hoc multiple comparison t-test
(n=6 per group).
3.2.6. MSDK modulates NFκB level in co-cultures of hMSCs and hPBMCs dependent upon
the type of culturing condition—layered or transwell
Nuclear factor kappa-B (NFκB) plays a vital role in RANK-mediated osteoclastogenesis
(Jimi, Aoki et al. 2004, Wada, Nakashima et al. 2006, Boyce and Xing 2008). Similarly, novel
roles for NFκB in osteoblasts are also emerging (Chang, Wang et al. 2009, Marie 2015). Therefore,
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levels of NFκB in response to MSDK were assessed in transwell as well as in layered co-cultures.
As shown in Figure 31A, hPBMCs grown as transwells with hMSCs and exposed to Os+ media
containing MSDK demonstrated significant increases in NFκB vs. Os-/MSDK and Os+/Veh (p<
.05 vs. Os+/Veh); no increases in NFκB occurred in the presence of osteogenic media (Os+/Veh)
alone. In contrast, exposure to Os+/Veh increased NFκB levels in layered co-cultures and no
further enhancement occurred in presence of MSDK (Figure 31B). The effects of Os+/MSDK on
NFκB levels in transwell osteoclasts are not easily explained considering that this same culture
condition (transwell and Os+/MSDK) decreased osteoclastogenesis (Figure 26A).

Figure 31. Effect of MSDK on NFκB. After 21 days of MSDK treatment, western blot was
performed to determine NFκB expression of osteoclasts grown in (A) transwell co-cultures, and
(B) layered co-cultures, respectively. Cell lysates were prepared on day 21 from the top chamber
(osteoclasts) in the transwell co-culture and from the whole plate containing both osteoblasts and
osteoclasts (layered co-culture). Protein levels in each co-culture was analyzed, normalized against
β-actin followed by normalization against Os-/MSDK and represented as mean (± S.E.M.).
*=p<.05, **=p<.01 and ***=p<.001; One-way ANOVA followed by Bonferroni’s post-hoc
multiple comparison t-test (n=6 per group).
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3.2.7. MSDK modulates PPAR and GLUT4 levels in co-cultures of hMSCs and hPBMCs
dependent upon the type of culturing condition—layered or transwell
The effects of MSDK on different metabolic proteins such as peroxisome proliferatoractivated receptor gamma (PPAR), glucose transporter type 4 (GLUT4) and beta subunit of
insulin receptor (IRβ) were evaluated due to their potential impact on bone cell differentiation and
activity (Akune, Ohba et al. 2004, Takada, Suzawa et al. 2007, Ferron, Wei et al. 2010, Li, Leslie
et al. 2013). It was in these proteins where the type of culturing condition played vital roles in their
expression in osteoblasts exposed to MSDK. For example, the addition of MSDK did not affect
PPARγ expression in osteoblasts grown as transwell co-cultures (Figure 32Ai). In contrast,
Os+/MSDK significantly reduced total PPARγ expression in osteoblasts and osteoclasts vs. Os+
alone (p< .01) in layered co-cultures (Figure 32Bi). Similarly, MSDK inhibited Os+/Vehmediated GLUT4 levels in layered osteoblasts (Figure 32Bii), but not in transwell osteoblasts
(Figure 32Aii). IRβ levels, though, were only modulated in transwell osteoblasts exposed to Os+
media alone (Figure 32Aiii). No effect on IRβ levels occurred in layered osteoblasts in response
to any of the treatments (Figure 32Biii).
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Figure 32. Effect of MSDK on metabolic proteins. After 21 days of MSDK treatment, expression
of metabolic proteins such as (i) PPAR, (ii) GLUT4 and (iii) IRβ were measured in (A) osteoblasts
grown in transwell co-cultures and (B) osteoblasts and osteoclasts grown in layered co-cultures.
Cell lysates were prepared on day 21 from the bottom (osteoblasts) and top (osteoclasts) chambers
in the transwell co-culture and from the whole plate (both osteoblast and osteoclast) in the layered
co-culture. Protein levels were normalized against β-actin and then to Os-/MSDK. Mean protein
levels were analyzed and compared between groups (Os-/MSDK, Os+/Veh, Os+/MSDK).
*=p<.05, **=p<.01 and ***=p<.001; One-way ANOVA followed by Bonferroni’s post-hoc
multiple comparison t-test (n=6 per group).

3.3. Discussion
The in vitro study was developed as part of the translational study to evaluate the
mechanism(s) underlying the clinical effects of MSDK therapy on bone formation and bone
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marker turnover in postmenopausal osteopenic women shown in the MOTS. These in vitro studies
expanded upon the outcomes of the MOTS with a focus on identifying if and how osteoblasts
modulate osteoclast activity using two novel co-culture systems consisting of human adult
mesenchymal stem cells (hMSCs) as osteoblast precursors and human peripheral blood monocytes
(hPBMCs) as osteoclast precursors—layered or transwell. This was intended to model the different
ways osteoblasts and osteoclasts interact and communicate in vivo and to get information about
how MSDK affects bone cells in their undifferentiated state rather than in already differentiated
state. To the best of our knowledge, this is the first study assessing if and how combination of
melatonin, strontium citrate, vitamin D3 and vitamin K2 regulate the formation and activity of
osteoblasts and osteoclasts in a way that favors bone formation. This preliminary study focused
only on the pathways that could potentially be regulated by MSDK, including the OPG/RANKL
pathway, MAPK, RUNX2, NFB and INTEGRIN 1 as well as on certain metabolic parameters
that affect bone function, including PPARγ and GLUT4. Deep exploration into these pathways is
required to obtain a full picture of the underlying mechanism of MSDK’s modulatory activity on
bone.
The complex relationship between osteoblasts and osteoclasts and their regulation of each
other’s activity during the bone remodeling process are still poorly understood. Bone remodeling
intrinsically depends on multiple modes of communication that occur between osteoblastic and
osteoclastic lineage cells at various stages of their differentiation. These include: direct cell-to-cell
contact to allow for the interaction between membrane-bound ligands and the initiation of
intracellular signaling; or via the release of diffusible paracrine factors such as growth factors,
cytokines, chemokines and other small molecules from either cell type to control each other’s
activity; or by forming gap junctions through which small molecules can pass between the two
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cells (Matsuo and Irie 2008, Sims and Gooi 2008). In the present study, the layered co-culture
allows for direct contact between osteoblasts and osteoclasts, whereas the transwell co-culture is
based on indirect contact through the release of paracrine factors from either cell. By mimicking
more closely the in vivo environment, these co-cultures systems were advantageous to evaluate
how MSDK modulates the intercellular communication between bone cells throughout their
transition from the immature to mature stage of life.
Calcium deposition and bone mineralization by mature osteoblasts is an important marker
of bone formation. The 21-day time period was chosen based on past studies, which showed that
continuous melatonin treatment for 21 days is required to induce osteoblast differentiation and
mineralization from hMSCs, as revealed by alkaline phosphatase (ALP) activity and calcium
deposition (alizarin red staining) assay (Sethi, Radio et al. 2010). Multi-potent human bone
marrow stromal cells are the primary osteoblast lineage cells, which were found to differentiate
into pre-osteoblast in 10 days when exposed to 50nM melatonin daily, as revealed by ALP activity
(Radio, Doctor et al. 2006). Osteogenic medium containing ascorbate, dexamethasone and βglycerophosphate was required to regulate hMSC differentiation into pre-osteoblasts and mature
osteoblasts, as basal growth media only induces hMSC proliferation (Radio, Doctor et al. 2006,
Sethi, Radio et al. 2010, Langenbach and Handschel 2013). Pre-osteoblasts proliferate and start to
differentiate into mature osteoblasts, which then begin to deposit calcium in the bone matrix.
Usually in vitro mineralization occurs between 14 to 12 days (Sethi, Radio et al. 2010) and so the
same was expected to occur in the present study. Therefore, hMSCs were cultured for 13 days so
that they would mature into pre-osteoblasts and begin secreting RANKL and M-CSF. This was to
facilitate osteoclastogenesis after peripheral blood monocytes were added to the culture on day 13.
By day 21, pre-osteoblasts differentiate into osteoblasts and stop osteoclastogenesis by producing
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OPG (Atkins, Kostakis et al. 2003, Boyce and Xing 2008). Successful differentiation of osteoblasts
from hMSCs and osteoclasts from hPBMCs in vehicle-treated culture (Os+/Veh) indicated that
both co-cultures were developed successfully without the external addition of RANKL and MCSF.
The 21 days of MSDK treatment greatly induced calcium deposition activity of the
differentiated osteoblasts, as revealed by alizarin red staining. Our findings regarding the
mineralization effect of melatonin in both cultures is consistent with previous in vitro studies,
which show stimulatory roles of melatonin in osteoblast differentiation and mineralization from
hMSCs and pre-osteoblasts (Radio, Doctor et al. 2006, Zaminy, Ragerdi Kashani et al. 2008, Sethi,
Radio et al. 2010, Zhang, Su et al. 2010, Park, Kang et al. 2011, Maria and Witt‐Enderby 2014).
In vitro bone-forming effects of melatonin are further supported by earlier preclinical and clinical
studies (Clafshenkel, Rutkowski et al. 2012, Kotlarczyk, Lassila et al. 2012, Witt‐Enderby, Slater
et al. 2012).
Numerous in vitro studies show that strontium ranelate stimulates osteogenic
differentiation of MSCs and pre-osteoblasts (Atkins, Welldon et al. 2009, Fromigué, Haÿ et al.
2009, Peng, Zhou et al. 2009); rebalances bone marrow osteoblastogenesis and adipogenesis
(Saidak, Haÿ et al. 2012); and increases osteoblast maturation, matrix mineralization and bone
nodule numbers in osteoblast cultures (Bonnelye, Chabadel et al. 2008, Atkins, Welldon et al.
2009, Querido and Farina 2013). Similar to published studies, strontium citrate alone in the MOTS
enhanced osteoblast differentiation and mineralization from hMSCs after 21 days of exposure in
the layered co-culture.
Published studies show an in vitro stimulatory effect of vitamin K2 (MK7) on the postproliferative stages of osteoblast differentiation and bone formation (i.e., the osteoblast to
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osteocyte transition) via a γ-carboxylation-dependent and independent mechanism (Yamaguchi,
Sugimoto et al. 2001, Katsuyama, Otsuki et al. 2005, Atkins, Welldon et al. 2009, Yamaguchi and
Weitzmann 2011). MK7 triggers osteocalcin protein expression (Yamaguchi and Weitzmann
2011) and induces the expression of osteogenic genes [e.g., growth differentiation factor 10
(GDF10), insulin- like growth factor 1 (IGF1), and vascular endothelial growth factors (VEGFA)]
(Gigante, Brugè et al. 2015). However, in the present study, no effect of MK7 alone on osteoblast
mineralization occurred in either co-culture. This could be due to the lower treatment concentration
of MK7 used in present study (18.5 nM) as compared to the concentrations used in past-published
studies (10-7 to 10-5 M) (Yamaguchi, Sugimoto et al. 2001, Atkins, Welldon et al. 2009, Yamaguchi
and Weitzmann 2011, Gigante, Brugè et al. 2015) or that the treatment duration was not long
enough to allow for the osteoblast-osteocyte transition.
The stimulatory effect of vitamin D3 on active calcium and phosphate absorption and
uptake into bone and overall homeostasis is well-established (Lips 2006) and past studies
demonstrate a complex relationship between vitamin D and osteoblasts. In our study, no effect of
vitamin D3 alone on osteoblast differentiation occurred in either co-culture, even though other
studies demonstrate the presence of the vitamin D receptor (VDR) and the protein disulfide
isomerase family A member 3 receptor (Pdia3R) (Chen, Dosier et al. 2013) in osteoblasts, which
allows for the direct action of vitamin D3 on osteoblast differentiation, proliferation and
mineralization (Anderson, Lam et al. 2013, Yang, Atkins et al. 2013). Vitamin D3 inhibits
osteogenic genes such as COL1A1 and ALP expression in pre-osteoblasts and enhances their
expression in the late differentiation stage in osteoblasts. The effect of vitamin D3 during the later
stage of bone formation is also demonstrated by inducing the osteoblast to osteocyte transition and
regulation of key genes such as FGF23 and DMP1 that stimulates osteocyte mineralization
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(Anderson, Lam et al. 2013, Kogawa, Findlay et al. 2013). However, for vitamin D3, the magnitude
of its osteogenic effect depends on the duration of exposure, dosage as well as the origin and
maturation stage of osteoblasts (Anderson, Lam et al. 2013, Yang, Atkins et al. 2013). Perhaps,
our study conditions were different than others’ in these aspects and explains why no increases in
calcium deposition following exposure to vitamin D3 occurred in the MOTS. Another explanation
could be that combination of vitamin D3 with other factors like MK7 (vitamin K2) may increase
vitamin D3’s effects. This idea is supported by Gigante et al. who rationalized that cosupplementation with MK7 enhances vitamin D3- regulated osteogenic gene expression and
differentiation of human MSCs. MK7 also maintains an optimum balance between the induction
and carboxylation of osteocalcin, required for its action on the extracellular matrix (ECM)
(Gigante, Brugè et al. 2015). These data further support our findings where the individual
compounds showed little or no significant mineralization effect; however, when combined, their
effects maximized even when they were used at their lowest concentrations.
The role of these compounds on osteoclast formation and activity is emerging. Little
evidence is available on melatonin’s effect on osteoclasts; however, others have shown that
melatonin produces an inhibitory effect on RANKL-mediated osteoclastogenesis perhaps due to
increases in OPG mRNA and protein expression in osteoblasts (Koyama, Nakade et al. 2002,
Maria and Witt‐Enderby 2014). These melatonin-mediated increases in OPG would block
osteoclastogenesis by acting as a RANKL decoy receptor (Gasser and Kneissel 2017).
Strontium ranelate prevents osteoclast differentiation via the OPG/RANKL/RANK
pathway and resorption activity by disrupting the organization of the actin cytoskeleton (Bonnelye,
Chabadel et al. 2008, Atkins, Welldon et al. 2009, Saidak and Marie 2012). Regarding strontium
citrate, no such data are available regarding its effects on osteoclasts and MK7 negatively regulates
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osteoclast survival and activity by inhibiting RANKL-mediated NFκB activation (Yamaguchi and
Weitzmann 2011).
Vitamin D3, in contrast, stimulates osteoclast differentiation from monocytes (Bar-Shavit,
Teitelbaum et al. 1983) and directly regulates bone resorption by activating human RANKL genes
in osteoblasts through vitamin D responsive elements (VDREs) (Kitazawa, Kajimoto et al. 2003).
These effects of vitamin D occur by increasing RANKL and decreasing OPG expression on
osteoblasts and stromal cells (Kogawa, Findlay et al. 2010). Circulating levels of vitamin D3
precursors [25(OH)D3] and its metabolism to 1,25(OH)2D3 by osteoclast precursors are important
regulators that optimize osteoclast differentiation via effects on gene expression and by promoting
the coupling of bone resorption to formation (Kogawa, Findlay et al. 2010, Anderson, Lam et al.
2013).
The effect of MSDK on osteoclast differentiation and function was measured by TRAP
because TRAP is an well-known marker of terminally differentiated osteoclasts (Angel, Walsh et
al. 2000, Halleen, Tiitinen et al. 2006). Osteoclast differentiation was inhibited following treatment
with MSDK-supplemented osteogenic media in transwell co-cultures, but not in layered cocultures even though MSDK inhibited resorption pit formation activity in layered co-cultures.
Osteoclasts, grown as layered co-cultures, were strongly inhibited in the presence of osteogenic
(Os+) medium alone and in combination with MSDK. This could be due to the direct cell-to-cell
contact or by release of paracrine factors between differentiating osteoblasts and osteoclasts
leading to co-regulation of each other’s state of differentiation and activity in these two co-culture
systems.
The discrepancy in the robustness of MSDK’s effects on osteoblast and osteoclast
differentiation, as observed between the culturing conditions (i.e., greater increase in transwell
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osteoblast differentiation vs. layered; greater decrease in layered osteoclast differentiation vs.
transwell), could be explained by the types of signaling pathways activated in both bone cells. For
example, osteoblast formation may be favored in both co-cultures; however, the mechanisms may
be very different especially in how osteoclasts modulate osteoblast differentiation. In transwell cocultures, paracrine factors (e.g., IGF I and II, FGF, TGF 1 and 2, BMPs 2, 3, 4, 6 and 7 and PDGF)
released by osteoclasts may favor osteoblast formation through these distinct signaling cascades
whereas in the layered co-culture model, with both cells in direct contact, osteoclasts may mediate
osteoblast differentiation through the contact-dependent ephrin signaling pathway. The contactdependent ephrin signaling pathway can, in turn, negatively regulate osteoclastogenesis
irrespective of their resorbing activity. As ephrin signaling requires close contact between
osteoclasts and osteoblasts, this inhibition was not observed in the transwell co-culture. Another
mechanism to explain these differences could be due to osteoblast-derived osteoclast inhibitory
lectin (OCIL), which is a type II transmembrane C- type lectin, that can suppress both osteoclast
differentiation (Kartsogiannis, Sims et al. 2008, Matsuo and Irie 2008) and osteoblast
differentiation and function in vitro (Nakamura, Ly et al. 2007, Matsuo and Irie 2008); this
pathway helps to maintain normal bone physiology. In our layered co-culture model, the cell-tocell contact between osteoblasts and osteoclasts may stimulate OCIL to inhibit the differentiation
of osteoblasts, osteoclasts or both resulting in an overall diminished state of differentiation.
Another possibility could be explained by the presence of vitamin D3, which can stimulate
osteoclastogenesis from monocytes (Bar-Shavit, Teitelbaum et al. 1983). Therefore, even if the
other components of MSDK (i.e., melatonin, strontium citrate and MK7) are inhibiting
osteoclastogenesis, some of these effects may be masked by vitamin D3’s stimulatory effects on
osteoclast differentiation. These data suggest that MSDK neither completely inhibited bone
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resorption like other conventional therapies, nor only assisted bone formation. Rather, it may be
working to switch the balance between bone-forming osteoblasts and bone-resorbing osteoclasts
towards equilibrium to maintain healthy bone remodeling. These data are consistent with the
findings of our MOTS clinical trial where postmenopausal osteopenic women taking MSDK
supplementation over one year had rebalanced serum bone marker (CTx:P1NP) turnover where
increases in serum P1NP was observed in the MSDK group, while steady levels of CTx were
maintained to keep bone remodeling (i.e. osteoblast:osteoclast ratios) balanced.
MSDK triggered osteoblasts to produce more OPG and less RANKL in the transwell cocultures even though the individual components (i.e., melatonin, strontium citrate, vitamin D3 and
K2) produced variable effects on OPG and RANKL. Melatonin and strontium ranelate positively
regulate OPG and negatively regulate RANKL in osteoblasts (Koyama, Nakade et al. 2002, Atkins,
Welldon et al. 2009, Saidak and Marie 2012) while vitamin K2 increases the expression of both
OPG and RANKL in osteoblastic MC3T3E1 cells (Katsuyama, Otsuki et al. 2005). The relative
expression of OPG and RANKL in osteoblasts is a critical transition point for balancing bone
mineralization (Boyce and Xing 2008). MSDK was more likely balancing osteoblast and osteoclast
activities initially through its differentiating effects on osteoblasts; these mature osteoblasts then
begin to express OPG to modulate RANKL-mediated osteoclastogenesis to maintain appropriate
bone remodeling. This concept is corroborated in the MOTS demonstrating a steady level of CTx
throughout MSDK treatment. This is also consistent with what was observed for RANKL
expression in osteoblasts in response to MSDK, that is, levels were significantly decreased in
response to the osteogenic media (Os+) and remained low even in the presence of MSDK. Because
RANKL production is largely regulated by immature osteoblasts (Atkins, Kostakis et al. 2003),
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maturation of osteoblasts in response to MSDK would result in less RANKL production as
observed in our study.
Besides being reduced as osteoblasts mature, RANKL can go through various stages of
processing to promote osteoclast activation which is generated from the ectodomain shedding of
membrane-bound RANKL via the action of matrix metalloproteases 3, 7 and 14 and ADAM 10,
17 (or TACE) and 19 (Nakashima, Kobayashi et al. 2000, Wada, Nakashima et al. 2006). In our
study, the addition of MSDK in osteogenic (Os+) medium decreased the 25kDa RANKL peptide
fragment in transwell co-culture but not in layered co-culture; this transwell effect of MSDK is
indicative of a facilitation of ADAM 10’s catalytic activity (Hikita, Yana et al. 2006). In the
transwell co-cultures, formation of the 24kDa RANKL peptide was inhibited in presence of
osteogenic (Os+) medium alone; no further decrease was observed with MSDK. The modulation
of the 24KDa fragment by Os+ in transwell osteoblasts indicates that MMP 14 may be playing
some type of role in osteoblastogenesis and osteoclastogenesis (Hikita, Yana et al. 2006).
The addition of MSDK did not further affect the levels of secreted OPG and RANKL as
measured in the cell culture media. In fact, osteoblastic differentiation and maturation correlated
more with an increase in secreted RANKL than with secreted OPG. Similar effects were observed
with parathyroid hormone (PTH)—the only bone anabolic agent currently available—which
increases sRANKL secretion from MC3T3-E1 cells, while not affecting sOPG, resulting in
reduced sOPG: sRANKL ratios (Coetzee, Haag et al. 2007).
The role of membrane-bound and secreted RANKL in osteoclastogenesis has not been fully
characterized. Nevertheless, studies show that the membrane-bound form of RANKL is more
efficient at inducing osteoclastogenesis than the soluble form (Nakashima, Kobayashi et al. 2000).
Therefore, the inhibitory effect of MSDK on osteoclastogenesis could possibly be attributed by
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the regulation of membrane bound OPG and RANKL, rather than secreted OPG and RANKL.
This, however, does not explain MSDK’s effects on osteoclastogenesis in the layered co-cultures.
Other variables like direct interference of osteoclasts on osteoblast functionality may play a role
because a less robust increase in osteoblast differentiation by MSDK in layered co-culture may
produce a less robust change in membrane-bound OPG and RANKL. This is supported in the
mono-culture studies where hMSCs grown in the absence of osteoclasts had robust increases in
both OPG and RANKL.
Osteoblast differentiation and proliferation involve multiple signaling pathways (Raucci,
Bellosta et al. 2008, Maria and Witt‐Enderby 2014). The present study focused on the effect of
MSDK on MAPKs, particularly ERK1/2 and ERK5, in modulating bone cell physiology. ERK1/2
are one of the key regulatory proteins involved in osteoblast differentiation (Ge, Xiao et al. 2007,
Ge, Xiao et al. 2009, Matsushita, Chan et al. 2009, Greenblatt, Shim et al. 2013) and thus play
essential roles in bone remodeling. Increased ERK1/2 signaling switches mesenchymal cell
differentiation towards osteoblasts from chondrocytes and vice-versa. Furthermore, specific
deletion of ERK1 and ERK2 in mouse limb mesenchyme results in low bone mineralization
(Matsushita, Chan et al. 2009). ERK also regulates ATF4, which is a late stage mediator of
osteoblast differentiation (Greenblatt, Shim et al. 2013). In the present study, MSDK treatment
enhanced ERK1/2 activation by downregulating total ERK1/2 levels in both co-culture models—
transwell and layered. ERK1/2 is also expressed in osteoclasts and plays a vital role in osteoclast
differentiation where high ERK1/2 is associated with increases in osteoclast activity (Matsushita,
Chan et al. 2009). In layered co-cultures, which contain both osteoblastic and osteoclastic ERK1/2,
MSDK may have increased pERK1/2 levels in both cells resulting in an increase in
osteoblastogenesis and a decrease in osteoclastogenesis. It is more likely that MSDK increased
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osteoblastic pERK1/2 because MSDK under these conditions inhibited osteoclasts. Previous in
vitro studies in our lab (Radio, Doctor et al. 2006, Sethi, Radio et al. 2010) and others’ (Zhang, Su
et al. 2010, Park, Kang et al. 2011) show that melatonin, through the activation of MT2 melatonin
receptors on hMSC monolayers, triggers ERK1/2 signaling (Radio, Doctor et al. 2006); this leads
to increases in osteogenic gene expression such as RUNX2, BMP2 and OC resulting in
osteoblastogenesis (Radio, Doctor et al. 2006, Sethi, Radio et al. 2010). Ge et al showed that
Runx2+/− mice expressing constitutively active and dominant-negative mutants of MAPK in their
osteoblasts exhibit low clavicular and calvarial bone mass and hypomineralization (Ge, Xiao et al.
2007). The bone mass is restored by breeding Runx2+/− mice with a constitutively active mutant
of the MEK1 transgene bearing mice (Ge, Xiao et al. 2009). These data demonstrate a direct
relationship between the ERK1/2 pathway and RUNX2 (Ge, Xiao et al. 2007, Ge, Xiao et al.
2009). Strontium ranelate also enhances Runx2 expression in murine osteoblasts via the RAS/ERK
1/2 MAPK signaling pathway (Peng, Zhou et al. 2009). Vitamin K2, at a 10 μM dose, induces
RUNX2/Runx2 and OSTERIX/Osterix expressions in primary bone marrow stromal cells and
MC3T3, respectively (Yamaguchi and Weitzmann 2011). The role of vitamin D3 on osteogenic
genes expression is species specific, as it increases BGLAP, SPP1, RUNX2 gene expression in
human primary osteoblasts while producing inhibitory effects on murine osteoblasts (Kogawa,
Findlay et al. 2010).
In our study, MSDK exposure induced transwell osteoblast RUNX2 expression beyond
that induced by Os+ alone; however, in layered co-cultures, MSDK produced no additional
increases in RUNX2 expression. Based on previous studies (Radio, Doctor et al. 2006, Sethi, Radio
et al. 2010) and the present study, we propose that the MSDK-mediated increases in RUNX2
expression and osteoblast differentiation from hMSCs in these co-cultures is occurring, in part, via
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the ERK1/2 pathway. Because other pathways, such as p38, JNK, BMPs, canonical Wnt, also
regulate RUNX2 transcriptional activity (Franceschi and Xiao 2003, Gaur, Lengner et al. 2005,
Rodríguez-Carballo, Gámez et al. 2016), these pathways cannot be ruled out and require further
investigation.
Even though the role of ERK1/2 in osteoblastic differentiation has been extensively
studied, little is known about the role of ERK5 in osteoblast physiology. ERK5 is well known for
regulating various cellular processes including proliferation, differentiation, transformation and
survival in certain cells types under certain conditions; however, most studies focused on its role
in cardiovascular development and neuronal differentiation (Nishimoto and Nishida 2006, Drew,
Burow et al. 2012). Some studies have shown an involvement of ERK5 in fluid shear stressmediated cell proliferation in osteoblasts (Li, Ma et al. 2012, Bo, Bin et al. 2016). Kaneshiro et al
recently demonstrated that the MEK5/ERK5 suppresses osteoblast differentiation, but promotes
osteoblastic cell proliferation in pre-osteoblastic MC3T3-E1 and bone marrow stromal cells
(Kaneshiro, Otsuki et al. 2015). This is consistent with what was seen in our hMSC mono-culture
studies where both total and phospho-ERK5 levels increased. However, in contrast to the
osteoblast mono-cultures, both total and phospho-ERK5 levels decreased in transwell osteoblasts
following exposure to Os+ alone and in the presence of MSDK possibly to allow for osteoblast
differentiation. This is consistent with the process of osteoblast differentiation where stages of
rapid cell proliferation are followed by stages of low proliferation and high differentiation. The
presence of osteoclasts in this co-culture may also be playing a role on osteoblast differentiation.
MSDK, added in combination with osteogenic (Os+) medium, slightly but significantly increased
phospho-ERK5 levels in transwell osteoblasts perhaps to increase the number of osteoblasts before
they enter a stage of differentiation.
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Even though ERK5 inhibits osteoblast differentiation, it is shown to produce a stimulatory
effect on osteoclast differentiation mediated via M-CSF and c-Fos induction (Amano, Chang et al.
2015). In the present study, MSDK exposure did not affect transwell osteoclast ERK5 expression
even though osteoclast differentiation was decreased. Failure to inhibit the ERK5 pathway in
osteoclasts supports the fact that ERK5 in transwell osteoclasts may not be involved in MSDKmediated inhibition of osteoclastogenesis; however, this can only be verified by use of MEK5specific inhibitors. The lack of an MSDK effect on ERK5 expression in layered co-cultures may
be attributed to the fact that both osteoblasts and osteoclasts express ERK5; MSDK may be
producing variable effects on ERK5 in osteoblasts and osteoclasts masking any increases or
decreases that may have occurred individually in the cells. Further downstream pathways as well
as related transcription factors are needed to be evaluated to get a clearer idea about the
involvement of ERK1/2 and ERK5 pathways in MSDK-mediated modulation of bone cell activity.
Integrin-mediated cell–cell and cell–matrix interactions (via cytoskeletal organization and
signal transduction) are key requirements for bone cell proliferation, differentiation, migration and
apoptosis as well as skeletal development and homeostasis (Clover, Dodds et al. 1992, Gronthos,
Stewart et al. 1997, Horton and Helfrich 2000). Osteoblasts primarily express β1 and β5 integrins,
depending on the type of osteoblast lineage, stage of differentiation, and culture conditions
employed. Usually, differentiated osteoblasts have increased expression of fibronectin receptor
α5β1 followed by collagen binding integrin α2β1 expression but at a much lower level (Horton
and Helfrich 2000). In the present study, INTEGRIN β1 expression in transwell osteoblasts was
decreased in response to osteogenic (Os+) medium, which remained low even in the presence of
MSDK. In layered co-cultures, however, exposure to Os+ medium increased INTEGRIN β1 levels,
which remained high when MSDK was added. These differences between co-cultures could be
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explained by the fact that unlike transwell co-cultures, layered co-cultures offer a direct cell-tocell communication for which integrin expression is required. Secondly, in the layered co-culture,
levels may be higher because INTEGRIN β1 levels were being measured in both the osteoblast
and osteoclast; osteoclasts and their precursors express different subunits of INTEGRIN β1 in
order to regulate actin ring reorganization and bone resorption (Clover, Dodds et al. 1992, Helfrich,
Nesbitt et al. 1996, Rao, Lu et al. 2006). Even though INTEGRIN β1 plays an important role in
osteoblast differentiation (Horton and Helfrich 2000, Mizuno, Fujisawa et al. 2000), MSDK
treatment showed no effect on INTEGRIN β1 expression in either co-culture, suggesting that either
MSDK’s activity occurs via a non-integrin dependent mechanism or that the peaks and troughs
observed following Os+ exposure for the layered and transwell co-cultures, respectively, reached
their maximums and no further effects by MSDK could be achieved.
RANKL-RANK mediated activation of the NFκB signaling pathway in osteoclasts plays a
crucial role in osteoclast differentiation and bone resorption (Jimi, Aoki et al. 2004, Wada,
Nakashima et al. 2006, Boyce and Xing 2008). In osteoblasts, high NFκB is associated with low
bone mass and an inhibition of osteoblast differentiation (Chang, Wang et al. 2009, Marie 2015).
Strontium ranelate and vitamin K2 produce suppressive effects on NFκB resulting in an increase
in osteoblastogenesis and an inhibition of osteoclastogenesis (Yamaguchi and Weitzmann 2011,
Yamaguchi and Weitzmann 2012). Melatonin is found to inhibit NFκB as part of its antiinflammatory effect on renal cells (Li, Nickkholgh et al. 2009). These findings prompted us to
determine if MSDK’s inhibitory effect on osteoclastogenesis was mediated via NFκB. In both
transwell and layered osteoblasts, levels of NFκB increased in the presence of osteogenic (Os+)
medium, which was not further enhanced by MSDK. These data suggest that MSDK did not induce
osteoblastogenesis or inhibit osteoclastogenesis via NFκB signaling.
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From here, we shifted our focus towards the effect of MSDK on the regulators of energy
metabolism. Metabolic regulators such as peroxisome proliferator-activated receptor gamma
(PPARγ), glucose transporter 4 (GLUT4) and insulin receptor beta (IRβ) expressed in osteoblasts
not only regulate glucose metabolism but each play an important role in osteoblast and osteoclast
function (Akune, Ohba et al. 2004, Lecka-Czernik and Suva 2006, Takada, Suzawa et al. 2007,
Ferron, Wei et al. 2010, Li, Leslie et al. 2013). Insulin receptor signaling in osteoblasts has been
shown to play a vital role in osteoblast-mediated effects on osteoclastic bone resorption (Ferron,
Wei et al. 2010). In our study, IRβ was assessed in both co-cultures—transwell and layered—and
only in transwell osteoblasts was IRβ modulated. Specifically, both Os+ alone or in combination
with MSDK decreased IRβ in transwell osteoblasts, which was not further decreased in the
presence of MSDK probably due to a bottoming effect. The decreases in IRβ in transwell
osteoblasts correlate with high OPG, which is consistent with insulin’s function in osteoblasts, that
is, to modulate bone resorption through OPG. In osteoblasts with normal insulin signaling, bone
resorption is high due to a lack of OPG expressed in the osteoblast, thus increasing RANKLmediated osteoclast activity (Ferron, Wei et al. 2010). In our study, MSDK decreased transwell
osteoblast IRβ, increased OPG, and decreased TRAP; this would explain the decrease in
osteoclastogenesis in response to MSDK.
PPARγ is a key regulator in adipogenesis, energy expenditure, and lipid, glucose, and
insulin metabolism. In bone, high levels of PPARγ may cause bone loss by switching the fate of
mesenchymal stem cells towards adipogenesis at the expense of osteoblastogenesis (Akune, Ohba
et al. 2004); this results in an increase in bone marrow fat content. A PPARγ insufficiency increases
bone mass by enhancing osteoblastogenesis (Akune, Ohba et al. 2004, Lecka-Czernik and Suva
2006, Takada, Suzawa et al. 2007). PPARγ also supports osteoclastogenesis by stimulating
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RANKL production (Akune, Ohba et al. 2004, Lecka-Czernik 2010), which may further contribute
to bone loss by activating osteoclasts. Melatonin and strontium ranelate directly inhibit adipogenic
differentiation of hMSCs and murine MSCs, respectively, by suppressing PPARγ expression in
favor of osteoblastogenesis (Zhang, Su et al. 2010, Saidak, Haÿ et al. 2012). PPARγ signaling is
mainly involved in the earlier stages of osteogenesis and adipogenesis and does not affect cell
function (Akune, Ohba et al. 2004). Therefore, the stimulatory effect of Os+ medium on PPARγ
expression in either co-culture could be explained by the fact that when the stem cell progenitors
are differentiated into osteoblasts, the osteogenic media is enhancing PPARγ expression to support
energy metabolism. Even though MSDK addition did not affect PPARγ levels in the transwell cocultures, it significantly decreased Os+-induced PPARγ levels in layered co-cultures. Because
osteoclasts were in direct contact with osteoblasts in this culture, reduced PPARγ expression by
MSDK could reduce the energy capabilities of osteoclasts preventing their differentiation and
reducing their activity. MSDK also decreased Os+-induced GLUT4 expression in layered
osteoblasts, but not in transwell osteoblasts, similar to its effect on PPARγ. A positive correlation
between PPARγ and GLUT4 exists. Specifically, the PPARγ agonists, rosiglitazone and
pioglitazone, enhance GLUT4 mRNA in diabetes mellitus type 2 (DM2) muscle tissue and a loss
of PPARγ results in a decrease in GLUT1 and GLUT4 function in adipocytes (Armoni, Harel et
al. 2007, Liao, Nguyen et al. 2007). GLUT4 mRNA levels increase during osteoblast
differentiation (Li, Leslie et al. 2013). In addition to GLUT4, GLUT1 also plays an important role
in bone formation and is 100 fold more abundant than other glucose transporters in bone cells
(Wei, Shimazu et al. 2014). Therefore, no effect of MSDK on GLUT4 could imply that a potential
role of insulin independent GLUT1 pathway in MSDK’s action. However, further analysis with
GLUT1 is required to reach to a plausible conclusion. Osteoblastogenesis requires a significant
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amount of energy, which could explain why both PPARγ and GLUT4 expression increased when
exposed to Os+ alone. Even more importantly, though, were the findings that MSDK, in
combination with Os+, significantly reduced their expression consistent with MSDK’s stimulatory
effect on osteoblastogenesis and inhibitory effect on osteoclastogenesis.
These findings also provide a potential mechanism for the increase in bone formation and
stabilization of weight in postmenopausal osteopenic women taking MSDK as shown in the
MOTS; and for the improvement in femoral bone mineral density (Amstrup, Sikjaer et al. 2015)
and decreases total fat mass (Amstrup, Sikjaer et al. 2015) observed in postmenopausal osteopenic
women taking melatonin in the MelaOst trial. These findings were underscored by another study
showing that melatonin induces osteoblast differentiation from human adipose-derived
mesenchymal stem cells (Maria, Swanson et al. 2017).
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Chapter 4: Strength and limitations
Limitations to this study include low number of subjects (n=22) and lack of a diverse
cohort, which made it difficult to generalize the MOTS to a larger heterogeneous population of
osteopenic women. Low number of subject could be a potential reason for not getting some
possible significant differences between groups, for example, a definite effect of MSDK on hip
BMD could be revealed with high “n”. Besides, ethnic variation may play a role in MSDK’s effects
on bone. For example, MOTS cohort only contained Caucasian women, all of which were welleducated, affluent and health conscious. Therefore, the study outcome does not necessary depict
the bone loss scenario and MSDK’s effect on the women from another ethnicity or following a
different lifestyle. Potential seasonal/diurnal effects may have occurred due, in part, to a revolving
recruitment paradigm. This was minimized by having the participants come to the Center for
Pharmacy Care at the same time of day throughout the entire year. Also, when stratified by season,
no significant differences in bone marker turnover was observed in MOTS participants enrolled in
the fall vs. the spring (see Appendix VII). Due to limited resources, we could not assess the
exclusive effect of each micronutrient alone on primary and secondary endpoints. For a similar
reason, bone histomorphometric analysis was not performed and so the effect of this therapy on
bone microarchitecture and quality could not be assessed.
There are several strengths to this study. The translational approach allows this study to
not only assess the clinical effect of MSDK in postmenopausal osteopenia, but also evaluated the
underlying mechanisms governing those effects enhancing the relevance and lending support to
the clinical findings. Although small, the clinical component of the MOTS was effectively
designed as a double-blinded, randomized and placebo-controlled trial to avoid statistical bias.
Allocation concealment was strictly followed throughout the study. Extensive inclusion and
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exclusion criteria ensured a homogeneous group of study population with no competing conditions
that could interfere with the outcomes. Unique to this study is that health-related QOL was assessed
alongside bone health measures in this postmenopausal cohort to provide a well-balanced study
assessing objective and subjective measures. The in vitro component of the MOTS was also
constructive to assess MSDK effects at a mechanistic level and supported the clinical findings.
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Chapter 5: Conclusions
In the Melatonin-micronutrients Osteopenia Treatment Study (MOTS; NCT01870115), we
investigated whether a novel combination of melatonin and three other natural bone-protective
micronutrients: strontium citrate, vitamins D3 and K2 could improve bone health without affecting
or even improving health related QOL in postmenopausal osteopenic women. The MOTS is among
the first randomized clinical trials to utilize melatonin to prevent bone loss in a postmenopausal
cohort by intervening at a critical time during a woman’s life, where susceptibility to bone loss is
high. This study utilizes a safe, complementary combination therapy MSDK based on the
hypothesis of chronosynergy—a novel treatment approach using several condition-targeted bone
restorative agents with melatonin to reverse bone loss hopefully reducing the need for osteoporosis
medications later. With continued study and validation, MSDK could become an early treatment
option in the time-course for managing postmenopausal and age-related bone loss; and could
potentially play a great role in changing the course of global epidemic of osteoporosis by reducing
its rising incidence, tremendous health and medical system burden and high costs of the current
status-quo of osteopenia treatment management.
While melatonin therapy alone was protective to bone in a similar cohort (i.e.
postmenopausal women with osteopenia) in MelaOst (Amstrup, Sikjaer et al. 2015) or in healthy
perimenopausal cohort in MOPS (Kotlarczyk, Lassila et al. 2012), there were differences between
the MOPS and MelaOst studies and the MOTS. For example, in the MelaOst trial, one-year
supplementation with melatonin (1 to 3mg/day) dose-dependently increases femoral neck BMD
by 1.4% sites in postmenopausal osteopenic cohort (n=81), but does not affect BMD at other sites
(Amstrup, Sikjaer et al. 2015). In the MOTS, melatonin (5mg) in combination with other three
micronutrients: strontium citrate (450mg), vitamin D3 (2000IU) and vitamin K2 (60mcg) per day
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(MSDK) significantly increases lumbar spine BMD by 4.3% and left femoral neck BMD by 2.2%,
with a trend (p=0.069) towards an increase in hip BMD from baseline after one year in a similar
postmenopausal osteopenic cohort (n=22). Consequently, the 10-year vertebral fracture risk
probability is decreased by 6.48% with MSDK, as compared to 10.8% increase in placebo. MSDK
also reduces bone marker turnover (CTx:P1NP ratios) in postmenopausal osteopenic women
primarily by increasing the bone formation marker P1NP, and maintaining the bone resorption
marker CTx at a steady level. Although melatonin treatment for 6 months renormalizes bone
marker turnover (NTx:OC) in the healthy perimenopausal women in the MOPS (Kotlarczyk,
Lassila et al. 2012), no such effects on bone maker turnover occur in postmenopausal osteopenic
women in the MelOst (Amstrup, Sikjaer et al. 2015). Melatonin treatment decreases total fat mass
and increases lean body mass by 2.6% compared to placebo in the MelaOst trial (Amstrup, Sikjaer
et al. 2015); this did not occur with MSDK treatment. Although a significant decrease in the
variation of weight change over the course of the MOTS occurred in women taking MSDK but
not in women taking placebo, suggesting that there was some effect of MSDK on metabolic
parameters in a similar cohort as the MelaOst. Quality of life in both the MOPS and MOTS
improved; however, what was improved was unique to each trial. For example, melatonin
improves QOL in healthy perimenopausal women in the MOPS by improving their physical
symptoms of menopause (Kotlarczyk, Lassila et al. 2012), and by improving mood and reducing
sleep interruption (Maria, Samsonraj et al. 2017). In the MelaOst trial, melatonin improves sleep
quality in an insomniac subgroup of participants but is without effect on overall QOL or sleep in
this cohort (Amstrup, Sikjaer et al. 2015). Whereas, in the MOTS, MSDK supplementation
exhibited beneficial effects on the QOL in postmenopausal osteopenic women, by apparently
lessening the sexual symptoms of menopause (not significant vs. placebo) and by showing
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improvements with respect to sleep. All these findings propose that that melatonin may be a better
choice for bone loss prevention in healthy middle-aged women transitioning through menopause
and MSDK for the early stage bone loss treatment in postmenopausal women.
In vitro studies showed that MSDK may be modulating osteoblast and osteoclast function
via the release of the paracrine factors, OPG and RANKL, from osteoblasts. MSDK showed an
increase in osteoblast differentiation and mineralization in favor of bone formation which was
associated with an increase in RUNX2 expression. Increased pERK1/2:tERK1/2 and decreased
total ERK5 levels may be contributing to MSDK-mediated osteoblastogenesis; however, future
research is warranted to confirm their role by use of inhibitors selective for MEK1/2 and MEK5.
Increased osteoblast differentiation by MSDK led to an increase in the ratio OPG:RANKL
production in osteoblasts by increasing OPG and decreasing RANKL expression; these changes
in OPG and RANKL would result in an increase in osteoblast differentiation and in the inhibition
in osteoclast differentiation, Because MSDK treatment did not completely inhibit
osteoclastogenesis, we conclude that MSDK is favoring bone remodeling to proceed towards
equilibrium by allowing osteoclastogenesis to some extent since balanced bone remodeling is
essential to making and maintaining healthy bone.
The in vitro part of this translational study also describes novel signaling cascades (Figure
33) underlying MSDK’s effects on osteoblastogenesis and osteoclastogenesis that include
pERK1/2, pERK5, RUNX2, PPARγ and GLUT4. By comparison and noted in Figure 33,
melatonin shows similar effects on osteoblastogenesis and osteoclastogenesis to MSDK by
decreasing RANKL leading to an increase in the ratio of OPG:RANKL, by increasing pERK1/2
and RUNX2, and by decreasing NFκB, PPARγ and GLUT4–all of these effects were dependent
upon the type of co-culture (Maria, Samsonraj et al. 2017). The differences in the clinical outcomes
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using melatonin alone (MOPS, MelaOst) versus a combination therapy (MSDK in the MOTS)
suggests that their unique mechanistic actions, especially on osteoclasts, may direct use of
melatonin for prevention of bone loss in men and women at risk and at the beginning stages of
osteopenia (T-scores close to -1) and use of MSDK in later stages of osteopenia (T-scores < -1.5).

Figure 33. Potential mechanism underlying MSDK effects on bone formation.
Overall, these in vitro studies support our MOTS clinical trial findings demonstrating that
MSDK reduces bone turnover rate by increasing P1NP expression, while maintaining steady levels
of CTx. MSDK’s effects on osteoblastogenesis was consistent with the increase in bone mineral
density that was observed in MOTS clinical study. Results from this study underscore the
complexity but therapeutically relevant effects of MSDK on bone cell development and activity
making MSDK a viable and potential alternative therapy for managing and/or treating osteopenia
in postmenopausal women. However, a large-scale, multicenter RCTs testing the efficacy of
MSDK to treat osteopenia are warranted to further clarify the effectiveness of MSDK in the overall
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osteopenic population.
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Chapter 7: Appendix
I. The study information in ClinicalTrials.gov
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II. Materials used for study advertisements
A. Flyer

The early stage of
osteoporosis is called
osteopenia
If left untreated,
osteopenia can lead to
brittle bone disease called
osteoporosis

The study will be conducted at Duquesne University by qualified
health care professionals

Duquesne University
IRB – Protocol #13-59
Approval date: May 23,2013
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B. Newspaper and DU daily articles

Article URL: http://www.post-gazette.com/news/health/2014/03/04/Bone-loss-study-seeks-20women-volunteers/stories/201403040055
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Article URL: http://triblive.com/news/allegheny/4448150-74/bone-duquesne-loss
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Article URL:
https://www.naturopathic.org/article_content.asp?edition=101&section=154&article=826
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Article published at Senior Living of Pittsburgh Catholic on Friday, August 16, 2011
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Article URL: http://www.duq.edu/news/clinical-trial-at-duquesne-university-to-examine-naturalbone-treatment
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III. Initial visit form
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IV. Study medication label
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V. Bone density T-scores at baseline and at the end of the treatment

Figure V. Bone mineral density in the left femoral neck, total left hip and lumbar spine area was
measured via DXA and Achilles (n=11 per group). Each dot in scatter pot represents the bone
mineral density t-score of individual participant at baseline and at month 12, in the (A) left femoral
neck, (B) total left hip, (C) lumbar spine (L1-L4) and (D) heel area, respectively for placebo (open
bar) and MSDK (closed bars). *p ≤ 0.05 and ***p ≤ 0.001 vs. placebo for changes in T-scores
from baseline to month 12.
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VI. Treatment effects on bone marker changes in every six months

185

Figure VI. Bone formation marker, (A) total procollagen type 1 amino-terminal propeptide (P1NP)
and (B) osteocalcin (OC; both intact and N-terminal mid-fragments); and (C) bone resorption
marker Collagen Type I C-Telopeptide (CTx) were measured at months 0, 6, and 12, respectively
via ELISA (n=11 per group). Each dot in scatter pot represents the mean (± S.E.M.) change in
bone marker of a participant from baseline to month 12 and then in every six months (baseline to
month 6, month 6 to month 12), respectively for placebo (open dots) and MSDK (closed dots). *p
≤ 0.05 and **p ≤ 0.01 vs. placebo, one-way ANOVA followed by Bonferroni post hoc t-test.
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VII. Bone markers (P1NP, OC and CTx) of participants enrolled in fall and spring

Figure VII. Bone markers, (A) total procollagen type 1 amino-terminal propeptide (P1NP) and (B)
osteocalcin (OC; both intact and N-terminal mid-fragments); and (C) bone resorption marker
Collagen Type I C-Telopeptide (CTx) of participants enrolled in fall (n=14, closed dots) and spring
(n=8, open dots), respectively. *p ≤ 0.05 vs. placebo, unpaired two tailed t-test with Welch’s
correction.
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